Export and modification of (poly)peptides in the lantibiotic way

TECHNICAL FIELD

[0001] The invention relates generally to biotechnology and, more particularly, to the field of lantibiotics and to the field of post-translational modifications of (poly)peptides.

BACKGROUND

[0002] Lantibiotics form a group of unique ribosomally synthesized and post-translationally modified antibiotic peptides that are produced by, and primarily act on, Gram-positive bacteria (for review, See McAuliffe et al., FEMS Microbiol. Rev. 25: 285-308 (2001)). Because by definition lantibiotics contain intramolecular thioether bridges or rings formed by the thioether amino acids lanthionine (Lan) and 3-methyllanthionine (MeLan) and lantibiotics all are peptide antibiotics with moderate to strong bactericidal activity, lantibiotics take their name from these most eye-catching properties.

[0003] Thioether rings protect peptides against proteolytic degradation. For instance, the lantibiotic nisin remains active after trypsin treatment. Thioether rings are also essential for some lantibiotic activities. For instance, opening of ring A or C in nisin causes deletion of the membrane permeabilization capacity. Ring A of nisin is necessary for its capacity to autoinduce its own synthesis and for nisin's capacity to block the peptidoglycan synthesis by interacting with lipid II. It is essential to have thioether rings and not disulfide rings since replacement of thioether rings by disulfide bridges leads to loss of antimicrobial activity.

[0004] Lantibiotics do not spoil the environment and are not toxic to animals or man. Lantibiotics may also have applications as biopreservatives in the preparation of food and beverages, or as a bactericidal agent in cosmetics and veterinary and medical products. Because the growing number of multidrug resistant pathogenic micro-organisms has created the threat of another “pre-antibiotic era” for many bacterial diseases, it is expected that lantibiotics also may serve as new lead compounds to remedy this alarming problem. For these reasons, lantibiotics have experienced a marked increase in basic and applied research activities in the past decade, leading to an extraordinary increase in the knowledge of the lantibiotics structural and functional properties, the mechanisms of action and of the genes and protein components involved in the biosynthesis and secretion of the lantibiotics. For example, lantibiotics have become subject to “protein engineering” projects, with the aim of altering, via site-directed mutagenesis, the lantibiotics activity, stability and spectrum of susceptible target cells. In this description, the linear (type A) lantibiotics are considered since at present, very little specific information is available for the circular (type B) lantibiotics.

[0005] The lantibiotics subtilin and nisin belong to, and are representative of, the peptide antibiotics or lantibiotics of type A. Subtilin and nisin contain the rare amino acids dehydroalanine (Dha), dehydrobutyrine (Dhb), meso-lanthionine and 3-methyllanthionine, as well as the characterizing thioether bridges.

[0006] Nisin is the most prominent lantibiotic and is used as a food preservative due to its high potency against certain Gram-positive bacteria. It is produced by Lactococcus lactis strains belonging to serological group N. The potent bactericidal activities of nisin and many other lantibiotics are based on their capacity to permeabilize the cytoplasmic membrane of target bacteria. Breakdown of the membrane potential is initiated by the formation of pores through which molecules of low molecular weight are released. In addition, nisin inhibits cell wall synthesis by binding to lipid II, a precursor of peptidoglycan synthesis, modulates the activity of autolytic enzymes and inhibits the outgrowth of spores (See also, Breukink and de Kruijff, Biochem. Biophys. Acta 1462: 223-234, 1999).

[0007] In several countries, nisin is used to prevent the growth of clostridia in cheese and canned food. The nisin peptide structure was first described by Gross & Morell (J. Am. Chem. Soc 93: 4634-4635, 1971), and its structural gene was isolated in 1988 (Buchmann et al., J. Biol. Chem. 263: 16260-16266, 1988). Nisin has two natural variants, nisin A and nisin Z, which differ in a single amino acid residue at position 27 (histidine in nisin A is replaced by asparagine in nisin Z).

[0008] Subtilin is produced by Bacillus subtilis (ATCC 6633). Subtilin's chemical structure was first unravelled by Gross & Kiltz (Biochem. Biophys. Res. Commun. 50: 559-565, 1973) and its structural gene was isolated in 1988 (Banerjee & Hansen, J. Biol. Chem. 263: 9508-9514, 1988). Subtilin has strong similarities to nisin with an identical organization of the lanthionine ring structures (FIG. 1). Further, nisin and subtilin possess similar antibiotic activities.

[0009] Due to its easy genetic analysis B. subtilis became a suitable model organism for the identification and characterization of genes and proteins involved in lantibiotic biosynthesis. The pathway by which nisin is produced is very similar to that of subtilin and the proteins involved share significant homologies over the entire proteins (for review, see also, De Vos et al., Mol. Microbiol. 17: 427-437, 1995).

[0010] Another well known and studied lantibiotic, produced by Staphylococcus epidermis 5, is Pep 5, which contains three ring structures (one MeLan and two Lan), an N-terminal oxobutyryl residue and two Dhb residues (Kellner et al., Angew. Chemie Int. Ed. Engl. 28: 616-619, 1989).

[0011] The respective genes of subtilin and nisin have been identified adjacent to the structural genes, and are organized in operon-like structures (FIG. 2). The genes are thought to be responsible for post-translation modification, transport of the modified prepeptide, proteolytic cleavage and immunity which prevents toxic effects on the producing bacterium. Further, biosynthesis of subtilin and nisin is strongly regulated by a two-component regulatory system which includes a histidine kinase and a response regulator protein.

[0012] According to a present model (FIG. 3), it is assumed that an extracellular growth phase-dependent signal may activate the membrane localized histidine kinase. The nature of the signal may be different for subtilin and nisin biosynthesis. In nisin biosynthesis, nisin has an inducing function, whereas it was shown for subtilin biosynthesis that its biosynthesis is sporulation dependent.

[0013] According to the model, after nisin's auto-phosphorylation, the SpaK and NisK histidine kinase transfer the phosphate residue to the response regulator which in turn activates the genes necessary for subtilin and nisin biosynthesis. Thereafter, the prepeptide is modified at a membrane localized modification complex (lantionine synthetase) including the intracellular SpaB/SpaC and the NisB/N is C proteins, respectively. According to the model, the proteins are also associated with the SpaT and the NisT transporter, respectively.

[0014] As in any lantibiotic, the presubtilin or prenisin molecule includes a leader segment and a mature segment, wherein the leader segment is thought to play several roles in the biosynthetic pathway. The leader segment is thought not to be just a translocation signal sequence, but also thought to provide recognition signals for the modification enzymes and to suppress antimicrobial activity until the mature peptide is released from the cell. As also postulated by Qiao and Saris, (Fems Microbiol. Let. 144: 89-93(1996)), the modified prepeptide is thought to be proteolytically cleaved after its transport through the cellular membrane or cleavage of the leader from the modified peptide occurs inside the cell before secretion. In the case of nisin, cleavage is performed by N is P, whereas in the case of subtilin, no specific protease has been found within the operon-like structure. However, B. subtilis is rich in extra-cellular proteases and possibly subtilisin, which also recognizes proline at position-2, could cleave the modified pre-subtilin.

[0015] The gene clusters flanking the structural genes for various linear (type A) lantibiotics have recently been characterized (for review, see, Siezen et al., Antonie van Leeuwenhoek 69: 171-184, 1996)). The best studied representatives are those of nisin (nis), subtilin (spa), epidermin (epi), Pep5 (pep), cytolysin (cyl), lactocin S (las) and lacticin 481 (let). Comparison of the antibiotic gene clusters shows that the clusters contain conserved genes that probably encode similar functions.

[0016] The nis, spa, epi and pep clusters contain lanB and lanC genes that are presumed to code for two types of enzymes that have been implicated in the modification reactions characteristic of all antibiotics, i.e. dehydration and thio-ether ring formation. The cyl, las and let gene clusters have no homologue of the lanB gene, but do contain a much larger lanM gene that is the lanC gene homologue. Most antibiotic gene clusters contain a lanP gene encoding a serine protease that is presumably involved in the proteolytic processing of the prelantibiotics. All clusters contain a lanT gene encoding an ATP-binding cassette (ABC)-like transporter spanning the plasma membrane of a cell and likely is involved in the export of (precursors of) the lantibiotics from the cell. The lanE, lanF and lanG genes in the nis, spa and epi clusters encode another transport system that is possibly involved in self-protection. In the nisin and subtilin gene clusters two tandem genes, lanR and lank, have been located that code for a two-component regulatory system.

[0017] Non-homologous genes are also found in some lantibiotic gene clusters. The nisL and spal genes encode lipoproteins that are involved in immunity, the pepL gene encodes a membrane-located immunity protein and epiD encodes an enzyme involved in a post-translational modification found only in the C-terminus of epidermin. Several genes of unknown function are also found in the las gene cluster. Commonly, a host organism or cell carrying one or more of the genes (e.g., lanT, lanl, lanA, lanP, lanB and lanC) in the cluster are identified with a shorthand notation such as lanTIAPBC. The above identified genes appear to be different from genes encoding the secretion apparatus for the non-lantibiotic lactococcins that includes two membrane proteins LcnC and LcnD, as discussed in Franke et al., J. Biol. Chem 274: 8484-8490, (1999).

[0018] A database has been assembled for all putative gene products of type A lantibiotic gene clusters. Database searches, multiple sequence alignment and secondary structure prediction have been used to identify conserved sequence segments in the LanB, LanC, LanE, LanF, LanG, LanK, LanP, LanM, LanR and LanT gene products that may be essential for structure and function (Siezen et al., ibid). The database allows for a rapid screening of newly determined sequences in lantibiotic gene clusters.

[0019] However, despite the above cited recent knowledge obtained in the field, attempts to engineer novel lantibiotic-like peptides comprising newly synthesized non-naturally occurring thioether bridges have been scarce, if not rather unsuccessful. In U.S. Pat. No. 5,861,275, nisin-subtilin chimeras have been produced in the Gram-positive Bacillus subtilus, that do not comprise thioether bridges other than those naturally occurring in either nisin or subtillin. In a different application (U.S. Patent Application Publication 2002/0019518), Bacillus subtilus was used to produce a chimeric polypeptide comprising a lantibiotic peptide and a subtilin leader segment, a lantibody, that remains associated within the cell wall.

[0020] A novel thioether bridge in lantibiotic Pep5 has been engineered by Bierbaum et al., Appl. Env. Microbiol. 62: 385-392, (1996) by modifying the Gram-positive bacterium Staphylococcus epidermis 5 by depleting the host organism of the gene cluster pepTIAPBC and replacing pepTIAPBC with a gene cluster peplAPBC, wherein pepA was or was not replaced with mutated structural genes encoding for Pep 5 peptide and wherein amino acids were substituted; genes coding for peptides with substitutions C27A (Cysteine to Alanine at position 27), C33A, A19C, Dhb16A, Dhb20A, K18Dha were generated. The A19C substitution resulted in novel thioether ring formation. The clone corresponding to the A19C substitution produced a small amount of a peptide that showed only little activity. It was thought that prolonged exposure of the peptide to intracellular protease of the producing transformed cell was causal to this disappointing result.

[0021] The K18Dha substitution in Pep 5 resulted in a clone that produced incompletely dehydrated serine at position 18. Kuipers et al. (J. Biol. Chem. 267: 24340-24346, 1992) engineered a new Dhb residue into nisin Z by substituting M17Q/G18T in the lantibiotic, but also obtained incomplete dehydration of the resulting threonine and no additional ring formation. The incomplete dehydration is generally thought to be a result of questionable substrate specificity of the dehydrating enzyme LanB in the transformed cell.

[0022] In short, no large measure of success has yet been achieved in providing novel thioether bridges to lantibiotics in Gram-positive organisms, let alone that engineered thioether bridge formation has been provided to polypeptides of non-lantibiotic descent or by organisms other than Gram-positive bacteria.

[0023] Paul, Leena K et al. (FEMS Microbiol. Lett. 176: 45-50, 1999) recently studied the subtilin leader peptide as a translocation signal in the Gram-negative E. coli. By default, devoid of a specific lantibiotic transporter system and provided a fusion-protein comprising the subtilin leader peptide and part of the mature subtilin attached to E. coli alkaline phosphatase (AP) to study the possible translocation. Although the fusion protein was translocated to the periplasmic side of the cytoplasmic membrane, the fusion protein remained associated with that membrane. In earlier work (Izaguirre & Hansen, Appl. Environ. Microbiol 63: 3965-3971, 1997), the same fusion protein was expressed in the Gram-positive Bacillus subtilis, where the fusion protein was cleaved off from the membrane after successful translocation, but where no dehydration of serines or threonines of the AP polypeptide, let alone thioether bridge formation, was observed. Novak J et al., ASM general meeting 96: 217 (1999), recently provided an E. coli host cell with an ORF (ORFI) encoding an ABC transporter of 341 amino acids thought to be involved in the translocation of the lantibiotic mutacin II in Streptococcus mutans. However, an intact gene product of the ORF1 was not produced in E. coli, whereas a truncated protein of unknown identity or functionality was observed.

[0024] For the purpose of protein engineering of lantibiotics (for an extensive review see, Kuipers et al., Antonie van Leeuwenhoek 69: 161-170, 1996) or for the purpose of engineering newly designed (poly)peptides with lantibiotic-type posttranslational modifications, i.e., for example for pharmaceutical use, much attention has recently (see, e.g., Entian & de Vos, Antoni van Leeuwenhoek supra; Siegers et al., J. Biol. Chem. 271: 1294-12301 (1996); Kiesau et al., J. Bacter. 179: 1475-1481 (1997)) been given to understanding the role of the LanB, LanC (or LanM) and LanT complex, the enzymes thought to be involved in dehydration, thioether ring formation and transportation of the lantibiotic out of the cell, respectively. However, the production of lantibiotic type heterologous proteins has not yet matured satisfactorily.

SUMMARY OF THE INVENTION

[0025] The invention provides a method allowing for the harvest of a desired (poly)peptide produced by a recombinant host cell. The method comprises the steps of a) selecting a recombinant host cell comprising a first nucleic acid comprising a first nucleic acid fragment encoding a leader peptide, and a second nucleic acid fragment encoding the desired (poly)peptide, whereby the first and second nucleic acid fragments are within the same open reading frame of the first nucleic acid and the leader peptide is at least functionally equivalent to a N-terminal leader peptide found with the prepeptide of a lantibiotic; b) selecting the host cell for the presence of a transporter protein commonly known as LanT or a functional equivalent thereof, and c) allowing the translation of the first nucleic acid and harvesting the desired (poly)peptide when the leader peptide (be it bound to or cleaved off from the desired (poly)peptide) is present in the culture medium of the cell.

[0026] In one embodiment, the leader peptide is freely available in the culture medium and is dissociated from host cell structures, such as the membrane or cell wall of the host cell. Considering the poor results obtained in the production of lantibiotic type heterologous proteins, it was realized by the present inventors that until now, insufficient guidance was available on how to determine that a host cell system, thought to be suitably equipped with the machinery to provide for newly designed (poly)peptides with lantibiotic-type posttranslational modifications, was up to the task. As presented herein, it is realized that the presence of leader peptide in the culture medium of such a host cell system is a reliable measure of the capability of the system to produce such desired (poly)peptides.

[0027] It suffices to determine when, for a given host cell system, the presence or time point of appearance of such leader peptide in the culture system can be established to ascertain that actual production of the desired (poly)peptide (be it in modified or in as yet unmodified form) by the host cell system is expected and harvest can begin. The leader peptide can be detected each and every time in a host cell culture system set up to produce the desired (poly)peptide. However, for established cultures systems, harvest can be performed at time-points which may be determined in pilot-experiments with the culture systems.

[0028] The present invention shows that, until now, the field of the study of lantibiotic production has been looking on the wrong side of the cell membrane. The unmodified peptide coupled to its leader peptide can be transported out of the cell without prior modification, and LanB and LanC (or LanM) may act not inside, or outside of the cell (see also, FIG. 4). Now that this guidance for determining the suitability of a host cell culture system is available, as disclosed herein it is particularly useful for the production of desired heterologous (poly)peptides, which are of non-Gram-positive nature (i.e., Gram-negative prokaryotic), or essentially eukaryotic or viral descent.

[0029] Where it was earlier thought that LanB and LanC act in concert to modify the peptide only before it is translocated, it is disclosed herein that after transportation, the as yet unmodified peptide may undergo its specific posttranslational modification extracellularly leading to dehydration and thioether bridge formation, bringing the role of the transporter protein and the function of the leader peptide herein to central stage to modify a (poly)peptide in the lantibiotic way, it being a prerequisite to present the unmodified peptide to the modification machinery. It however also provides for improved production of unmodified or only partly modified heterologous proteins or peptides.

[0030] Thus, the invention also discloses the insight that dehydration of a serine or threonine of a (poly)peptide and subsequent thioether bridge formation can satisfactorily occur when a pre(poly)peptide has been transported out of the host cell wherein it was produced by translation, such as by a transporter protein such as an ABC transporter, or at least functionally corresponding to a transporter commonly identifiable as LanT. Dehydration (and optionally thioether bridge formation) is enzymatically catalyzed by an enzyme or enzymes that are at least functionally corresponding to LanB and/or LanC. The transporter transports the to-be-modified (poly)peptide through the membrane of the host cell where it is positioned in working proximity to extra-cellular located LanB for dehydration.

[0031] In a further embodiment, the invention discloses a method further comprising harvesting the desired (poly)peptide after detecting the presence of the leader peptide (be it bound to or cleaved off from the desired (poly)peptide) in the culture medium or supernatant of the cell (see also, FIG. 5). For detecting the presence, it is desirable that the medium contains a few nutrients, i.e., a so-called minimal medium. Also, it is desired that the presence is detected by harvesting the supernatant by aspirating and dispensing the supernatant into and out of a pipet tip (or other harvesting device) that contains a microvolume bed of affinity chromatography media fixed at the end of the tip that is without dead volume. This procedure is herein called “ziptipping” and allows, after subsequent elution, for relatively pure presentation of desired (poly)peptide for further analysis.

[0032] By using the combination of growth in minimal medium and ziptipping the supernatant of the culture, samples of sufficient purity can be obtained that are well suited for detection or analysis by high resolution MALDI-TOFMS. This allows a most significant measurement of leader peptide and, thus, prediction of desired (poly)peptide content, suitability of the host cell system used and suitable time-of-harvest of desired (poly)peptide. Detection of the leader peptide can, thus be used to ascertain the export of (poly)peptide coupled to this lantibiotic leader, such as in those cases where the leader peptidase acts extracellularly.

[0033] In a further embodiment, the invention discloses a method wherein the host cell producing the desired (poly)peptide is essentially devoid of leader peptidase (lanP) activity, thus allowing the production and extracellular harvest of desired (poly)peptide that is essentially still coupled to its leader peptide. In this way, potential intracellular toxic effects of desired (poly)peptide provided with thioether bridges are reduced. It suffices to design a leader peptide that cannot be cleaved by the leader peptidase of the host cell used. In both cases, the desired (poly)peptide can later be obtained free from the leader peptide, by, e.g., specific proteolytic cleavage using added lanP or another suitable protease capable of cleaving the leader peptide from the desired (poly)peptide.

[0034] It is also herein disclosed that in a desired (poly)peptide, a serine or serines that are N-terminally located from cysteines are dehydrated and coupled to more C-terminally located cysteines. As further exemplified herein, a (poly)peptide sequence with a serine and a cysteine “S-C” contains (after thioether bridge formation) alanines in the positions of the serine and cysteine: “A-A.” These alanines are coupled by, aside from the peptide backbone, a thioether bridge.

[0035] Generally, a method as provided herein allows a high detection level for measuring levels of (lantibiotic) (poly)peptides directly from the culture supernatant, considering that the ratio leader peptide versus desired (poly)peptide is essentially 1:1. Such guidance allows for efficient culture methods to produce the desired polypeptide and allows for determining appropriate or optimal time-points at which the culture may be harvested.

[0036] In another embodiment, the invention discloses a method and a (poly)peptide wherein the desired (poly)peptide is selected from the group of peptide hormones, fragments of the peptide hormones or analogues from the peptide hormones originating from hypophysis and/or peptide hormones with similar actions including vasopressin, terlipressin, desmopressin, cispressin, oxytocin, adrenocorticotropic hormone and human growth hormone.

[0037] In yet another embodiment, the invention discloses a method and a (poly)peptide wherein the desired (poly)peptide is selected from the group of peptide hormones, fragments of the peptide hormones or analogues from the peptide hormones originating from hypothalamus, and/or peptide hormones with similar actions such as gonadoliberinII, luteinizing hormone, releasing hormone, leuprolide, and other synthetic analogues of LHRH including gonadoreline, gosereline, busereline, leuproreline, nafareline, triptoreline, cetrorelix, somatostatin, analogues of somatostatin, such as Octreotide, Somatostatine, corticotropin inhibiting peptide, corticotropin-release factor, urocortin, urotensin II and growth hormone release factor. Specific LHRH-peptide analogues that are provided with a thioether ring structure is disclosed herein (see, Table 1).

[0038] Such distinct LHRH1 and LHRH2 and thioether bridge containing analogs are, for example, based on the peptide sequence QHWSYGLRPG (LHRHI) (SEQ ID NO:_or QHWSHGWYPG (LHRH2) (SEQ ID NO:_). Such peptide sequences may be generated via recombinant means as described herein linked to a leader peptide, such as the nisin leader peptide STKDFNLDLVSVSKKDSGASPR (SEQ ID NO:_. As disclosed herein, particular LHRH1- and LHRH2 thioether analogs were synthesized by exploiting the lantibiotic enzymes of the nisin producing Lactococcus lactis strain NZ9700. These enzymes involve a transporter molecule, NisT, a dehydrating enzyme, NisB that dehydrates serines and threonines and an enzyme, N is C that couples the dehydrated serines and threonines to cysteines giving the thioether ring.

[0039] Thioether bridged peptide-analogues were, for example, generated by cloning on a plasmid a nucleotide sequence that codes for a specific LHRH mutant behind the nisin leader (the particular LHRH analog coding sequence being followed by a stop codon).

[0040] In another embodiment, the invention discloses a method and a (poly)peptide wherein the desired (poly)peptide is selected from the group of peptide hormones, fragments of the peptide hormones or analogues from the peptide hormones originating from adrenocortex, adrenal medulla, kidney and heart and/or peptide hormones with similar actions such as adrenomedullin, angiotensin I, atrial natriuretic factor, bradykinin, brain natriuretic peptide, C-type natriuretic peptide and vasonatrin peptide.

[0041] In a further embodiment, the invention discloses a method and (poly)peptide wherein the desired (poly)peptide is selected from the group consisting of peptide hormones, fragments of the peptide hormones or analogues from the peptide hormones originating from other endocrine/exocrine organs such as the pancreas, thyroid, and parathyroid and/or peptide hormones with similar actions such as calcitonin, osteocalcin, glucagon, insulin, insulin-like growth factor-I or II, parathormone, and cholecystokinin.

[0042] In another embodiment, the invention disclosed a method and a (poly)peptide wherein the desired (poly)peptide is selected from the group of peptide hormones, fragments of the peptide hormones or (synthetic) analogues from the peptide hormones with antibiotic (-like) activity and/or peptide hormones with similar actions such as dermaseptin, defensin I, bombinin-like peptide, histatin-5, indolicidin, magainin-1 and ceratotoxin A.

[0043] In one embodiment, the invention discloses a method and a (poly)peptide wherein the desired (poly)peptide is selected from the group of biological active peptides, fragments of the biological active peptides and/or hormones or analogues from the biological active peptides and/or peptides with similar actions, such as exendin-3, secretin, human pancreatic polypeptide, peptide YY, gastric inhibitory polypeptide, big gastrin-I, pentagastrin, gastrin releasing peptide, motilin, neuropeptide Y, galanin, alpha-neurokinin, deltorphin, alpha-endorphin, beta-endorphin, leu-enkephalin, met-enkephalin, allatostatin I, anthopleurin-A, anti-inflammatory peptide 1, delta sleep inducing peptide, alpha-dendrotoxin, eledoisin, echistatin, small cardioactive peptide A or B, cerebellin, charybdotoxin, conopressin G, conotoxin EI, corazonin, experimental allergic encephalitogenic peptide, experimental autoimmune encephalomyelitis complementary peptide, tocinoic acid/pressinoic acid, brain derived acidic fibroblast growth factor (1-11), brain derived acidic fibroblast growth factor (102-111), brain derived basic fibroblast growth factor (1-24), fibrinogen binding inhibitor peptide, fibroblast growth factor inhibitory peptide and transforming growth factor alpha.

[0044] In a further embodiment, the invention disclosed a method and a (poly)peptide wherein the desired (poly)peptide is selected from the group of biological active peptides, fragments of the biological active peptides and/or hormones or analogues from the biological active peptides and/or peptides with similar actions such as guanylin, helospectin I, hepatitis B surface antigen fragment, intercellular adhesion molecule, tachyplesin I, HIV (gp120) antigenic peptide fragment, HIV (gp 41) antigenic peptide 1 fragment, HIV (gp41) antigenic peptide 5, HIV protease inhibitors, IGF II 69-84, interleukin-8 fragment, interleukin-2 fragment(60-70), leucokinin I, leukopyrokinin, mastoparan, melanin concentrating hormone, melittin, and ras oncogene related peptides.

[0045] Considering that lanthionine formation between, for example, dehydrobutyrine and cysteine is energetically possible at room temperature and can also occur spontaneously, the transported (poly)peptide can form thioether bridges spontaneously or where it is positioned in working proximity to extra-cellular located LanC for subsequent enzymatically induced thioether bridge formation. Alternatively, the transporter transports the to-be-modified polypeptide through the membrane of the host cell where it is positioned in working proximity to extra-cellular located LanM for dehydration and subsequent thioether bridge formation.

[0046] The invention discloses a method from which several fields can benefit. In short, the invention discloses use of lantibiotic exporters (LanT) for export of peptides or proteins which may have been converted by lantibiotic enzyme(s), in particular, enabling extracellular formation of lanthionines and other rings. Amino acids are able to form short sequences (peptides) and longer sequences (proteins). Peptides and proteins (herein also referred to as “(poly)peptides”) are both important classes of biomolecules for nutrition, for pest control and for fighting disease. The lantibiotics importance is illustrated by the number and range of therapies based on the antibiotics recently created by the biochemical and pharmaceutical industries. There is also a large number of protein and peptide based pharmaceuticals and it should also be understood that the use of therapeutic pharmaceuticals is not limited to humans, but also extends to animal, plant and other biosystems. However, the manufacture of many present and potential protein or peptide pharmaceuticals has limitations since many protein or peptide pharmaceuticals are prepared in living cells (in vivo), but the cells must be ruptured or lysed (killed) and the contents extracted, separated, and purified in order to provide a given quantity of the peptide or protein. Since this is a complex process, the amount of any desired peptide or protein in any cell at any time is limited.

[0047] The present invention bypasses this problem by introducing a factor into the living cells which allows the cells to continuously transport proteins or peptides and export them through the cell wall, so that the product produced intercellularly may be collected extracellularly and the cells may remain vital and continue to produce materials. It is evident that this permits a substantially easier and higher rate of production of the desired products.

[0048] Since it is known that the Lan T transporter or functional equivalent thereof acts on unmodified (poly)peptide to which the leader is still attached, one field relates to the expression and production of recombinant (poly)peptides, other than bacterial descent, and relates to expression and/or production of a (poly)peptide of eukaryotic (i.e., plant, animal or fungal origin) or viral descent. Such peptides are widely produced by recombinant means for use in the production of pharmaceuticals, such as active compounds including a (poly)peptide hormone, or cytokine, or antibody fragment, or biopesticide agent, or as antigens for a vaccine or immunogenic composition. It is now possible to use a lantibiotic-type transporter system to export peptides of eukaryotic, viral, and of bacterial (prokaryotic) descent.

[0049] In one embodiment, the invention disclosed a method that allows for extra-cellular harvest of a desired (poly)peptide (which may be out of the realm of bacterial antibiotics or even be of eukaryotic or viral descent) produced by a recombinant host cell. The method comprises a) selecting a recombinant host cell comprising or provided with a first recombinant nucleic acid having a first nucleic acid fragment encoding a leader peptide and a second nucleic acid fragment encoding the desired (poly)peptide wherein the first and second nucleic acid fragments are within the same open reading frame of the first nucleic acid and the leader peptide is at least functionally equivalent to a N-terminal leader peptide found with the prepeptide of a lantibiotic; and b) selecting the host cell for the presence of a lantibiotic transporter protein commonly known as LanT, (such a host cell can be a Gram-positive or Gram-negative prokaryote or an eukaryote provided with such a transporter) and allowing for the translation of the first nucleic acid. In this embodiment, the cell is essentially devoid of leader peptidase activity, or comprises leader peptidase that cannot cleave the specific leader pep tide used. Such a host cell may be obtained by deleting or functionally deleting, the lan P gene.

[0050] In another embodiment, the invention discloses a method allowing for extra-cellular harvest of a desired (poly)peptide which has not undergone intra-cellular post-translational modification comprising dehydration of a serine or a threonine and/or thioether bridge formation. As described herein, it is demonstrated how to obtain nisin prepeptide (i.e., nisin leader and unmodified nisin) extracellularly. The nisin prepeptide was obtained using a host cell selected for the presence of two plasmids, one plasmid encoding the nisin prepeptide and one plasmid encoding NisT, wherein the host cell is further characterized by at least the functional absence of at least one of the other gene products derived from the N is-gene cluster, such as NisB, NisC, or NisP.

[0051] The invention thus discloses a (poly)peptide harvestable after the (poly)peptide has been transported from the producing host cell, obviating the need to lyse or disrupt the host cells to harvest the (poly)peptide. Alternatively, the desired polypeptide may be harvested from within the cell. Cultures of cells provided with the transporter protein can be kept alive and in use, wherein the desired (poly)peptide can be harvested from the supernatant of spun-down host cells. The host cells need not be of Gram-positive descent per se, since Gram-negative prokaryotes or even eukaryotes can be provided with a properly placed transporter. Thus, the gamut of expression systems that can be used to express and produce a desired (poly)peptide is enhanced.

[0052] Furthermore, the invention discloses a method allowing for extra-cellular modification of a desired (poly)peptide produced by a recombinant host cell. The method comprises a) selecting a recombinant host cell comprising a first nucleic acid comprising a first nucleic acid fragment encoding a leader peptide and a second nucleic acid fragment encoding the desired (poly)peptide, wherein the first and second nucleic acid fragments are within the same open reading frame of the first nucleic acid and the leader peptide is at least functionally equivalent to a N-terminal leader peptide found with the prepeptide of a wild-type lantibiotic; b) selecting the host cell for the presence of a transporter protein such as LanT, or a functional equivalent thereof; c) selecting the host cell for the presence of an essentially extra-cellular protein (such as LanB, LanC or LanM) capable of providing post-translational modification; and d) allowing for the translation of the first nucleic acid.

[0053] In one embodiment, the invention discloses a method allowing for extra-cellular modification of a desired (poly)peptide which has not undergone intra-cellular post-translational modification comprising dehydration of a serine or a threonine and/or thioether bridge formation. In this embodiment, the essentially extra-cellular, albeit preferably cell-surface-bound, enzyme is capable of dehydrating a serine or a threonine, or is capable of providing for thioether bridge formation.

[0054] Further, the invention disclosed a method for lantibiotic-type modification of non-lantibiotic polypeptides, even when the (poly)peptide is of essentially eukaryotic or viral descent. This is useful for altering various characteristics of such products, for example related to stability or pharmacological profiles of useful polypeptides. It is of course useful to use a leader peptide or functional equivalents thereof.

[0055] Furthermore, the invention discloses a method allowing for extra-cellular modification of a desired (poly)peptide produced by a recombinant host cell, wherein the modification comprises thioether bridge formation. The location of serines, threonines or cysteines in the desired (poly)peptide may be selected such that thioether ring formation by the enzyme system selected follows naturally. For example, serine and threonine dehydration, may be followed by thioether ring formation by coupling to cysteines as follows. In the case of lantibiotic enzymes belonging to the type B lantibiotics, ring formation may occur from dehydrated serines/threonines to more C-terminally or to more N-terminally located cysteines. In the case of lantibiotic enzymes belonging to type A lantibiotics, ring formation may occur from dehydrated serines/threonines to more C-terminally located cysteines. Conversion by enzymes belonging to type A lantibiotics occurs in time from N to C-terminal direction from dehydrated serines/threonines to the nearest more C-terminally located available cysteine. In the case of enzymes belonging to type A lantibiotics, a preferential distance of one to four amino acids to available cysteines is disclosed to form lanthionines. It is possible that 2 to 3 amino acids are between a dehydrated serine/threonine on the one hand and a cysteine on the other hand, wherein the optimal distance is two amino acids.

[0056] As disclosed in Table 1, peptides with the above preferred distances for optimal thioetherbridge formation may be selected. At distances between four and thirteen amino acids, lanthionine formation can occur but is less efficient. At these distances, dehydration of serines and threonines without subsequent lanthionine formation and next to no dehydration of serine/threonine occurs. It is possible to have flanking regions of serines and threonines that allow activity of the dehydrating enzyme. To achieve this, at least the six to eight amino acids (three to four on each side) surrounding dehydrated serines/threonines are substantially hydrophobic. At each of these positions in 40-80% of the cases, the amino acid is hydrophobic, in 20-40% hydrophilic, of which in 5-15% positively charged. For best efficiency, negatively charged amino acids rarely occur. The composition of the flanking regions on the desired (poly)peptide may differ from the one of serine and threonine in lantibiotic-type leader peptides. In leader peptides, serines and threonines occur, but are not dehydrated, whereas cysteines do not occur. The six to eight positions most proximate to leader serines/threonines contain less hydrophobic amino acids and more negatively charged amino acid than in positions around propeptide serine/threonine per position around 20-40% of the cases the amino acid is hydrophobic and around 20% of the cases a negatively charged amino acid is disclosed.

[0057] With respect to the peptidase cleavage site, at least two types of leader peptides exist from which guidance can be obtained to design better cleavable peptides or proteins. One type used the subtilisin-like serine protease LanP for cleavage, which occurs after Pro-Gin, Pro-Arg, Ala-Asp, or Ala-Glu. In the case of nisin, a positively charged residue at position −1 and a hydrophobic residue at position −4 appears necessary for interaction with N is P. This subtilisin-like serine protease LanP acts on the prepeptides of Pep5, Epilancin K7, Nisin A, Nisin-Z, Epidennin, and Gallidermin.

[0058] In the other type, the leader peptides are cleaved after Gly-Gly, Gly-Ala or Gly-Ser sequences. The latter holds for many other non lantibiotic bacteriocin leader peptides. The subtilisin like proteases are not known to cleave these sequences and a different type of protease is cleaving these leader peptides. It has been shown that in some bacteriocins, both lantibiotic and non lantibiotic this second protease is a domain of the transport system LanT. This type of leader peptidase acts on prepeptides of Lacticin-481, Variacin, Mutacin-II, Streptococcin-A-FF22, Salivaricin-A, and Sublancin.

[0059] In addition, a two component lantibiotic, Cytolysin-LL/Cytolysin LS, exists of which each component is cleaved twice. One cleavage is by the “double glycine type” and the other cleavage is by the subtilisin-like peptidase.

[0060] The invention further disclosed a method for the modification of a desired polypeptide wherein the host cell is a Gram-negative prokaryote or a eukaryote. The invention also discloses a (poly)peptide modified, using a method of the invention.

[0061] The invention further discloses a host cell, such as a Gram-negative prokaryote or an eukaryote, provided with a recombinant nucleic acid comprising a first nucleic acid fragment encoding a leader peptide and a second nucleic acid fragment encoding a desired (poly)peptide, wherein the first and second nucleic acid fragments are within the same open reading frame of the first nucleic acid and the leader peptide is at least functionally equivalent to a N-terminal leader peptide found with the prepeptide of a lantibiotic. In one embodiment, a host cell is disclosed wherein the desired (poly)peptide is of essentially eukaryotic or viral descent, such as those disclosed in Table 1 and/or wherein the leader peptide is one of those disclosed in Table 2.

[0062] The invention also discloses a host cell provided with or selected for the presence of at least a LanT protein, or a functional equivalent thereof, wherein the host cell is further characterized by at least the functional absence of at least one of the other gene products derived from the Lan-gene cluster, such as LanB, LanC, (or a functional part from LanM) or LanP. The host cell comprises a Gram-negative prokaryote or a eukaryote.

[0063] The host cell disclosed herein has a specific use in a method of producing a (poly)peptide for harvest or modification, as disclosed herein above. For the purpose of harvest, LanT is present, but LanB and/or Lan C (or LanM) are absent, or at least functionally absent, in that they are hampered in binding to or interfering with the polypeptide to be harvested. For the purpose of modification, LanT and an essentially extra-cellular protein allowing extra-cellular modification is present. The extra-cellular protein may be LanB, Lan C, LanM, or an N-terminal) LanM fragment having LanB function, on a C-terminal LanM fragment having LanC function. A further extended or even complete lantibiotic gene-product cluster is preferably not, at least not functionally present.

[0064] The invention further discloses a recombinant nucleic acid comprising a first nucleic acid fragment encoding a leader peptide and a second nucleic acid fragment encoding a desired (poly)peptide, wherein the first and second nucleic acid fragments are within the same open reading frame of the first nucleic acid and the leader peptide is at least functionally equivalent to a N-terminal leader peptide found with the prepeptide of a lantibiotic, and wherein the desired (poly)peptide is of essentially eukaryotic or viral descent.

[0065] The invention also disclosed a proteinaceous substance comprising a polypeptide encoded by a nucleic acid. Such a proteinaceous substance can be harvested, or modified as previously disclosed herein. Use of a host cell, nucleic acid or proteinaceous substance of the present invention for the production of a desired (poly)peptide, and its use in producing a pharmaceutical composition are herein also disclosed. In particular, the invention discloses a (poly)peptide of Gram-negative prokaryotic, viral or eukaryotic descent (such as those of Table 1) wherein a serine or threonine has been dehydrated or which has been provided with a thioether bridge. The advantage of such a polypeptide lays in the creation of variants of known peptides or protein based drugs, where the dose or frequency of administration can be reduced to lower treatment cost, treatment time, and patient inconvenience.

[0066] The creation of variants of new protein or peptide based drugs, where the drug may not have been effective or admitted for use in an unstabilized form, and the creation of new therapeutic entities per se is further explained in the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0067]
FIG. 1: Peptide structure of mature nisin and subtilin.

[0068]
FIG. 2: Genomic organization of genes involved in subtilin and nisin biosynthesis.

[0069]
FIG. 3: Model for nisin biosynthesis wherein modification occurs intra-cellularly.

[0070]
FIG. 4: Model for nisin biosynthesis wherein modification occurs extra-cellularly. Nisin prepeptide is exported by NisT (“T”), dehydrated by extracellular NisB (B) and subjected to thioether ring closure by extracellular N is C(C). Extracellular leader peptidase, N is P(P) cleaves of the leader peptide. Nisin interacts with a membrane bound histidine kinase NisK (K) which phosphorylates a response regulator N is R(R), which in its turn switches on transcription of the nis-genes (+, +). The producer cells are protected against nisin by the concerted action of the lipopeptide NisI and the transport system NisEFG.

[0071]
FIG. 5: Detection of lantibiotic leader peptide from the culture medium by MALDI-TOFMS. By using the combination of growth in minimal medium and ziptipping the supernatant of the culture, samples of sufficient purity were obtained for high resolution MALDI-TOFMS. This allowed most significant measurement of nisin leader peptide. The detection of lantibiotic leader peptide can be used to ascertain the export of (poly)peptide coupled to this lantibiotic leader, i.e., in those cases where the leader peptidase acts extracellularly. Generally the method allows a high detection level for measuring (lantibiotic) (poly)peptides directly from the culture supernatant.

[0072]
FIG. 6: The NisT transporter can transport unmodified nisin prepeptide. Lactococcus lactis strain NZ9000 with plasmids coding for the transporter, NisT and for the nisA product, nisin prepeptide, was grown in M17 medium and transcription of nisT and nisA was induced in minimal medium. Samples were prepared by ziptipping the culture supernatant and analyzed by MALDI TOFMS. A mass peak (theoretical mass of 5,831.8 Da) corresponding to unmodified nisin prepeptide was measured. A second peak has a mass consistent with the nisin prepeptide with methionine of position 1 still attached to it (theoretical mass of 5,963 Da). This demonstrates that NisT is sufficient for the transport of unmodified prepeptide to the exterior of the cell. For detailed information see example 1.

[0073]
FIG. 7A: MALDI TOFMS analysis of ziptipped minimal medium supernatant from NZ9700+pNG-nisinleader-(L7C)LHRH. The peak at 1,169.9 Da corresponds to thioether ring containing LHRH and the peak of 2,351.8 to the nisin leader. Secretion of thioether ring stabilized (L7C)LHRH by Lactococcus lactis NZ9700. L7C-LHRH (a luteinizing hormone release hormone mutant) was fused to the nisin leader peptide by cloning the L7C-LHRH coding sequence behind the nisin leader in an expression vector. The lactococcal strain NZ9700 (a nisin producing L. lactis strain) is used for expression of the leader peptide-(L7C)LHRH fusion. The enzyme NisB dehydrates serine at position 4 and this dehydrated residue is coupled to the cysteine of position 7 by enzyme N is C to form a thioether bridge. The leader peptidase N is P cleaves of the leader peptide.

[0074]
FIG. 7B: Structure of the nisin leader and thioether LHRH.

[0075]
FIG. 8: Suitable LHRH analogues.

DETAILED DESCRIPTION

[0076] Lantibiotic enzymes are special. There is no strong homology with other enzymes. DNA and amino acid sequences of many lantibiotic enzymes are known, but no structures have been determined. The genes involved in the biosynthesis, processing and export of lantibiotics are present in a lanA B C/M (D) P R K T F E G I cluster. No uniform order or orientation of the genes in the different clusters exists indicating that rearrangements have occurred in the evolution.

[0077] Lanthionines are the most typical post-translationally formed residues in antibiotics. They are formed via two steps. First, propeptide serines and threonines are dehydrated giving rise to dehydro-alanines and dehydrobutyrines, respectively. LanB has been proposed to play a role in dehydration, since it has a weak homology to IIvA, a threonine dehydratase from E. coli. It has also been shown that overexpression of NisB increases the occurrence of dehydration of serine 33 in nisin A, from 10% in the normal situation up to 50% in the case of overexpressed NisB. The LanB protein includes about 1,000 residues. LanB is a membrane associated protein.

[0078] LanC is thought to be responsible for the subsequent addition of cysteine SH groups to the dehydro amino acids, which results in the thioether rings. In the case of PepC, experimental data support this idea. Known LanC proteins include about 400 residues. In type A lantibiotics, the N-terminal part of lanthionine and methyllanthionine residues are formed by the dehydroalanine or dehydrobutyrine residues, whereas the C-terminal half is formed by the cysteine residues. Lanthionine formation between dehydrobutyrine and cysteine is energetically possible at room temperature and can also occur spontaneously.

[0079] Lantibiotic maturation and secretion is thought to occur at membrane-associated multimeric lanthionine synthetase complex including proteins LanB, LanC and the ABC transporter molecules LanT. At least two molecules of LanC and two molecules of LanT are part of the modification and transport complex. Some lantibiotics do not have the lanB gene, but have a larger lanM gene, whose product has some C-terminal homology with the lanC gene product. Since no lanB homologue is present in LanM producing clusters, the N-terminal part of the LanM protein may perform the dehydration reaction typically performed by LanB.

[0080] Lantibiotics may be chemically synthesized, but the process is extremely costly and time consuming. Several mutant lantibiotics containing amino acid substitutions have been obtained by genetic engineering. However, despite many studies, only in the lantibiotic Pep5 one lanthionine ring has a new position been obtained.

[0081] The lantibiotic export systems, LanT, (whose sequences are known) are thought to be dedicated for the transport of the fully modified lantibiotic. The two enzymes involved in the lanthionine formation in nisin (NisB and N is C) have been reported to be located intracellularly in a NisBCT membrane associated complex (Siegers et al., 1996). Such intracellular localization suggests that the prepeptides are dehydrated by LanB where rings are formed by LanC and followed by export by LanT. Further, if the thioether ring forming enzymes, NisB (which is responsible for dehydration, the first step in ring formation) or N is C (responsible for ring formation between dehydrated residues and cysteines) are inactivated by an in frame deletion of 61 aa or by plasmid insertion respectively, no peptide is exported. The latter suggests that absence of (methyl)lanthionines prevent export.

[0082] However, it has been measured that prepeptide, such as nisin prepeptide, can be transported through the nisin transporter. This result was obtained using a strain with two plasmids, one plasmid coding for the nisin prepeptide and one plasmid coding for the nisin transporter. No prepeptide production was observed in a control experiment in which a strain with only the plasmid coding for the prepeptide was used. Some lantibiotics contain dehydrated serines/threonines that do not participate in thioether ring formation. From the latter, in combination with the observation that an unmodified peptide is exported, it may also be theorized that translocation of prepeptide without thioether rings, but with dehydrated residues, is possible. It is known that the second step in lanthionine ring formation is less difficult to achieve since it can also occur spontaneously at room temperature. After production of prepeptides with dehydrated residues, lanthionine rings can be formed extracellularly.

[0083] The finding disclosed herein provides the possibility to make new lantibiotics and, thus, to stabilize peptides/proteins by thioether rings, D-alanines or other residues formed by lantibiotic enzymes. Before (methyl) lanthionine formation, the distance of dehydrated to cysteines is typically 2-5 residues, but larger distances are possible. (Methyl)lanthionines can be formed from dehydrated residues to more N-terminally located or to more C-terminally located cysteines. In addition, the lantibiotic transport system can be used for the export of other proteins by inserting the sequence coding for the leader peptide in front of the protein DNA sequence.

[0084] Several uses are foreseen. For instance, peptide/protein drugs that are rapidly degraded in the blood plasma can be protected from proteolysis by thioether rings. Also, new lantibiotics can be used as antibiotics, especially against Gram-positive bacteria. This is useful since there is a growing and spreading resistance against classical antibiotics. New lantibiotics can be also be used as food additives to prevent bacterial growth and increase the shelf life of food products. Mastering the enzymatic synthesis of thioether rings further furnishes the possibility of synthesizing a broad variety of new antimicrobial peptides, which gives many possibilities to circumvent resistance. Lantibiotics have a variety of antimicrobial activities including membrane permeabilization, inhibition of cell wall synthesis, modulation of enzyme activities, and inhibition of outgrowth of spores. New lantibiotic-type peptides or proteins have modulated activity or a different spectrum of activity. A selection of such peptides or proteins is described herein in the examples given below.

EXAMPLE 1

The NisT Transporter can Transport Unmodified Nisin Prepeptide.

[0085] This example involves a L. lactis strain that lacks the entire chromosomal nisin gene cluster, but simultaneously produces plasmid encoded NisT and the NisA prepeptide. Unmodified NisA can be found in the culture supernatant, which demonstrates that NisT is sufficient for the transport of unmodified prepeptides to the exterior of the cell.

[0086] Materials and Methods. Use for the nisin inducible expression of nisT in L. lactis a pNZ8048 (Kuipers et al. 1997, Tibtech. 15: 135-140) derived plasmid. The nisT gene is amplified using primers NisT.fw (5′-CGG TCT CCC ATG GAT GAA GTG AAA GAA TTC ACA TCA AAA C (SEQ ID NO:)) and NisT.rev (5′-CGG TCT CTC TAG ATT ATT CAT CAT TAT CCT CAT ATT GCT CTG (SEQ ID NO:)) with chromosomal DNA of NZ9700 (a nisin producing L. lactis strain; Kuipers et al. 1997, Tibtech. 15: 135-140) as template. PCR conditions used include: 5 min 94° C., 30 times (30s 94° C., 30s 50° C., 3 min 72° C.), 10 min 72° C. The PCR products are purified with the Roche PCR-isolation kit. The expression vector is digested with NcoI/XbaI and the PCR fragments are digested with Eco31I (underlined in the primers, the sticky ends it generates are indicated in italics and are compatible with NcoI and XhaI) and the fragments are subsequently ligated using T4 ligase (Roche). The resulting plasmid is designated pNG-nisT and contains a chloramphenicol (Cm) resistance gene as a selection marker.

[0087] Use for the nisin inducible production of the NisA prepeptide in L. lactis a variant of pNZ8048 that contains an erythromycin (Em) resistance selection marker instead of a Cm marker. The nisA gene is amplified using primers NisA.fw (5′-CGG TCT CTC ATG AGT ACA AAA GAT TTT AAC TTG GAT TTG G (SEQ ID NO:)) and NisA.rev (5′-TAT ATG GAT CCT TTG CTT ACG TGA ATA CTA CAA TGA CAA G (SEQ ID NO:)) and chromosomal DNA of strain NZ9700 as a template under the same conditions as described above. The PCR product is purified with the Roche PCR-isolation kit. The expression vector is digested with NcoI/BamHI and the PCR fragment is digested with Eco31I and BamHI (underlined in the primers, the sticky ends it generates are indicated in italics and are compatible with NcoI and BamHlI) and the fragments are subsequently ligated using T4 ligase (Roche). The resulting plasmid is designated pNG-nisA.

[0088]

L. lactis
strains NZ9000 or PA1001 (a NZ9000 derivative lacking AcmA activity to abolish cell lysis (Buist et al. 1995, J. Bacteriol. 177: 1554-1563) and lacking HtrA to diminish extracellular proteolytic activity (Poquet et al. 2000, Mol. Microbiol. 35: 1042-1051)) with both pNG-nisT (Cm) and pNG-nisA (Em) are grown in M17-based medium (Terzaghi and Sandine, Appl. Microbiol., 29: 807-813 (1975)) to an OD600 of 0.4. The cells are collected by centrifugation and resuspended in the same volume of Minimal Medium (Jensen and Hammer, 1993, Appl. Environ. Microbiol. 59: 4363-4366) and expression of NisT and NisA prepeptide is induced by addition of nisin as described (Kuipers et al. 1997, Tibtech. 15: 135-140). After overnight induction and subsequent centrifugation, the culture supernatants are pipeted up and down in C18 ZIPTIPS™ (Millipore) two times using 10 μl 50% acetonitril, followed by two times using 10 μl demineralized water, followed by eight times using 10 μl supernatant. The culture supernatants are then washed two times with 10 μl demineralized water, followed by elution two times with 10 ul 50% acetonitril containing 0.1% TFA. The final eluent is vacuum dried and stored at −20° C. until analysis by mass spectrometry. Prior to analysis, the dry material is resuspended in 2.5 μl of 50% acetonitril containing 0.1% TFA and 1 μl is applied to the target. After drying, 1 μl of matrix (10 mg/ml alpha-cyano-4-hydroxycinnamic acid completely dissolved (by mildly heating and vortexing) in 50% acetonitril containing 0.1% TFA) is applied to the target. The following MALDI-TOFMS (linear mode) laser settings were used: 100% coarse energy, 50% fine, source 20 KV, extra 19800, force 15000, suppression 500, pulse time 40, pulse voltage 2200, sampling rate 500 MHz, sensitivity 50 mV, shots 15.

[0089] Results: Analyze culture-supernatants of the following induced cultures and analyze by MALDI-TOFMS:

[0090] NZ9000 (or PA1001);

[0091] NZ9000 (pNG-nisA) (or PA1001(pNG-nisA)); and

[0092] NZ9000 (pNG-nisA+pNG-nisT) or (PA1001(pNG-nisA+pNG-nisT)).

[0093] No peaks were observed in samples derived from cultures A and B. Two main peaks were observed in sample C. The first peak is close to, or identical, to 5832.8 Da which corresponds to the unmodified nisin prepeptide: (5831.8 plus 1 proton). The second peak was about 130 Da higher mass than the first peak, which might correspond to the nisin prepeptide with two zinc atoms (Bierbaum, G. 1999, Ed. J. W. Kelly, Amino acids, Peptides, Porphyrins, Alkaloids 4, 275-301. Elsevier, Comprehensive Natural Products Chemistry, Eds. D. Barton, K. Nakanishi & O. Meth-Cohn) or the nisin prepeptide with the methionine in position 1 still present. This first peak is consistent with unmodified nisin prepeptide being transported by the nisin transporter NisT. This result demonstrates that NisT is sufficient for the transport of the nisin prepeptide and that modification is not required prior to transport.

EXAMPLE 2

Secretion of the Hydrophobin SC3 of the Fungus Schizophyllum commune by Lactococcus Lactis Through the use of the Nisin A Leader Peptide and the Nisin Transport System NisT.

[0094] To study the role of the nisin A leader peptide in secretion through NisT in L. lactis, a strain that lacks the entire chromosomal nisin gene cluster was constructed, but produces simultaneously encoded plasmid NisT and the fungal hydrophobin SC3 fused to the NisA leader peptide. The fusion product is present in the culture supernatant, which demonstrates that the NisA leader peptide can be used to drive the transport of polypeptides other than nisin derivatives through the NisT transporter.

[0095] Materials and methods. A NisA leaderpeptide-SC3 fusion was constructed in a pNZ8048 expression vector that contains a c-myc epitope, which can be used for the detection of expressed polypeptides. For that purpose, a BglII-NcoI fragment upstream the c-myc epitope in the vector was replaced by a BglII-NcoI fragment of the NZ9700 chromosomal DNA that contains the nisA promoter and the nisA leader peptide (ending at amino acid sequence: . . . GASPR). A chromosomal fragment was obtained by PCR amplification using primers: NisA.fw3 (5′-CGG TCT CAG ATC AAT AGA AAC ATT AAC AAA TCT AAA ACA G (SEQ ID NO:)) and NisA.rev3 (5′-CGG TCT CA CAT GGA GCG TGG TGA TGC ACC TGA ATC (SEQ ID NO:)). The same PCR conditions used in Example 1 were applied. The PCR product was purified with the Roche PCR-isolation kit and digested with Eco31I (sites are underlined in the primer sequences). This process results in a PCR fragment with BglII-NcoI sticky ends (indicated in italics in the primer sequences). The BglII-NcoI digested vector and the cut PCR fragment were ligated and the newly obtained vector with the NisA leader peptide sequence upstream the c-myc epitope sequence was designated pNG-nisl. The SC3 gene was PCR amplified using primers SC3.fw2 (5′-CGG TCT CTA ATT CTT GGT GGC CAC CCG GGC ACG (SEQ ID NO:)) and SC3.rev2 (5′-CGG TCT CTA GCT CTT AGA GGA TGT TGA TGG GGG TGC (SEQ ID NO:)) with cDNA isolated from Schizophyllum commune as a template. The PCR product was purified with the Roche PCR-isolation kit. The vector pNG-nisl was digested with EcoRI and HindIII. The PCR product was cut with Eco31I (underlined in the primer sequences) to generate EcoRI and HindIII sticky ends (in italics in the primer sequences). The two fragments were ligated and fused in the resulting plasmid, pNG-nisl-SC3, SC3, in frame, downstream from the NisA leader peptide and the c-myc epitope.

[0096] Plasmid pNG-nisT (Example 1) and pNG-nisl-SC3 were established together in L. lactis strain NZ9000 by Electroporation (Holo and Nes, 1995, Methods Mol. Biol. 47: 195-199). Expression was induced and secreted peptides were purified as described in Example 1. MALDI-TOFMS analysis was performed as described in Example 1 with the following modifications: 7 shots instead of 15 and suppression at 1,000 instead of 500. The same was performed for the control strains NZ9000, NZ9000(pNG-nisl-SC3).

[0097] Results. Culture-supernatants of the following induced cultures were analyzed by MALDI-TOFMS:

[0098] A. NZ9000;

[0099] B. NZ9000(pNG-nisl-SC3); and

[0100] C. NZ9000(pNG-nisl-SC3+pNG-nisT).

[0101] No peaks were observed in samples derived from cultures A and B. In sample C, the main peaks correspond to SC3, but are about 2351 Da larger mass, which corresponds to the mass of the NisA leader peptide. This shows that the eukaryotic SC3 preceded by the nisin A leader peptide is secreted by L. lactis via the nisin transporter NisT.

EXAMPLE 3

Export of Nisin Prepeptide across the Cytoplasmic Membrane of Escherichia Coli Protease Deficient SF120 (Gram-Negative Bacterium), via the Nisin Transporter NisT.

[0102] Materials and methods. nisT was cloned in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E. coli SF120 (Baneyx, F., and Georiou, G. 1991, J. Bacteriol. 173, 2696-2703). nisA was cloned in a second plasmid with a different antibiotic marker and transformed to the above strain. The resulting strain, as well as a control strain without pBAD-nisT, was grown and induced overnight with 0.3% arabinose and/or another adequate signal. The cells were pelleted and washed in milliQ to disrupt the outer membrane. The cells were pelleted and the supernatant was subjected to ZIPTIPPING™ and MALDI-TOFMS as in Example 1.

[0103] Results. A mass spectrometry signal was identical to Example 1, which is consistent with export of the nisin prepeptide across the cytoplasmic membrane in the strain with both plasmids, nisT and nisA.

EXAMPLE 4A

Export of Nisin Prepeptide Across the Cytoplasmic Membrane of Escherichia Coli Protease Deficient SF120 (Gram-Negative Bacterium) via the Nisin Transporter NisT and Dehydration by NisB.

[0104] The nisin prepeptide includes a leader with the sequence: (M)STKDFNLDLVSVSKKDSGASPR (SEQ ID NO:). Neither serines nor threonines are dehydrated in the leader. The second part of the prepeptide is the nisin propeptide: ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK (SEQ ID NO:). Most of the serines and all threonines can be dehydrated by NisB.

[0105] Materials and methods. nisBT is cloned in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E. coli SF120. nisA is cloned in a second plasmid with a different antibiotic marker and transformed to the above strain. The resulting two plasmid strains, as well as a control strain without pBAD-nisBT, are grown and induced overnight with 0.3% arabinose and/or another adequate signal. The cells are pelleted and washed in milliQ to disrupt the outer membrane. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS as performed in example 1.

[0106] Results. A mass consistent with the export of the nisin prepeptide, with dehydrated serines and threonines in the propeptide region, across the cytoplasmic membrane in the strain with both plasmids (nisBT and nisA).

EXAMPLE 4B

Export of Nisin Prepeptide Across the Cytoplasmic Membrane of Escherichia Coli Protease Deficient SF120 (Gram-Negative Bacterium) via the Nisin Transporter NisT and dehydration by NisB.

[0107] Materials and methods. nisABT is cloned with a stop triplet between nisA and nisB in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E. coli SF120. The cells are grown at 25° C. and induced overnight with 0.3% arabinose and/or another adequate signal. The cells are pelleted and washed in milliQ to disrupt the outer membrane. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS as in Example 1.

[0108] Results. A mass consistent with the export of the nisin prepeptide across the cytoplasmic membrane is present, with in the propeptide region most serines and all threonines dehydrated.

EXAMPLE 5

Export of Nisin Leader Coupled to Mature Nisin Across the Cytoplasmic Membrane of Escherichia Coli Protease Deficient SF120 (Gram-Negative Bacterium) via the Nisin Transporter NisT.

[0109] Materials and methods. nisABTC is cloned with a stoptriplet between nisA and B in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E coli SF120. The resulting strain is grown at 25° C. and induced overnight with 0.3% arabinose and/or another adequate signal. The cells are pelleted and washed in milliQ to disrupt the outer membrane. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS as in example 1.

[0110] The above ZIPTIPPED™ material and the crude supernatant is treated after outer membrane disruption with trypsin. This material is applied to the agar well assay to determine antibacterial activity. Also, the capacity of the trypsinated solutions to induce the nisin promoter is tested via the Gus assay (Kuipers et al., 1995, J. Biol. Chem. 270: 27299-27304).

[0111] Results. A mass spectrometry signal of about 5690 Da is consistent with export of the nisin prepeptide coupled to mature nisin across the cytoplasmic membrane. Trypsinated samples have antimicrobial activity in the agar well assay and nisin promoter induction capacity. These results show export of the nisin prepeptide which has undergone thioether ring formation, since trypsin cleaves off the leader and liberates the active nisin which has antimicrobial activity and induction capacity.

EXAMPLE 6

Export of Alpha Neurokinin (Table 1) Across the Cytoplasmic Membrane of Escherichia Coli Protease Deficient SF120 (Gram-Negative Bacterium) via the Variacin Transporter VarT.

[0112] VarT has simultaneous transport and leader peptidase activity. As a consequence, export of the fusion protein including a variacin-leader (Table II) and alpha neurokinin through VarT results in extracellular release of the alpha neurokinin without the leader. Alpha neurokinin has the (C9)-sequence: HKTDSFVGCM (Table 1).

[0113] Materials and methods. varT is cloned in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E coli SF120. A construct with leader variacin preceding neurokinin alpha is cloned in a second plasmid with a different antibiotic marker and transformed to the above strain. The resulting strain, as well as a control strain without pBAD-varT, is grown and induced overnight with 0.3% arabinose and/or another adequate promoter related signal. The cells are pelleted and washed in milliQ to disrupt the outer membrane. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS as in Example 1.

[0114] Results. A mass spectrometry signal corresponding to alpha neurokinin. This result is consistent with export of alpha neurokinin through VarT.

EXAMPLE 7

Export of Glucagon (Table 1) via Multi T out of Saccharomyces Cerevisiae (Eukaryotic Organism).

[0115] MutT has simultaneous transport and leader peptidase activity. As a consequence export of the fusion protein including a MutacinII-leader and glucagon through MutT results in extracellular release of glucagon without the leader.

[0116] The (C5,S24,C29)-Sequence of glucagon is: HSQGCFTSDYSKYLDSRRAQD FVSWLMNC (SEQ ID NO:) (Table 1).

[0117] Materials and methods. mutT is cloned in a suitable vector and transformed to S. cerevisiae. A construct is cloned with leader mutacinII preceding glucagon in a second plasmid which has a different antibiotic marker and the construct is transformed to the above strain. The resulting strain, as well as a control strain without mutt, is grown and induced overnight with an adequate signal. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS as in Example 1.

[0118] Results. A mass spectrometry signal corresponds to glucagon. This shows that the mutacin II leader drives the export of glucagon out of S. cerevisiae.

EXAMPLE 8A

Export of Nisin Prepeptide via the Nisin Transporter NisT and Modification by the Nisin Dehydrating Enzyme NisB without Subsequent Enzymatic Thioether Bridge Formation.

[0119] Materials and methods. NisBT is cloned as described in Example 1 using the primers nisB fw, (5′-CGG TCT CGC ATG ATA AAA AGT TCA TTT AAA GCT CAA CCG TTT TTA GTA AG (SEQ ID NO:)) and nisT rev (5′-CGG TCT CTC TAG ATT ATT CAT CAT TAT CCT CAT ATT GCT CTG (SEQ ID NO:)).

[0120] NZ9000+pNG-nisBT (Cm) are transformed with pNG-nisA (Em). NZ9000+pNG-nisBT+pNG-nisA cells are grown and induced as in Example 1. 50 μM TPEN (N,N,N′,N′-Tetrakis(2-Pyrimidyl)ethylenediamine), a specific zinc chelator, is added to the supernatant and incubated 1 hour under stirring. The supernatant is Ziptipped and analyzed by MALDI-TOFMS as performed in Example 1.

[0121] Results. A MALDI-TOFMS peak around 5690 Da in the sample derived from the supernatant from NZ9000+pNG-nisBT+pNG-nisA cells is present. Absence of the peak in samples derived from the supernatant of NZ9000+pNG-nisT+pNG-nisA (example 1), which is consistent with dehydration of most serines and all threonines.

EXAMPLE 8B

Export of Nisin Prepeptide via the Nisin Transporter NisT and Modification by the Nisin Dehydrating Enzyme NisB without Subsequent Enzymatic Thioether Bridge Formation.

[0122] Materials and methods. The plasmid pNG-nisABT is constructed similar to the organization of the genes in the wild type nisin producer NZ9700, which includes a stop triplet between the nisA and the nisBT genes. This plasmid is transformed to NZ9000, grown and induced. After induction, nisBT is transcribed in low quantities by limited read through. The supernatant is subjected to TPEN treatment as in Example 7A followed by ziptipping and MALDI-TOFMS as in Example 1.

[0123] Results. A MALDI-TOFMS peak present around 5690 is consistent with export of the nisin prepeptide and dehydration of propeptide serines (most) and threonines (all).

EXAMPLE 9

Export of Nisin Prepeptide via the Nisin Transporter NisT and Modification by the Nisin Dehydrating Enzyme NisB Followed by N is C-Mediated Thioether Bridge Formation, Involving a pNG-nisABTC Plasmid.

[0124] Materials and methods. The plasmid pNG-nisABTC is constructed similar to the organization of the genes in the wild type nisin producer NZ9700, which includes a stop triplet between the nisA and the nisBTC genes. NZ9000+pNG-nisABTC are grown and induced. The supernatant is analyzed as in Example 1. Trypsin treated supernatant is subjected to the agar well assay by pouring the trypsinated supernatant in an agar well and overlaying with a nisin sensitive strain. In addition, the trypsinated supernatant is tested for its capacity to induce the nisin promoter with the Gus assay (Kuipers et al. 1995, J. Biol. Chem. 270:27299-27304).

[0125] Results. A peak with a mass corresponding to nisin prepeptide including the unmodifed leader peptide coupled to mature nisin, which has undergone dehydration reactions, and the lanthionine ring formation of nisin. Halos are present in the case of trypsinated supernatant and halos are absent, or significantly smaller, than halos in the case of trypsinated medium or untrypsinated supernatant. The halos indicate the induction capacity of the trypsinated supernatant.

[0126] These results are consistent with export of the nisin prepeptide which has undergone lanthionine bridge formation since trypsin cleaves off the leader and liberates active nisin which includes antimicrobial activity and induction capacity.

EXAMPLE 10

Secretion of Thioether Ring Stabilized Vasopressin by Use of the NisA Leader Peptide in Lactococcus lactis NZ9800.

[0127] Vasopressin is a 9 amino acid (aa) peptide antidiuretic hormone. It has cysteines in position 1 and 6: CYFQNCPRG (SEQ ID NO:) that form an internal disulfide bond. This example involves ring formation by interaction between aa1 and aa6 through the use of the nisin modification system that forms thioether bridges between a dehydrated serine or threonine and a downstream located cysteine. Conversion of the cysteine at position 1 by genetic modification into a serine enables thioether ring formation by the nisin modifying lantibiotic enzymes. This example involves a precise fusion of serine altered vasopressin (SerVaso) to the NisA leader peptide by genetic modification. The lactococcal strain NZ9800 (Kuipers et al. 1993, Eur. J. Biochem. 216, 281-291), used for expression of the leader peptide-Servaso fusion, contains all the components for the nisin secretion and modification machinery, but lacks the nisA structural gene.

[0128] Materials and methods. To obtain a precise and “in frame” fusion of SerVaso with the NisA leader peptide, a first plasmid pNG-nisl-SC3 (example 2) is converted into a general NisA leader peptide secretion vector. Suitable restriction sites are introduced and the c-myc-SC3 sequences are removed by PCR amplification of the entire plasmid using the following primers: pLP.1 (5′-CGG TCT CAG CGT GGT GAT GCA CCT GAA TC (SEQ ID NO:)) and pLP.2 (5′-CCA CGC TGA GAC CGC AGC TGG GAT CCG GCT TGA AAC GTT CAA TTG AAA TGG (SEQ ID NO:)). The PCR product is cut with Eco31I (underlined sequences in the primers) resulting in sticky ends (in italics in the primer sequences) that are compatible for self-ligation of the plasmid. After self-ligation, the resulting plasmid, pLPI, can be used for precise fusion of peptides and proteins after the . . . GASPR aa sequence of the NisA leader peptide by using the Eco31I restriction site. DNA fragments to be inserted at this position should contain a 5′-ACGC sticky end to allow ligation. At the 3′-end, the DNA fragment should contain a sticky end that is compatible with BamHI (site introduced by primer pLP.2, indicated in bold).

[0129] The SerVaso gene is obtained by annealing two oligo's: VP.1: 5′-ACG CTC ATA TTT TCA AAA TTG TCC TCG TGG TTA AG (SEQ ID NO:) and VP.2: 5′-GAT CCT TAA CCA CGA GGA CAA TTT TGA AAA TAT GA (SEQ ID NO:). The annealed fragment includes a stopcodon and has the ACGC overhang at its 5′-end and a BamHI compatible sticky end at the 3′-end. The SerVaso gene fragment is ligated into Eco31I and BamHI digested pLP1 and the resulting plasmid is designated pLP1vp.

[0130] Strain NZ9800 carrying pLPvp is induced for expression as described in Example 1. The secreted peptide is purified and analyzed using MALDI-TOFMS (linear mode) essentially as described in Example 1.

[0131] Results. A MALDI-TOFMS mass consistent with production of processed and thioether ring modified vasopressin.

EXAMPLE 11

EpilancinBC-Mediated Synthesis by Staphylococcus Epidermis (Prokaryote, Gram-Positive) of Epilancin Leader (Table 2) Coupled to Glucagon (Table 1) with Thioether Rings.

[0132] The (C5, S24, C29)-sequence of glucagon is HSQGCFTSDYSKYLDSRRAQD FVSWLMNC (SEQ ID NO:) (Table 1). This sequence allows the epilancin K7 enzymes to form thioether rings between S2-C5 and S24-C29.

[0133] Materials and methods. A construct leader-epilancin K7 is cloned and followed in an open reading frame mutant glucagon. A plasmid with the above construct is transformed to wild type epilancin K7 producing Staphylococcus epidermis. Transcription of the leader-glucagon reading frame is induced. Overnight cell growth in minimal medium is performed, the cells are centrifuged and ziptipping of the supernatant and MALDI-TOFMS analysis are performed (linear mode).

[0134] Results. A MALDI-TOFMS peak consistent with production of glucagon with dehydrated serines and threonines and thioether rings as indicated in Table 1 is present.

EXAMPLE 12

Production by Streptococcus Salivarius (Prokaryote Gram Positive) of (S3, S12) Tachyplesin I (Table 1) Following Export via SalT.

[0135] Materials and methods. A construct salivaricin-leader (Table 2) is cloned and followed in an open reading frame by mutant tachyplesin (Table 1). SalivaricinT is cloned on a second plasmid with a different antibiotic marker. Both plasmids are transformed to a Streptococcus salivarius strain devoid of salivaricin genes. Transcription of both plasmids is induced during 2-4 hours of continued growth. Every 30 min, 0.2 mM pmsf (protease inhibitor) is added. Ziptipping is performed as in Example 1 and analyzed by MALDI-TOFMS (linear mode) is performed.

[0136] Results. A mass spectrometry peak is present which corresponds to tachyplesin.

EXAMPLE 13A

Production by Streptococcus Salivarius (Prokaryote Gram Positive) of (S3, S12) Tachyplesin I (Table 1) with salivaricinB-Dehydrated Serine-3 and Serine-12 without Subsequent Enzymatic Thioether Ring Formation.

[0137] Tachyplesin has the following (S3,S12)-sequence: KWSFRVCYRGISYRRCR (SEQ ID NO:).

[0138] Materials and methods. A construct salivaricin leader (Table 2) is cloned and followed in an open reading frame by mutant tachyplesin (Table 1). SalivaricinBT is cloned on a second plasmid with a different antibiotic marker. This plasmid is transformed to a Streptococcus salivarius strain devoid of salivaricin genes. Transcription of both plasmids is induced during 2-4 hours of continued growth and ziptipping is performed as in Example 1 and analyzed by MALDI-TOFMS (linear mode).

[0139] Results. A mass spectrometry peak corresponding to tachyplesin with dehydrated serines is present.

EXAMPLE 13B

Production by Streptococcus Salivarius (Prokaryote Gram Positive) (S3, S12) Tachyplesin I (Table 1) with salivaricinB-Dehydrated S3 and S12 without Subsequent Enzymatic Thioether Ring Formation.

[0140] Tachyplesin has the following (S3, S12)-sequence: KWSFRVCYRGISYRRCR (SEQ ID NO:).

[0141] Materials and methods. A construct salivaricin-leader (Table 2) is cloned and followed in an open reading frame by mutant tachyplesin (Table I) including a stop triplet and, thereafter, salivaricinBT. This plasmid is transformed to a Streptococcus salivarius strain devoid of salivaricin genes. Transcription is induced during 2-4 hours of continued growth and ziptipping is performed as in Example 1 and analyzed by MALDI-TOFMS (linear mode).

[0142] Results. A mass spectrometry peak corresponding to tachyplesin with dehydrated serines is present.

EXAMPLE 14

Production by Streptococcus Salivarius (Prokaryote Gram Positive) of SalivaricinBC-Modified (S3, S12) Tachyplesin I (Table 1) with SalivaricinBC-Mediated Thioether Rings Instead of Disulfide Bridges.

[0143] Tachyplesin has the following (S3,S12)-sequence: KWSFRVCYRGISYRRCR. This sequence allows the salivaricin enzymes to form thioether rings between S3-C7 and S12-C16.

[0144] Materials and methods. A construct salivaricin-leader (Table 2) is cloned and followed in an open reading frame by mutant tachyplesin (Table 1). A plasmid is transformed with the above construct into a wild type salivaricin producing Streptococcus salivarius (prokaryote Gram positive). Transcription of the salivaricin-leader-tachyplesin reading frame is induced during 2-4 hours of continued growth in minimal medium. The cells are centrifuged and ziptipping of the supernatant is performed as in Example 1 and MALDI-TOFMS analyzed (linear mode).

[0145] Results. A mass spectrometry peak corresponding to tachyplesin with thioether rings is present.

EXAMPLE 15

Production by Lactococcus Lactis (Prokaryote, Gram-Positive) via LacticinT of Vasonatrin (Table 1) Without Modifications.

[0146] Lacticin 481-T has leader peptidase activity and, thus, in this particular example, the supernatant of the cell culture vasonatrin is found without leader. Vasonatrin is amongst others involved in vaso relaxation. Its sequence is: GLSKGCFGLKLDRIGSMSGLGC NSFRY (SEQ ID NO:).

[0147] Materials and methods. A construct lacticin 481-leader (Table 2) is cloned and followed in an open reading frame by vasonatrin (Table 1). Lacticin 481-T is cloned on a second plasmid having a different antibiotic marker. Both plasmids are transformed to a L. Lactis strain devoid of lacticin 481 genes. Transcription of both plasmids is induced during overnight growth in minimal medium and ziptipping is performed as in Example 1 and analyzed by MALDI-TOFMS (linear mode).

[0148] Results. A mass spectrometry peak corresponding to vasonatrin is present.

EXAMPLE 16

Production by Lactococcus Lactis (Prokaryote, Gram-Positive) via LacticinT of Vasonatrin (Table 1), with Lacticin M Mediated Thioether Rings.

[0149] Vasonatrin is amongst others involved in vaso relaxation. It has an amino acid sequence that without mutations permits the formation of two lanthionine rings. Its sequence is: GLSKGCFGLKLDRIGSMSGLGCNSFRY (SEQ ID NO:). The lanthionine rings can be formed from S3-C6 and from S16-C22.

[0150] Materials and methods. A construct lacticin 481-leader (Table 2) is cloned and followed in an open reading frame by vasonatrin (Table 1). The plasmid is transformed to a wild type lacticin 481 producing strain and transcription of the plasmid is induced during overnight growth in minimal medium. Ziptipping is performed as in Example I and analyzed by MALDI-TOFMS (reflectron mode).

[0151] Results. A mass spectrometry peak corresponding to vasonatrin with two thioether rings and two more dehydrated serines.

EXAMPLE 17

Production by Escherichia Coli SF120 (Prokaryote, Gram-Negative) of Epilancin K7 Leader (Table 2) Coupled to HIV (gp41) Antigenic Peptide 1 (Table 1) Without Modifications. HIV (gp41) Antigenic Peptide 1 has the Sequence: (S2)-Sequence: GSSGKLICTTAVPWNAS (SEQ ID NO:) (Table 1).

[0152] Materials and methods. EpilancinT is cloned in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E coli SF120. A construct with epilancin-leader preceding HIV (gp41) antigenic peptide 1 is cloned in a second plasmid having a different antibiotic marker and transformed to the above strain. The resulting strain with the two plasmids and a control strain without pBAD-varT is grown at 25° C. and induced overnight with 0.3% arabinose and/or another adequate promoter related signal. The cells are pelleted and washed in milliQ to disrupt the outer membrane. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0153] Results. A mass spectrometry signal corresponding to the epilancin leader coupled to HIV (gp41) antigenic peptide 1.

EXAMPLE 18A

Production by E. Coli SF120 (Prokaryote, Gram Negative) of Epilancin K7 Leader (Table 2) Coupled to HIV (gp41) Antigenic Peptide 1 (Table 1) with an Epilancin B-Dehydrated S2, Without Subsequent EpilancinC-Mediated Thioether Ring Formation.

[0154] HIV (gp41) antigenic peptide 1 has the (S2)-sequence: GSSGKLICTTAVPWNAS (SEQ ID NO:) (Table 1).

[0155] Materials and methods. EpilancinBT is cloned in a suitable vector, such as the pBAD vector, and transformed at 25° C. to E coli SF120. A construct with epilancin-leader preceding HIV (gp41) antigenic peptide 1 is cloned in a second plasmid having a different antibiotic marker and transformed to the above strain. The resulting strain at and a control strain without pBAD-varBT are grown at 25° C. and induced overnight with 0.3% arabinose and/or another adequate promoter related signal. The cells are pelleted and washed in milliQ to disrupt the outer membrane. The cells are pelleted and the supernatant is subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0156] Results. A mass spectrometry signal corresponding to the unmodified epilancin leader coupled to HIV (gp41) antigenic peptide 1, with dehydrated serines and threonines.

EXAMPLE 18B

Production by E. Coli SF120 (Prokaryote, Gram Negative) of Epilancin K7 Leader (Table 2) Coupled to HIV (gp41) Antigenic Peptide 1 (Table 1) with an Epilancin B-Dehydrated S2, Without Subsequent EpilancinC-Mediated Thioether Ring Formation.

[0157] HIV (gp41) antigenic peptide 1 has the (S2)-sequence: GSSGKLICTTAV PWNAS (SEQ ID NO:) (Table 1).

[0158] Materials and methods. A plasmid, such as pBAD or another suitable vector, with epilancin-leader preceding HIV (gp41) antigenic peptide 1, preceding a stop triplet, preceding epilancinBT was constructed and transformed at 25° C. to E coli SF120. The resulting strain and a control strain without plasmid was grown at 25° C. and induced overnight with 0.3% arabinose and/or another adequate promoter related signal. The cells were pelleted and washed in milliQ to disrupt the outer membrane. The cells were pelleted and the supernatant was subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0159] Results. A mass spectrometry signal corresponding to the unmodified epilancin leader coupled to HIV (gp41) antigenic peptide 1 with dehydrated serines and threonines was present.

EXAMPLE 19

Production by E. Coli SF120 (Prokaryote, Gram Negative) of Epilancin K7 Leader (Table 2) Coupled to HIV (gp41) Antigenic Peptide 1 (Table 1) with an Epilancin BC Synthesized Thioether Ring.

[0160] HIV (gp41) antigenic peptide 1 has the sequence: (S2)-sequence: GSSGKLICTTAVPWNAS (SEQ ID NO:) (Table 1). This sequence allows the epilancin enzymes formation of the thioether ring S2-C8.

[0161] Materials and methods. A plasmid such as pBAD, or another suitable vector, with epilancin-leader preceding HIV (gp41) antigenic peptide 1, preceding a stop triplet, preceding epilancinBTC was cloned and transformed at 25° C. to E. coli SF120. The resulting strain and a control strain without plasmid were grown at 25° C. and induced overnight with 0.3% arabinose and/or another adequate promoter related signal. The cells were pelleted and washed in milliQ to disrupt the outer membrane. The cells were pelleted and the supernatant was subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0162] Results. A mass spectrometry signal corresponding to the unmodified epilancin leader part coupled to modified HIV (gp41) antigenic peptide 1 with one thioether ring and dehydrated serines and threonines.

EXAMPLE 20

Production by S. Cerevisiae (Eukaryote) of Epicidium Leader (Table 2) Coupled to (S1) Calcitonin (Table 1) via EpicidiumT Without Modifications.

[0163] The (S 1)-sequence of calcitonin is: SGNLSTCMLGTYTQDFNKFHTFPQTAI GVGAP (SEQ ID NO:).

[0164] Materials and methods. EpicidiumT was cloned in a suitable vector and transformed to Saccharomyces cerevisiae. A construct with epicidium-leader preceding calcitonin (Table 1) was cloned in a second plasmid having a different antibiotic marker and transformed to the above strain. The resulting strain and a control strain without epicidiumT were grown and induced overnight with an adequate promoter related signal in the presence of a 2 times added mixture of protease inhibitors. The cells were pelleted and t the supernatant was subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0165] Results. A mass spectrometry signal corresponding to the epicidium leader coupled to calcitonin.

EXAMPLE 21A

Production by S. Cerevisiae of Epicidium Leader (Table 2) Coupled to (S1) Calcitonin (Table 1) with EpicidumB-Dehydrated Serines and Threonines Without Enzymatic Thioether Ring Formation.

[0166] The (S1)-sequence of calcitonin is: SGNLSTCMLGTYTQDFNKFHTFPQTAI GVGAP (SEQ ID NO:).

[0167] Materials and methods. EpicidiumBT was cloned in a suitable vector and transformed to Saccharomyces cerevisiae. A construct with epicidium-leader preceding calcitonin (Table 1) was cloned in a second plasmid having a different antibiotic marker and transformed to the above strain. The resulting strain and a control strain without epicidiumT was grown and induced overnight with an adequate promoter related signal in the presence of a 2 times added mixture of protease inhibitors. The cells were pelleted and the supernatant was subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0168] Results. A mass spectrometry signal corresponding to the unmodifed epicidium leader coupled to modified calcitonin with dehydrated serines and threonines.

EXAMPLE 21B

Production by Saccharomyces Cerevisiae (Eukaryote) of Epicidium Leader (Table2) Coupled to (S1) Calcitonin (Table 1) with EpicidumB-Dehydrated Serines and Threonines Without Enzymatic Thioether Ring Formation to cys7. The (S1)-Sequence of Calcitonin is: SGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP (SEQ ID NO:).

[0169] Materials and methods. A construct with epicidium-leader preceding calcitonin preceding a stop triplet preceding epicidiumBT was cloned in a suitable plasmid and transformed to S. cerevisiae. The resulting strain was grown and induced overnight with an adequate promoter related signal in the presence of a 2 times added mixture of protease inhibitors. The cells were pelleted and the supernatant was subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0170] Results. A mass spectrometry signal corresponding to the unmodified epicidium leader coupled to modified calcitonin with dehydrated serines and threonines was present.

EXAMPLE 22

Production by S. Cerevisiae of Epicidum Leader (Table 2) Coupled to (S1) Calcitonin (Table 1) with Dehydrated Serines and Threonines and one EpicidumBC-Mediated Thioether Ring. The (S1)-Sequence of Calcitonin is: SGNLSTCMLGTYTQDFNKFHTFPQTA IGVGAP (SEQ ID NO:). This Sequence Allows the Epicidium Enzymes to form the Lanthionine S1-C7.

[0171] Materials and methods. A construct with epicidium-leader preceding calcitonin preceding a stop triplet preceding epicidiumBTC was inserted in a suitable plasmid and transformed to Saccharomyces cerevisiae. The resulting strain was grown and induced overnight with an adequate promoter related signal. The cells were pelleted and the supernatant was subjected to ziptipping and MALDI-TOFMS (linear mode) as in Example 1.

[0172] Results. A mass spectrometry signal corresponding to the unmodified epicidium leader coupled to modified calcitonin with dehydrated serines and threonines and one thioether ring was present.

EXAMPLE 23

Secretion of Thioether Ring Stabilized (L7C)LHRH by use of the NisA Leader Peptide in Lactococcus lactis NZ9700.

[0173] L7C-LHRH (luteinizing hormone release hormone) is a 10-amino acid (aa) peptide. Replacing the leucine at position 7 with a cysteine enables thioether ring formation by the nisin modifying lantibiotic enzymes. These modifying enzymes form a complex with the transporter NisT and the modifications are coupled to transport. Therefore, the (poly)peptide to be modified should be preceded by the nisin leader which directs the fusion peptide to the nisin transporter. This example involves the precise fusion of L7C-LHRH to the nisin leader peptide by genetic modification. The lactococcal strain NZ9700 (a nisin producing L. lactis strain; Kuipers et al. 1997, Tibtech. 15: 135-140) is used for expression of the leader peptide-(L7C)LHRH fusion and contains the components for the nisin secretion (NisT) and modification machinery (NisB and NisC). The enzyme NisB dehydrates serine at position 4 and the dehydrated residue is coupled to the cysteine of position 7 by enzyme N is C to form a thioether bridge.

[0174] Materials and methods. Use for the nisin inducible expression of (L7C)LHRH preceded by the nisin leader in Lactococcus lactis a pNZ8048 (Kuipers et al. 1997, Tibtech. 15: 135-140)-derived plasmid. This plasmid, termed pLP1, is constructed in such a way that allows precise fusion of peptides and proteins after the . . . GASPR aa sequence of the NisA leader peptide by making use of an Eco31I restriction site. DNA fragments to be inserted at this position should contain a 5′-ACGC sticky end to allow ligation. The DNA fragment should contain a sticky end at the 3′-end that is compatible with BamHI.

[0175] The (L7C)LHRH gene is obtained by annealing two oligo's: LHRH1: 5′-A CGC CAA CAC TGG TCA TAT GGT TGT CGT CCT GGT TAA G (SEQ ID NO:) and LHRH2: 5′-GA TCC TTA ACC AGG ACG ACA ACC ATA TGA CCA GTG TTG (SEQ ID NO:). The annealed fragment includes a stopcodon and includes the ACGC overhang at the 5′-end and a BamHI compatible sticky end at the 3′-end. The (L7C)LHRH gene fragment is ligated into Eco31I and BamHI and digested pLP1 and the resulting plasmid is designated pLP1-LHRH1.

[0176] The vector pLP1-LHRH1 is transformed to Lactococcus lactis NZ9700 (a nisin producing L. lactis strain; Kuipers et al. 1997, Tibtech. 15: 135-140). The resulting NZ9700+pLP1-LHRHl is grown in M17-based medium (Terzaghi and Sandine, 1975, Appl. Microbiol. 29: 807-813) to an OD600 of 0.4. The cells are collected by centrifugation and resuspended in the same volume of Minimal Medium (Jensen and Hammer, 1993, Appl. Environ. Microbiol. 59: 4363-4366). After overnight incubation and subsequent centrifugation, samples are preprepared using C18 ziptips (Millipore) as follows: pipet two times with 10 μl 50% acetonitril, followed by two times with 10 μl milliQ water, followed by eight times with 10 μl supernatant, followed by two times washing with 10 μl MilliQ water, followed by elution two times with 10 μl 50% acetonitril containing 0.1% TFA. The final eluent is vacuum dried and stored at 20° C. until analysis by mass spectrometry. Prior to analysis, the dry material is resuspended in 6 μl of 50% acetonitril containing 0.1% TFA and 1 μl is applied to the target. After drying, 1 μl of matrix (10 mg/ml alpha-cyano-4-hydroxycinnamic acid completely dissolved (by mildly heating and vortexing) in 50% acetonitril containing 0.1% TFA) is applied to the target. The following MALDI-TOFMS (linear mode) laser settings are used: 100% coarse energy, 90% fine, source 20 KV, extra 19800, force 15000, suppression 350, pulse time 40, pulse voltage 1400, sampling rate 500 MHz, sensitivity 50 mV, shots 15.

EXAMPLE 24

This Example Describes the Production of a Lantibiotic with the Leader Peptide Still Attached to it by Using a Strain that does not Express the Leader Peptidase. In the Case of Some Novel Lanthionine Containing (Poly)Peptides, this Provides the Advantage of Reduced Toxicity of the Novel Lantibiotic Towards the Producer Cell.

[0177] Materials and methods. A ΔNisP strain from Lactococcus lactis NZ9700 is constructed.

[0178] A delta nisP strain is made using the plasmid pOR1280 (Leenhouts et al., 1996, Mol. Gen. Genet. 253, 217-224.). This disruption of nisP is made by removing the start codon of the coding gene. The advantage is the absence of the whole protein without a major alteration of the mRNA. Two PCR products of about 1 Kb are generated wherein one product starts before the gene ending before the mutated start codon and the second product starts from the startcodon. These PCR products are coupled by a second PCR reaction and cloned in the pOR1280 vector in the multiple cloning site. The result is a 2 Kb genomic fragment with the changed stopcodon in the middle. Finally, two subsequent single cross overs transfer the mutation into the genome.

[0179] Sequence around startcodon NisP:

[0180] The priming sites are highlighted, the startcodon is shown in bold face and the boxed area is replaced by NotI restriction site in the mutant strain.

[0181] The following primers are used dnisp1:

[0182] 5′-cggtctctctagacctcctgattatgacgtgattg-3′ (SEQ ID NO:)

[0183] Eco31I site is double underlined, XbaI site is underlined.

[0184] dnisp2:

[0185] 5′-gtagcgggacctctagtttcctaccttcgttgc-3′ (SEQ ID NO:)

[0186] NotI site underlined, changed startcodon (into stopcodon) highlighted.

[0187] dnisp3:

[0188] 5′-gtagcggccgcactaggtttcctttttatcgtttgttcg-3′ (SEQ ID NO:)

[0189] NotI site underlined.

[0190] dnisp4:

[0191] 5′-cggtctctagatctccataaacatattggtaccagccag-3′. (SEQ ID NO:)

[0192] Eco31I site is double underlined, BglII site is underlined.

[0193] Two separate PCRs are performed on chromosomal DNA of the NZ9700 strain. One PCR is performed with primers dnisp1 and dnisp2 to form product of about 1.5 kb in length. A second PCR is performed with primers dnisp3 and dnisp4 to form a product of about 1.5 kb. Both fragments are purified and digested with NotI. The fragments are ligated together and a third PCR is performed on the ligation mixture with primers dnispl and dnisp4 to form a product of about 3 kb.

[0194] The product is digested with Eco31I or BglII/XbaI and cloned in pOR1280. The plasmid is transformed to L. lactis NZ9700 and growth is selected on erythromycin plates. Specific insertions into N is P gene (PCR, decrease in nisin production) are positively identified by growing a colony for 36 generations, plating out on X-gal/IPTG plates and screening for white colonies. The white colonies should be sensitive to erythromycin and be hampered in nisin production (no or small halo formation). The produced nisin should contain the leader sequence attached to the nisin.

[0195] The mutation is checked by PCR and sequencing. The above generated Delta NisP strain is grown overnight in M17 medium (Terzaghi and Sandine, 1975, Appl. Microbiol. 29: 807-813), diluted 100 fold and grown to OD600 equal to 0.4. Subsequently, the cells are pelleted and resuspended in minimal medium (Jensen and Hammer, 1993, Appl. Environ. Microbiol. 59: 4363-4366) supplemented with protease inhibitors 0.2 mM pmsf, 0.2 mM TPCK and filtered supernatant of the nisin producing L. lactis NZ9700 at 1000 fold dilution. After 1, 2 and 3 hours, more 0.2 mM pmsf, 0.2 mM TPCK are added and followed by overnight incubation. The cells are pelleted and the supernatant of the samples are subjected to: a) ziptipping as in described Example 1 and analyzed by MALDI-TOFMS using the settings given in Example 1; b) treatment with leader peptidase or trypsin and followed by either ziptipping and MALDI-TOFMS, or a halo assay; or c) binding to a column with antibodies against the nisin leader peptide. Elution and experiments a) and b).

[0196] Results: a) a masspec signal consistent with nisin (with all its thioether rings) to which the leader is still attached is present; b) a nisin masspec signal is present or halo formation by the samples treated by leader peptidase or trypsin is observed; and c) results as under a) and b) respectively.

[0197] Growth medium. When analyzing peptide and protein samples by mass spectrometry, the purity of the samples is a major issue. Contamination of the sample may drastically decrease the detection level of peptides and proteins. In order to prepare samples that have a relatively high purity and allow an optimal sensitivity when measuring exported peptides and proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOFMS), bacterial cells are grown in a very poor medium. The poor medium essentially contains a mixture of specific salts, specific vitamins, glucose, asparagine and casamino acids. The medium does not contain: trypton, soya peptone, meat digest or yeast extract.

[0198] The following minimal medium can be prepared for use with Lactococci:

[0199] Stock solutions:

1SOLUTION A(NH4)2SO4 2.0 g;Na2HPO4 6.0 g;KH2PO4 3.0 g;Na2SO4 0.011 g; andNaCl 1.0 g are dissolved in 200 ml H2O.SOLUTION BCasamino acids 10.0 g;Na-acetate 2.0 g;Asparagine 0.08 g;MgCl2 0.2 g;CaCl2 0.01 g; andFeCl3(7H2O)0.0006 g are dissolved in 800 ml H2O.GLUCOSE 20%Glucose 20 g is dissolved in 100 ml H2O.VITAMIN MIXbiotin 0.01 g;folic acid 0.1 g;riboflavin 0.1 g;nicotinic acid 0.1 g;pantotheic acid 0.1 g; andpyridoxal 0.2 g are dissolved in 100 ml H2O.

[0200] Solution A, B and the glucose solution are autoclaved separately, while the vitamin mix is filter sterilized.

[0201] To prepare 100 ml of medium, after sterilization (and cooling down), 20 ml of solution A is added to 80 ml of solution B, 2.5 ml glucose 20% is added and 100 ul of vitamin mix is added. If necessary, appropriate antibiotics are added.

[0202] Purification of peptides and proteins from minimal culture medium. Peptide and protein samples for analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOFMS) was prepared as follows. Cultures of bacteria grown in minimal medium were centrifuged in order to pellet the cells. The supernatant is aspirated and dispensed several times into and out of a pipet tip that contains a microvolume bed of affinity chromatography media fixed at the end of the tip that is without dead volume. This procedure has been referred to herein as “ziptipping.” A washing step follows in order to wash away contaminants and unwanted biomolecules. The washing step is performed by aspirating and dispensing, for instance, milliQ water. Finally, the peptide or protein is eluted in 1-20 μl of suitable solvent and applied directly on the target, or vial, or speedvacced and stored at −20 Celsius. Prior to MALDI TOFMS analysis, the sample is resuspended in 1 to 5 ul (or further dilution) suitable solvent of which 1 ul is applied on the target or vial.

[0203] Table 1: (poly)peptides of which the coding DNA is preceded by lantibiotic leader coding DNA in an open reading frame. Mutation possibilities allowing posttranslational thioether ring(s) formation given, for example, for vasopressin applies also to other sequences, including those which have already one ring, within other (poly)peptides in Table 1, taking into account the description of thioether ring formation mentioned in the text.

2TABLE 1AVasopressin: Function as an Antidiuretic hormone:(S1, R8)-sequence: SYFQNCPRG-NH2 (SEQ ID NO:); lanthionine ring S1-C6(S1, C2, R8)-sequence: SCFQNCPRG-NH2 (SEQ ID NO:); lanthionine ring S1-C2(S1, C3, R8)-sequence: SYCQNCPRG-NH2 (SEQ ID NO:); lanthionine ring S1-C3(S1, C4, R8)-sequence: SYFCNCPRG-NH2 (SEQ ID NO:); lanthionine ring S1-C4(S1, C5, R8)-sequence: SYFQCCPRG-NH2 (SEQ ID NO:); lanthionine ring S1-C5(S1, A6, C7, R8)-sequence: SYFQNACRG-NH2 (SEQ ID NO:); lanthionine ring S1-C7(S1, A6, C8)-sequence: SYFQNAPCG-NH2 (SEQ ID NO:); lanthionine ring S1-C8(S1, R8, C9)-sequence: SYFQNCPRC-NH2 (SEQ ID NO:); lanthionine ring S1-C9(A1, S2, R8)-sequence: ASFQNCPRG-NH2 (SEQ ID NO:); lanthionine ring S2-C6(A1, S2, C3, R8)-sequence: ASCQNCPRG-NH2 (SEQ ID NO:); lanthionine ring S2-C3(A1, S2, C4, R8)-sequence: ASFCNCPRG-NH2 (SEQ ID NO:); lanthionine ring S2-C4(A1, S2, C5, R8)-sequence: ASFQCCPRG-NH2 (SEQ ID NO:); lanthionine ring S2-C5(A1, S2, A6, C7, R8)-sequence: ASFQNACRG-NH2 (SEQ ID NO:); lanthionine ring S2-C7(A1, S2, A6, C8)-sequence: ASFQNAPCG-NH2 (SEQ ID NO:); lanthionine ring S2-C8(A1, S2, A6, R8, C9)-sequence: ASFQNAPRC-NH2 (SEQ ID NO:); lanthionine ring S2-C9(A1, S3, R8)-sequence: AYSQNCPRG-NH2 (SEQ ID NO:); lanthionine ring S3-C6(A1, S3, C4, R8)-sequence: AYSCNCPRG-NH2 (SEQ ID NO:); lanthionine ring S3-C4(A1, S3, C5, R8)-sequence: AYSQCCPRG-NH2 (SEQ ID NO:); lanthionine ring S3-C5(A1, S3, A6, C7, R8)-sequence: AYSQNACRG-NH2 (SEQ ID NO:); lanthionine ring S3-C7(A1, S3, A6, C8)-sequence: AYSQNAPCG-NH2 (SEQ ID NO:); lanthionine ring S3-C8(A1, S3, A6, R8, C9)-sequence: AYSQNAPRC-NH2 (SEQ ID NO:); lanthionine ring S3-C9(A1, S4, R8)-sequence: AYFSNCPRG-NH2 (SEQ ID NO:); lanthionine ring S4-C6(A1, S4, C5, R8)-sequence: AYFSCCPRG-NH2 (SEQ ID NO:); lanthionine ring S4.-C5(A1, S4, A6, C7, R8)-sequence: AYFSNACRG-NH2 (SEQ ID NO:); lanthionine ring S4-C7(A1, S4, A6, C8)-sequence: AYFSNAPCG-NH2 (SEQ ID NO:); lanthionine ring S4-C8(A1, S4, A6, R8, C9)-sequence: AYFSNAPRC-NH2 (SEQ ID NO:); lanthionine ring S4-C9(A1, S5, R8)-sequence: AYFQSCPRG-NH2 (SEQ ID NO:); lanthionine ring S5-C6(A1, S5, A6, C7, R8)-sequence: AYFQSACRG-NH2 (SEQ ID NO:); lanthionine ring S5-C7(A1, S5, A6, C8)-sequence: AYFQSAPCG-NH2 (SEQ ID NO:); lanthionine ring S5-C8(A1, S5, A6, R8, C9)-sequence: AYFQSAPRC-NH2 (SEQ ID NO:); lanthionine ring S5-C9(A1, S6, C7, R8)-sequence: AYFQNSCRG-NH2 (SEQ ID NO:); lanthionine ring S6-C7(A1, S6, C8)-sequence: AYFQNSPCG-NH2 (SEQ ID NO:); lanthionine ring S6-C8(A1, S6, R8, C9)-sequence: AYFQNSPCG-NH2 (SEQ ID NO:); lanthionine ring S6-C9(A1, S7, C8)-sequence: AYFQNCSCG-NH2 (SEQ ID NO:); lanthionine ring S7-C8(A1, S7, R8, C9)-sequence: AYFQNCSRC-NH2 (SEQ ID NO:); lanthionine ring S7-C9(A1, S7, C9)-sequence: AYFQNCPSC-NH2 (SEQ ID NO:); lanthionine ring S8-C9.

[0204] Terlipressin (antidiuretic hormone):

[0205] S4-Sequence: GGGSYFQNCPKG-NH2 (SEQ ID NO:)

[0206] Posttranslational lanthionine: S4-C9.

[0207] Desmopressin (antidiuretic hormone):

[0208] S1-Sequence: SYFQNCPRG-NH2 (arginine is D-arginine) (SEQ ID NO:)

[0209] Posttranslational lanthionine ring: S1-C6.

[0210] Cispressin (antidiuretic hormone):

[0211] S4-Sequence: GGGSYFNCPKG-NH2 (SEQ ID NO:)

[0212] Posttranslational lanthionine ring: S4-C8.

[0213] Adrenomedullin Hypotensive peptide, may function as a hormone in circulation control

3A13,S16-Sequence:YRQSMNNFQGLRAFGSRFGTCTVQKLAHQIYQFTDKD(SEQ ID NO:)KDNVAPRSKISPQGY-NH2

[0214] Posttranslational lanthionine: S16-C21.

[0215] Allatostatin I (neuropeptide inhibitor of juvenile hormone synthesis)

[0216] C6-Sequence: APSGACRLYGFGL-NH2

[0217] Posttranslational lanthionine: S3-C6.

[0218] Angiotensin I

[0219] S7,C10-Sequence: DRVYIHSFHC (SEQ ID NO:)

[0220] Posttranslational lanthionine S7-C10

[0221] Function: In response to lowered pressure, the enzyme renin cleaves angiotensin 1, from angiotensinogen, then removes a dipeptide to yield the physiologically active angiotensin II, the most potent pressor substance known, which helps regulate volume and mineral balance of body fluids.

[0222] Anthopleurin-A (neuropeptide)

4A4-Sequence:GVSALCDSDGPSVRGNTLSGTLTLYPSGCPSGWHNCK(SEQ ID NO:)AHGPTIGWCCKQ

[0223] Posttranslational lanthionine rings: S3-C6, S27-C31, S33-C38, T44-C48.

[0224] Anti-inflammatory peptide I (anti-inflammation)

[0225] S1,C6-Sequence: SQMKKCLDS (SEQ ID NO:)

[0226] Posttranslational lanthionine: S1-C6

[0227] Dermaseptin (antimicrobial peptide)

[0228] C10-Sequence:

[0229] ALWKTMLKKCGTMALHAGKAALGAAADTISQGTQ (SEQ ID NO:)

[0230] Posttranslational lanthionine: T5-C10.

[0231] Bombinin-like peptide (antimicrobial peptide)

[0232] C8-Sequence: GIGASILCAGKSALKGLAKGLAEHFAN-NH2 (SEQ ID NO:)

[0233] Posttranslational lanthionine: S5-C8.

[0234] Histatin-5 (antimicrobial salivary peptide)

[0235] S4,C7-Sequence: DSHSKRCHGYKRKFHDKHHSHRGY (SEQ ID NO:)

[0236] Posttranslational lanthionine: S4-C7.

[0237] Indolicidin (antimicrobial peptide)

[0238] S2,C5-Sequence: ISPWCWPWWPWRR-NH2 (SEQ ID NO:)

[0239] Posttranslational lanthionine: S2-C5.

[0240] Magainin-1 (antimicrobial peptide)

[0241] C13-Sequence: GIGKFLHSAGKFCKAFVGEIMKS (SEQ ID NO:)

[0242] Posttranslational lanthionine: S8-C13.

[0243] Atrial Natriuretic Factor (potent vasoactive substance with a key role in cardiovascular homeostasis and cGMP-stimulating activity).

[0244] Sequence: SLRRSSCFGGRMDRIGAQSGLGCNSFRY (SEQ ID NO:)

[0245] Posttranslational lanthionines: S1-C7, S19-C23.

[0246] Bradykinin (important role in renal physiology and behavior).

[0247] C9-Sequence: RPPGFSPFC (SEQ ID NO:)

[0248] Posttranslational lanthionine: S6-C9.

[0249] Brain Natriuretic Peptide (acts as a cardiac hormone involved in natriuresis, diuresis, vasorelaxation, inhibition of renin and aldosteron secretion, improves heart function)

[0250] S16,C19-Sequence: SPKMVQGSGCFGRKMSRICSSSGLGCKVLRRH (SEQ ID NO:)

[0251] Posttranslational lanthionine: S8-C10, S16-C19

[0252] C-type Natriuretic peptide (exhibits natriuretic and vasodepressor activity)

5Sequence:DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGC(SEQ ID NO:)FGLKLDRIGSMSGLGC

[0253] Posttranslational lanthionine ring: S34-C37, S47-C53.

[0254] Vasonatrin peptide (vasorelaxation)

[0255] Sequence: GLSKGCFGLKLDRIGSMSGLGCNSFRY (SEQ ID NO:)

[0256] Posttranslational lanthionine ring: S3-C6,S17-C22.

[0257] Delta sleep inducing peptide (delta sleep induction)

[0258] S2,C6-Sequence: WSGGNCSGE (SEQ ID NO:)

[0259] Posttranslational lanthionine ring: S2-C6.

[0260] Deltorphin

[0261] S4,C7-Sequence: YMFSLMC-NH2 (D-methionine2)

[0262] Posttranslational lanthionine ring: S4-C7 (SEQ ID NO:)

[0263] Function: opiate-like activity.

[0264] Alpha-dendrotoxin

6S11,S26-Sequence:Pyr-PRRKLCILHRSPGRCYDKIPAFYYNSKKKQCER(SEQ ID NO:)FDWSGCGGNSNRFKTIEECRRTCIG

[0265] Posttranslational lanthionine: S11-C15, S26-C31

[0266] Function: affects potassium chaimels.

[0267] Eledoisin

[0268] C4-Sequence: pyr-PSKCAFIGLM-NH2 (SEQ ID NO:)

[0269] Posttranslational lanthionine ring: S2-C4

[0270] Function: neuron excitation, causing behavioral responses, vasodilators, secretagogues, causing contraction of smooth muscles.

[0271] Echistatin

7Sequence:ECESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTC(SEQ ID NO:)DCPRNPHKGPAT

[0272] Posttranslational lanthionine rings: S4-C7, T18-C20, T36-C37

[0273] Function: Inhibitor of fibrinogen-dependent platelet aggregation.

[0274] alpha-endorphin

[0275] S2,C6-Sequence: YSGFMCSEKSQTPLVT (SEQ ID NO:)

[0276] Posttranslational lanthionine ring: S2-C6

[0277] Function: opioid.

[0278] beta-endorphin

[0279] S21,C26-Sequence: YGGFMTSEKSQTPLVTLFKNSIIKNCYKKGE (SEQ ID NO:)

[0280] Posttranslational lanthionine ring: S21-C26

[0281] Function: opioid.

[0282] Defensin I

[0283] S2,S 12-Sequence: ASYCRIPACIAGSRRYGTCTYQGRLWAFCC (SEQ ID NO:)

[0284] Posttranslational lanthionine rings: S2-C4, S13-C19

[0285] Function: antimicrobial peptide.

[0286] Secretin

[0287] S23,C26-Sequence: HSDGTFTSELSRLREFARLQRLSQGCV-NH2 (SEQ ID NO:)

[0288] Posttranslational lanthionine ring:S23-C26

[0289] Function: pH regulation in the stomach.

[0290] Urocortin

8C19-Sequence:DNPSLSIDLTFHLLRTLLCLARTQSQRERAEQNRIIFDSV-NH2(SEQ ID NO:)

[0291] Posttranslational lanthionine ring: T16-C19

[0292] Function: stimulates ACTH secretion.

[0293] Urotensin II

[0294] S5-Sequence: AGTASCFWKYCV (SEQ ID NO:)

[0295] Posttranslational lanthionine rings: T3-C6, S5-C11

[0296] Function: osmoregulation and corticotropinrelease factor.

[0297] Small Cardioactive Peptide A

[0298] S4,C7-Sequence: ARPSYLCFPRM-NH2 (SEQ ID NO:)

[0299] Posttranslational lanthionine:S4-C7

[0300] Function: inhibits acetylcholine release

[0301] Small Cardioactive peptide B

[0302] S4,C7-Sequence: MNYSAFCRM-NH2 (SEQ ID NO:)

[0303] Posttranslational lanthionine: S4-C7

[0304] Function: stimulates contraction in the gut, increases amplitude of the heart beat.

[0305] Ceratotoxin A

[0306] C9-Sequence: SIGSALKKCLPVAKKIGKIALPIAKAALP (SEQ ID NO:)

[0307] Posttranslational lanthionine: S4-C9

[0308] Function: antimicrobial, hemolytic peptide with activity against Gram-positive and Gram-negative bacteria, stable at 100 degrees Celsius.

[0309] Cerebellin

[0310] C7-Sequence: SGSAKVCFSAIRSTNH (SEQ ID NO:)

[0311] Posttranslational lanthionine: S3-C7

[0312] Function: neuromudulation, stimulation of norepinephrine release, enhances indirectly adrenocortical secretion.

[0313] Charybdotoxin

9S33-Sequence:pyr-FTNVSCTTSKECWSVCQRLHNTSRGKCMNKKSRCYS(SEQ ID NO:)

[0314] Posttranslational (methyl)lanthionine: T3-C7, T8-C13, S15-C17, T23-C28, S33-C35

[0315] Function: inhibitor calcium- and voltage activated potassium channels.

[0316] Cholecystokinin

[0317] C8-Sequence: KAPSGRMCIVKNLQQLDPSHRISDRYMGWMDF-NH2 (SEQ ID NO:)

[0318] Posttranslational lanthionine: S4-C8

[0319] Function: Gall bladder contraction and release of pancreatic enzymes in the gut.

[0320] Conopressin G

[0321] S1-Sequence: SFIRNCPKG-NH2 (SEQ ID NO:)

[0322] Posttranslational lanthionine: S1-C6

[0323] Function: behavioral control.

[0324] alpha-Conotoxin E1

[0325] S2,S5-Sequence: RSHCSYHPTCNMSNPQIC-NH2 (SEQ ID NO:)

[0326] Posttranslational lanthionine: S2-C4, S5-C10, S13-C18

[0327] Function: blocking nicotinic acetylcholine receptors.

[0328] Corazonin

[0329] C9-Sequence: Pyr-TFQYSRGWCN-NH2 (SEQ ID NO:)

[0330] Posttranslational lanthionine: S5-C9

[0331] Function: Regulation heart beat.

[0332] Leu-enkephalin

[0333] S2,C3-Sequence: YSCFL (SEQ ID NO:)

[0334] Posttranslational lanthionine ring: S2-C3

[0335] Function: opioid

[0336] Met-enkephalin

[0337] S2,C3-Sequence: YSCFM (SEQ ID NO:)

[0338] Posttranslational lanthionine ring: S2-C3

[0339] Function: opioid.

[0340] Oxytocin

[0341] (S1)-Sequence: SYIQNCPLG-NH2 (SEQ ID NO:)

[0342] Posttranslational lanthionine ring S1-C6

[0343] Function: Oxytocin stimulates uterine contraction and lactation; increases Na+ secretion;

[0344] stimulates myometrial GTPase and phospholipase C.

[0345] Exendin-3

10C35-Sequence:HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGCPPPS-NH2(SEQ ID NO:)

[0346] Posttranslational lanthionine ring: S32-C35

[0347] Function: secretin-like.

[0348] Experimental Allergic Encephalitogenic peptide

[0349] C5-Sequence: FSWGCEGQR (SEQ ID NO:)

[0350] Posttranslational lanthionine ring: S2-C5

[0351] Function: myelin membrane stabilization.

[0352] Experimental Autoimmune Encephalomyelitis Complementary peptide

[0353] S4,C7-Sequence: VFISGPCRLLG (SEQ ID NO:)

[0354] Posttranslational lanthionine ring: S4-C7

[0355] Effect: having a role in autoimmune encephalomyelitis.

[0356] GonadoliberinII

[0357] (C9)-sequence: QHWSHGWYCG (SEQ ID NO:)

[0358] Posttranslational lanthionine ring: S4-C9

[0359] Function: stimulates the secretion of gonadotropins; it stimulates the secretion of both luteinizing and follicle stimulating hormones.

[0360] Tocinoic acid/pressinoic acid

[0361] (S1,I3)-Sequence: SYIQNC (SEQ ID NO:)

[0362] posttranslational lanthionine ring S1-C6

[0363] Function: Tocinoic acid is an oxytocin inhibitor, induces maternal behavior.

[0364] Leuprolide

[0365] Sequences:

[0366] XHWSYGCRPX (SEQ ID NO:)

[0367] Posttranslational thioether ring: S4-C7

[0368] XHWSYXCRX

[0369] Posttranslational thioether ring: S4-C7

[0370] Function: LHRH agonist.

[0371] Calcitonin

[0372] Accession number: P01258

[0373] (S1)-Sequence: SGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP

[0374] Posttranslational thioether ring S1-C7

[0375] Function: CaPi incorporation in bones.

[0376] ACTH, Adrenocorticotropic hormone

[0377] (Q5, C6)-Sequence: SYSMQCFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF

[0378] posttranslational lanthionine ring S1-C6

[0379] Function: ACTH stimulates synthesis and secretion of glucocorticoids by adrenal cortex.

[0380] Corticotropin inhibiting peptide

[0381] S4,C8-Sequence: FRWSKPVCKKRRPVKVYPNGAEDSAEAFPLE

[0382] Posttranslational lanthionine: S4-C8

[0383] Function: inhibition ACTH.

[0384] Corticotropin-Release Factor

[0385] S30,C33-Seq: SEEPPISLDLTFHLLREVLEMARAEQLAQSAHCNRKLMEI1—NH2

[0386] Posttranslational lanthionine: S30-C33

[0387] Function: release of corticotrophin.

[0388] Somatostatin

[0389] (S3)-Sequence:AGSKNFFWKTFTSC

[0390] posttranslational lanthionine ring S3-C14

[0391] Function:somatotropin release inhibition factor, growth hormone release inhibiting factor.

[0392] Human pancreatic polypeptide

[0393] (S18, C21)-Sequence: APLEPVYPGDNATPEQMSQYCADLRRUINMLTRPRY-NH2,

[0394] Posttranslational lanthionine ring S18-C21

[0395] Function: Agonist at Y4 neuropeptide receptors.

[0396] Peptide YY

[0397] (S22,C25,T29,C32)-Sequence:

[0398] YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2

[0399] Posttranslational (methyl)lanthionine rings S22-C25, T29-C32

[0400] Function: Gut hormone that inhibits both secretin- and cholecystokinin-stimulated pancreatic secretion.

[0401] Glucagon

[0402] (C5,S24,C29)-Sequence: HSQGCFTSDYSKYLDSRRAQDFVSWLMNC

[0403] Posttranslational lanthionine rings S1-C5, S24-C29

[0404] Function: restoring blood glucose level when too low.

[0405] alpha-neurokinin

[0406] (C9)-sequence: HKTDSFVGCM-nh2

[0407] posttranslational lanthionine ring S5-C9

[0408] function: tachykinin antagonist.

[0409] LHRH, Luteinizing Hormone Releasing Hormone fragment

[0410] (C7)-Sequence: DHWSYGCRPG-NH2

[0411] Posttranslational lanthionine ring S4-C7

[0412] Function: regulates secretion of gonadotropins, luteinizing hormone and sex steroids.

[0413] LHRH1, Luteinizing Hormone Releasing Hormone fragment

[0414] Function: regulates secretion of gonadotropins, luteinizing hormone and sex steroids.

[0415] (Q1, C7)-Sequence: (Q instead of pGlu)QHWSYGCRPG(—NH2)

[0416] Posttranslational lanthionine ring S4-C7

11(S1, C4)-Sequence:SHWCYGLRPGposttr. ring: S1-C4(S1, A4, C5)-Sequence:SHWACGLRPGposttr. ring: S1-C5(S1, A4, C6)-Sequence:SHWAYCLRPGposttr. ring: S1-C6(Q1, S2, A4, C5)-Sequence:QSWACGLRPGposttr. ring: S2-C5(Q1, S2, A4, C6)-sequence:QSWAYCLRPGposttr. ring: S2-C6(Q1, S2, A4, C7)-sequence:QSWAYGCRPGposttr. ring: S2-C7(Q1, S3, A4, C6)-sequence:QHSAYCLRPGposttr. ring: S3-C6(Q1, S3, A4, C7)-sequence:QHSAYGCRPGposttr. ring: S3-C7(Q1, S3, A4, C8)-sequence:QHSAYGLCPGposttr. ring: S3-C8(Q1, C8)-sequence:QHWSYGLCPGposttr. ring: S4-C8(Q1, C9)-sequence:QHWSYGLRCGposttr. ring: S4-C9(Q1, A4, S5, C8)-sequence:QHWASGLCPGposttr. ring: S5-C8(Q1, A4, S5, C9)-sequence:QHWASGLRCGposttr. ring: S5-C9(Q1, A4, S5, C10)-sequence:QHWASGLRPCposttr. ring: S5-C10(Q1, A4, S6, C9)-sequence:QHWAYSLRCGposttr. ring: S6-C9(Q1, A4, S6, C10)-sequence:QHWAYSLRPCposttr. ring: S6-C10(Q1, A4, S7, C10)-sequence:QHWAYGSRPCposttr. ring: S7-C10.

[0417] LHRH2, Luteinizing Hormone Releasing Hormone fragment

[0418] Function: regulates secretion of gonadotropins, luteinizing hormone and sex steroids.

[0419] (Q1, C7)-Sequence: (Q instead of pGlu)QHWSHGCYPG(—NH2)

[0420] Posttranslational lanthionine ring S4-C7

12(S1, C4)-Sequence:SHWCHGWYPGposttr. ring: S1-C4(S1, A4, C5)-Sequence:SHWACGWYPGposttr. ring: S1-C5(S1, A4, C6)-Sequence:SHWAHCWYPGposttr. ring: S1-C6(Q1, S2, A4, C5)-Sequence:QSWACGWYPGposttr. ring: S2-C5(Q1, S2, A4, C6)-sequence:QSWAHCWYPGposttr. ring: S2-C6(Q1, S2, A4, C7)-sequenee:QSWAHGCYPGposttr. ring: S2-C7(Q1, S3, A4, C6)-sequence:QHSAHCWYPGposttr. ring: S3-C6(Q1, S3, A4, C7)-sequence:QHSAHGCYPGposttr. ring: S3-C7(Q1, S3, A4, C8)-sequenee:QHSAHGWCPGposttr. ring: S3-C8(Q1, C8)-sequence:QHWSHGWCPGposttr. ring: S4-C8(Q1, C9)-sequence:QHWSHGWYCGposttr. ring: S4-C9(Q1, A4, S5, C8)-sequence:QHWASGWCPGposttr. ring: S5-C8(Q1, A4, S5, C9)-sequence:QHWASGWYCGposttr. ring: S5-C9(Q1, A4, S5, C10)-sequence:QHWASGWYPCposttr. ring: S5-C10(Q1, A4, S6, C9)-sequence:QHWAHSWYCGposttr. ring: S6-C9(Q1, A4, S6, C10)-sequence:QHWAHSWYPCposttr. ring: S6-C10(Q1, A4, S7, C10)-sequence:QHWAHGSYPCposttr. ring: S7-C10.

[0421] Brain derived acidic fibroblast growth factor (102-111)

[0422] (S103,C109)-Sequence: HSQKHWFCGL

[0423] Posttranslational lanthionine ring S103-C109

[0424] Function:growth factor.

[0425] Brain derived basic fibroblast growth factor (1-24)

[0426] Sequence:PALPEDGGSGAFPPCHFKDPKRLY

[0427] Posttranslational lanthionine ring S11-C17

[0428] Function: growth factor.

[0429] Insulin

13Sequences:alpha-chain:GIVEQCCASVCSLYQLENYCN(SEQ ID NO:)(S9-C14, T27-C30)-beta chain:FVNQHLCGSHLVECLYLVCGERGFFYTPKC(SEQ ID NO:)

[0430] Posttranslational (methyl)lanthionine rings S9-C14, T27-C30

[0431] disulfide bonds: alpha 6-11 alpha 7-beta 7, alpha 20-beta 19

[0432] function: diabetes treatment.

[0433] Parathormone:

14(S36-C39, T79-C82)-Sequence:SVSEIELMHNLGKHLNSMERVEWLRKKLQDVHNFVSL(SEQ ID NO:)GCPLAPRDAGSERPRKKEDNVLVESHEKSLGEADKADVNVLTKACSE

[0434] Posttranslational (methyl)lanthionine rings S36-C39, T79-C82

[0435] Function: modulation of serum calcium content affecting the mineral and bone physiology.

[0436] Fibrinogen Binding Inhibitor peptide

[0437] S6,C9-Sequence: HHLGGSKQCGDV

[0438] Posttranslational lanthionine: S6-C9.

[0439] Fibroblast growth factor inhibitory peptide

[0440] S1,C3-Sequence: SPCGHYKG

[0441] Posttranslational lanthionine ring: S1-C3

[0442] Effect: inhibition fibroblast growth factor.

[0443] Galanin

[0444] C10-Sequence: GWTLNSAGYCLGPHAVGNHRSFSDKNGLTS

[0445] Posttranslational lanthionine ring: S6-C10

[0446] Function: contracts smooth muscle of the gastrointestinal and genitourinary tract, regulates growth hormone release, modulates insulin release.

[0447] Gastric Inhibitory Polypeptide

[0448] S28,C31-Sequence:

[0449] YAEGTFISDYSIAMDKIHQQDFVNWLLSQKCKKNDWKHNITQ

[0450] Function: potent stimulation of insulin secretion and relatively poor inhibitor of gastric acid secretion.

[0451] Big Gastrin-I

[0452] S8,C 11-Sequence: Pyr-LGPQGPPSLVCDPSKKQGPWLEEEEEAYGWMDF-NH2

[0453] Posttranslational lanthionine ring: S8-C11

[0454] Function: stimulates gastric HCl secretion, pancreatic enzyme secretion, smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine.

[0455] Pentagastrin

[0456] S1,C4-Sequence: Boc-beta-SWMCF-NH2

[0457] Posttranslational lanthionine ring: S1-C4

[0458] Gastrin Releasing Peptide

[0459] S9,C 12-Sequence: VPLPAGGGSVLCKMYPRGNHWAVGHLM-NH2

[0460] Posttranslational lanthionine ring: S9-C12

[0461] Function: gastrin release.

[0462] Transforming growth factor alpha

15Sequence:VVSHFNDCPDSHTQFCFHGTCRFLVQEDKPACVCHSGYVGARCEHADLLA

[0463] Posttranslational (methyl)lanthionine ring: S3-C8, T21-C22, S37-C44

[0464] Function: TGF alpha is a mitogenic polypeptide that is able to bind to the egf receptor and act synergistically with TGF beta to promote anchorage-independent cell proliferation in soft agar.

[0465] Human growth hormone

[0466] C7-Sequence: FPTIPLCRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYS

[0467] Posttranslational methyllanthionine ring: T3-C7

[0468] Function: growth hormone, stimulates amongst others protein synthesis and amino acid uptake.

[0469] Growth hormone release factor

[0470] C22-Sequence:

[0471] YADAIFTNSYRKVLGQLSARKCLQDIMSRQQGESNQERGARARL-NH2

[0472] Posttranslational lanthionine ring: S18-C22

[0473] Function: release of growth hormone.

[0474] Guanylin

[0475] Sequence: PGTCEICAYAACTGC

[0476] Posttranslational lanthionine ring: T3-C4, T13-C15

[0477] Function: activator of guanylate cyclase.

[0478] Helospectin I

[0479] S15,C 18-Sequence: HSDATFTAEYSKLLSKLCLQKYLESILGSSTSPRPPSS

[0480] Posttranslational lanthionine ring: S15-C18

[0481] Hepatitis B surface antigen fragment

[0482] C6-Sequence: MGTNLCVPNPLGFFPDHQLDP

[0483] Posttranslational methyllanthionine ring: T3-C6

[0484] Function: exendin-1: secretin-like.

[0485] Intercellular adhesion molecule

[0486] Sequence: NAQTSVSPSKVILPRGGSVLVTC

[0487] Posttranslational lanthionine ring: S18-C23

[0488] Function: anti-hiv.

[0489] Tachyplesin I

[0490] (S3,S12)-Sequence: KWSFRVCYRGISYRRCR-NH2

[0491] Posttranslational lanthionine rings S3-C7, S12-C16

[0492] Function Hiv cell fusion inhibitor, anti tumor peptide, antimicrobial peptide.

[0493] HIV (gp120) antigenic peptide fragment

[0494] (S10,C 14)-Sequence: CGKIEPLGVSPTKCKRRVVQREKR

[0495] Posttranslational lanthionine ring S10-C14.

[0496] HIV (gp 41) antigenic peptide 1 fragment

[0497] (S2)-Sequence: GSSGKLICTTAVPWNAS

[0498] Posttranslational lanthionine S2-C8.

[0499] HIV (gp41) antigenic peptide 5

[0500] (S20)-Sequence:RVTAIEKYLQDQARLNSWGSAFRQVCHTTVPWVNDS-NH2

[0501] Posttranslational lanthionine ring S20-C26.

[0502] HIV protease inhibitors

[0503] Sequence: ac-TVSFCF

[0504] Posttranslational lanthionine ring T1-C5

[0505] Function: inhibitor HIV protease.

[0506] Insulin-like growth factor-I analog

[0507] S1,C4-Sequence: SYACPLKPAKSC

[0508] Posttranslational lanthionine rings: S1-C4, S11-C12.

[0509] IGF II 69-84:

[0510] (C7)-Sequence: DVSTPPCVLPDNFPRY (SEQ ID NO:)

[0511] Posttranslational lanthionine ring S3-C7.

[0512] Interleukin-8 fragment:

[0513] (S6, C10)-Sequence: AVLPRSAKEC (SEQ ID NO:)

[0514] Posttranslational lanthionine ring S6-C 10

[0515] Function: attraction neutrophils, basophils and T-cells, but not monocytes. It is involved in neutrophil activation and is released from several cell-types in response to inflammation.

[0516] Interleukin-2 fragent(60-70) (T-cell growth factor)

[0517] Sequence: LTFKFYMSKKC (SEQ ID NO:)

[0518] Posttranslational lanthionine ring S67-C70.

[0519] Leucokinin I (neuroactive peptide)

[0520] C8-Sequence: DPAFNSWC-NH2 (SEQ ID NO:)

[0521] Posttranslational lanthionine ring: S6-C8.

[0522] Leukopyrokinin

[0523] C4-Sequence: pyr-TSFCPRL-NH2 (SEQ ID NO:)

[0524] Posttranslational lanthionine ring:T1-C4

[0525] Function: mediates visceral muscle contractile activity.

[0526] Mastoparan

[0527] S5,C8-Sequence: INLKSLACLAKKIL-NH2 (SEQ ID NO:)

[0528] Posttranslational lanthionine ring: S5-C8

[0529] Function: Wasp venom membrane-active toxin.

[0530] Melanin concentrating hormone

[0531] S11-Sequence: DFDMLRCMLGSVYRPCWQV (SEQ ID NO:)

[0532] Posttranslational lanthionine ring: S11-C16

[0533] Function: possible neurotransmitter, involved in the regulation of goal directed behavior.

[0534] Melittin

[0535] C14-Sequence: GIGAVLKVLTGLPCLISWIKRKRQQ-NH2 (SEQ ID NO:)

[0536] Posttranslational lanthionine ring: T10-C14

[0537] Function: Bee venom membrane-active peptide.

[0538] Motilin

[0539] C9-Sequence: FVPIFTYGCLQRMQEKERNKGQ (SEQ ID NO:)

[0540] Posttranslational lanthionine ring: T6-C9

[0541] Function: regulation of interdigestive gastrointestinal motility.

[0542] Neuropeptide Y

16C26-Sequence:YPSRPDNPGEDAPAEDMARYYSALRCYINLITRNRY-ND2(SEQ ID NO:)

[0543] Posttranslational lanthionine ring S22-C26

[0544] Function:control of feeding and secretion of gonadotropin-release hormone.

[0545] Osteocalcin

17S4,C8-Sequence:YLYSWLGCPVPYPDPDELADHIGFQEAYRRFYGPV(SEQ ID NO:)

[0546] Posttranslational lanthionine ring: S4-C8

[0547] Function: constitutes 1-2% of the total bone protein, it binds strongly to apatite and calcium.

[0548] (N-acetyl-)beta-endorphin 1-27

[0549] (C21)-Sequence: YGGFMTSEKSQTPLVTLFKNCIIKNAY (SEQ ID NO:)

[0550] Posttranslational methyllanthionine T16-C21

[0551] Functions: analgesia, behavioral changes, growth hormone release.

[0552] Ras oncogene related peptide

[0553] HU-rasha

[0554] (S2, C5)-Sequence: GSGGCGKS (SEQ ID NO:)

[0555] Posttranslational lanthionine ring S2-C5.

[0556] Ras oncogene related peptide

[0557] Hu-rasT24

[0558] (S2, C5)-Sequence: GSVGCGKS (SEQ ID NO:)

[0559] Posttranslational lanthionine ring S2-C5.

[0560] Ras oncogene related peptide

[0561] Hu-(Hu-ras124)-Lys

[0562] (S3, C6)-Sequence: YGSVGCGKSK (SEQ ID NO:)

[0563] Posttranslational lanthionine ring S3-C6.

18TABLE 1BAlbuminAccession number:P02768Sequence:DTHKSE IAHRFKIDLGE EHFKGLVLIA FSQYLQQCPF DEHVKLVNELTEFAKTCVAD ESHAGCEKSL HTLFGDELCK VASLRETYGD MADCCEKQEPERNECFLSHK DDSPDLPKLKPDPNTLCDEF KADEKIKFWGK YLYEIARRHPYFYAPELLYY ANICYNGVFQE CCQAEDKGAC LLPKIETMRE KVLASSARQRLRCASIQKFG ERALKAWSVA RLSQKIFPKAE FVEVTKLVTD LTKVHKECCHGDLLECADDR ADLAKYICDN QDTISSKLKE CCDKPLLEKS HCIAEVEKDAIPENLPPLTA DFAEDKDVCK NYQEAKDAFL GSFLYEYSRR HPEYAVSVLLRLAKEYEATL EECCAKDDPH ACYSTVFDKL KHLVDEPQNL IKQNCDQFEKLGEYGFQNAL IVRYTRKVPQ VSTPTLVEVS RSLGKVGTRC CTRPFSERMPCTEDYLSLIL NRLCVLHEKT PVSEKVTKCC TESLVNRRPC FSALTPDETYVPKAFDEKLF TFHADICTLP DTEKQIKKQT ALVELLKHKP KATEEQLKTVMENFVAFVDK CCAADDKEAC FAVEGPKLVV STQTALA

[0564] Disulfide bonds: 77-86;99-115; 114-125; 148-193; 192-201;224-270;269-277;289-303;302-313;340-385;384-393;416-462;461-472;485-501;500-511;538-583;582-591 (numbers correspond to the precursor protein which contains 24 amino acids more, N-terminally)

[0565] Function: regulation colloidal osmotic pressure of the blood plasma, binding blood plasma molecules.

[0566] Alglucerase

[0567] Accession number: P04062

19Sequence:A RPCIPKSFGY SSVVCVCNAT YCDSFDPPTF PALGTFSRYESTRSGRRMEL SMGPIQANHT GTGLLLTLQP EQKFQKVKGFGGAMTDAAAL NILALSPPAQ NLLLKSYFSE EGIGYNIIRVPMASCDFSIR TYTYADTPDD FQLHNESLPE EDTKLKIPLIHRALQLAQRP VSLLASPWTS PTWLKTNGAV NGKGSLKGQPGDIYHQTWAR YFVKFLDAYA EHKLQFWAVT AENEPSAGLLSGYPFQCLGF TPEHQRDFIA RDLGPTLANS THHNVRLLMLDDQRLLLPHW AKVVLTDPEA AKYVHGIAVH WYLDFLAPAKATLGETHRLF PNTMLFASEA CVGSKFWEQS VRLGSWDRGMQYSHSIITNL LYHVVGWTDW NLALNPEGGP NWVRNFVDSPIIVDITKDTF YKQPMFYHLG HFSKFIPEGS QRVGLVASQKNDLDAVALMH PDGSAVVVVL NRSSKIDVPLT IKIDPAVGFLETISPGYSIHT YLWHRQ

[0568] Function: glucosylceramidase.

[0569] Alpha-galactosidase

[0570] Accession number: P06280

20Sequence:LDNGLARTP TMGWLHWERE MCNLDCQEEP DSCISEKLFMEMAELMVSEG WKDAGYEYLC IDDCWMAPQR DSEGRLQADPQRFPHGIRQL ANYVHSKGLK LGIYADVGNK TCAGFPGSFGYYDIDAQTFA DWGVDLLKFD GCYCDSLENL ADGYKHMSLALNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFADIDDSWKSIK SILDWTSFNQ ERIVDVAGPG GWNDPDMLVIGNFGLSWNQQ VTQMALWAIM AAPLFMSNDL RHISPQAKALLQDKDVIAIN QDPLGKQGYQ LRQGDNFEVW ERPLSGLAWAVAMTNRQEIG GPRSYTIAVA SLGKGVACNP ACFITQLLPVKRKLGFYEWT SRLRSHINPT GTVLLQLENT MQMSLKDLL

[0571] Function: galactosidase.

[0572] Alteplase

[0573] Accession number: P00750

21Sequence:SYQVI CRDEKTQMIY QQHQSWLRPV LRSNRVEYCW CNSGRAQCHSVPVKSCSEPR CFNGGTCQQA LYFSDFVCQC PEGFAGKCCEIDTRATCYED QGISYRGTWS TAESGAECTN WNSSALAQKPYSGRRPDAIR LGLGNHNYCR NPDRDSKPWC YVFRAGKYSSEFCSTPACSE GNSDCYFGNG SAYRGTHSLT ESGASCLPWNSMILIGKVYT AQNPSAQALG LGKHNYCRNP DGDAKPWCHVLKNRRLTWEY CDVPSCSTCG LRQYSQPQFR IKGGLFADIASHPWQAAIFA KHRRSPGERF LCGGILISSC WILSAAHCEQERFPPHHLTV ILGRTYRVVP GEEEQKFEVE KYIVHKEFDDDTYDNDIALL QLKSDSSRCA QESSVVRTVC LPPADLQLPDWTECELSGYG KHEALSPFYS ERLKEAHVRL YPSSRCTSQHLLNRTVTDNM LCAGDTRSGG PQANLHDACQ GDSGGPLVCLNDGRMTLVGI ISWGLGCGQK DVPGVYTKVT NYLDWIRDNM RP

[0574] wgetz?-e+(SWIS SPROT_features-id: TPA_HUMAN—17)

[0575] Disulfide: 41-71; 69-78; 86-97; 91-108;110-119; 127-208; 148-190; 179-203; 215-296;236-278; 267-291; 299-430; 342-358; 350-419; 444-519; 476-492;509-537 (counted with 35 additional N-terminal aa)

[0576] Function: cleaves plasminogen to form plasmin

[0577] Antithrombin III

[0578] Accession number: P01008

22Sequence:HGSPVDIC TAKPRDIPMN PMCTYRSPEK KATEDEGSEQKIPEATNRRV WELSKANSRF ATTFYQHLAD SKNDNDNIFLSPLSISTAFA MTKLGACNDT LQQLMEVFKF DTISEKTSDQIHFFFAKLNC RLYRKANKSS KLVSANRLFG DKSLTFNETYQDISELVYGA KLQPLDFKEN AEQSRAATNK WVSNKTEGRITDVTPSEAIN ELTVLVLVNT IYFKGLWKSK FSPENTRKELFYKADGESCS ASMMYQEGKF RYRRVAEGTQ VLELPFKGDDITMVLILPKP EKSLAKVEKE LTPEVLQEWL DELEEMMLVVHMPRFRIEDG FSLKEQLQDM GLVDLFSPEK SKLPGIVAEGRDDLYVSDAF HKAFLEVNEE GSEAAASTAV VIAGRSLNPNRVTFKANRPF LVFTREVPLN TIIFMGRVAN PCVK

[0579] Disulfide: 40-160;53-127; 279-462 (counted with 32 aa signal sequence)

[0580] Function: inhibition coagulation.

[0581] Aprotinin

[0582] Accession number: P00974

23Sequence:RPDFC LEPPYTGPCK ARIIRYFYNA KAGLCQTFVY GGCRAKIRNNFKSAEDCMRTC GGA

[0583] Disulfide: 40-90; 49-73; 65-86 (counting with 35 aa N-terminal)

[0584] Function: Inhibits trypsin, kallikrein, chymotrypsin and plasmin.

[0585] Asparaginase

[0586] Accession number: P20933

24Sequence:alpha-chain:SPLPLV VNTWPFKNAT EAAWRALASG GSALDAVESG CAMCEREQCDGSVGFGGSPD ELGETTLDAM IMDGTTMDVG AVGDLRRIKN AIGVARKVLEHTTHTLLVGE SATTFAQSMG FINEDLSTSA SQALHSDWLA RNCQPNYWRNVIPDPSKYCG PYKPPGILKQ DIPIHKETED DRGHDbeta-chain:TIGMV VIHKTGHIAA GTSTNGIKFK IHGRVGDSPI PGAGAYADDTAGAAAATGNG DILMRFLPSY QAVEYMRRGE DPTIACQKVI SRIQKHFPEFFGAVICANVT GSYGAACNKL STFTQFSFMV YNSEKNQPTE EKVDCI

[0587] Disulfide: 64-69; 163-179; 286-306; 317-345 (counted with 23 extra N-terminal aa)

[0588] Function: Cleaving glycoproteins.

[0589] Becaplermin

[0590] Accession number: P01127

25Sequence:SLGSLTIAE PAMIAECKTR TEVFEISRRL IDRTNANFLVWPPCVEVQRC SGCCNNRNVQ CRPTQVQLRP VQVRKIEIVRKKPIFKKATV TLEDHLACKC ETVAAARPVT RSPGGSQEQRAKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG

[0591] Disulfide: 97-141; 130-178; 134-180;124-124 INTERCHAIN; 133-133 INTERCHAIN.

[0592] (counting with 81 aa N-terminal)

[0593] Function: growth factor from platelet.

[0594] Bone morphogenic protein 7

[0595] Accession number: P34819

26Sequence:GKHNSAPMFM LDLYNAMAVE EGGGPAGQGF SYPYKAVFSTQGPPLASLQD SHFLTDADMV MSFVNLVEHD KEFFHPRYHHREFRFDLSKI PEGEAVTAAE FRIYKDYIRE RFDNETFRISVYQVLQEHLG RESDLFLLDS RTLWASEEGW LVFDITATSNHWVVNPRHNL GLQLCVETLD GQSINPK

[0596] Function: induces bone formation, involved in Ca regulation.

[0597] Catalase

[0598] Accession number: P04040

27Sequence:ADSRDPASDQ MQHWKEQRAA QKADVLTTGA GNPVGDKLNVITVGPRGPLL VQDVVFTDEM AHFDRERIPE RVVHAKGAGAFGYFEVTHDI TKYSKAKVFE HIGKKTPIAV RFSTVAGESGSADTVRDPRG FAVKFYTEDG NWDLVGNNTP IFFIRDPILFPSFIHSQKRN PQTHLKDPDM VWDFWSLRPE SLHQVSFLFSDRGIPDGHRH MNGYGSHTFK LVNANGEAVY CKFHYKTDQGIKNLSVEDAA RLSQEDPDYG IRDLFNAIAT GKYPSWTFYIQVMTFNQAET FPFNPFDLTK VWPHKDYPLI PVGKLVLNRNPVNYFAEVEQ IAFDPSNMPP GIEASPDKML QGRLFAYPDTHRHRLGPNYL HTPVNCPYRA RVANYQRDGP MCMQDNQGGAPNYYPNSFGA PEQQPSALEH SIQYSGEVRR FNTANDDNVTQVRAFYVNVL NEEQRKRLCE NIAGHLKDAQ IFIQKKAVKNFTEVHPDYGS HIQALLDKYN AEKPKNAIHT FVQSGSHLAA REKANL

[0599] Function: protection against H2O2

[0600] Cecropin B

[0601] Accession number: P01508

[0602] Sequence: KWKV FKKIEKMGRN IRNGIVKAGP AIAVLGEAKA LG

[0603] Modified: 61 AMIDATION (G-62 PROVIDE AMIDE GROUP).

[0604] Function: Antibacterial.

[0605] Cellulase

[0606] Accession number: P23548

28Sequence:MKKKGLKKTF FVIASLVMGFTLYGYTPVSA DAASVKGYYHTQGNKIVDES GKEAAFNGLN WFGLETPNYT LHGLWSRSMDDMLDQVKKEG YNLIRLPYSN QLFDSSSRPD SIDYHKNPDLVGLNINQIMD KLIEKAGQRG IQIILDRHRP GSGGQSELWYTSQYPESRWI SDWKMLADRY KNNPTVIGAD LHNEPHGQASWGTGNASTDW RLAAQRAGNA ILSVNPNWLI LVEGVDHNVQGNNSQYWWGG NLTGVANYPV VLDVPNRVVY SPHDYGPGVSSQPWFNDPAF PSNLPAIWDQ TWGYISKQNI APVLVGEFGGRNVDLSCPEG KWQNALVHYI GANNLYFTYW SLNPNSGDTGGLLLDDWTTW NRPKQDMLGR IMKPVVSVAQ QAEAAAE

[0607] Function: hydrolysis cellulose.

[0608] Choriogonadotropin alpha

[0609] Accession number: P01215

29Sequence:APDVQD CPECTLQENP FFSQPGAPIL QCMGCCFSRA YPTPLRSKKTMLVQKNVTSE STCCVAKSYN RVTVMGGFKV ENHTACHCST CYYHKS

[0610] Function: A heterodimer of a common alpha chain and a unique beta chain confers biological specificity to thyrotropin, lutropin, follitropin and gonadotropin.

[0611] Choriogonadotropin beta

[0612] Accession number: P01233

30Sequence:SKIEPLRPRCR PINATLAVEK EGCPVCITVN TTICAGYCPTMTRVLQGVLP ALPQVVCNYR DVRFESIRLP GCPRGVNPVVSYAVALSCQC ALCRRSTTDC GGPKDHPLTC DDPRFQDSSSSKAPPPSLPS PSRLPGPSDT PILPQ

[0613] Disulfide: 29-77; 43-92; 46-130; 54-108; 58-110; 113-120

[0614] Function: stimulates steroid production.

[0615] Chymopapain

[0616] Accession number: P14080

31PQSID WRAKGAVTPV KNQGACGSCW AFSTIATVEG TNKIVTGNLLELSEQELVDC DKHSYGCKGG YQTTSLQYVA NNGVHTSKVYPYQAKQYKCR ATDKPGPKVK ITGYKRVPSN CETSFLGALANQPLSVLVEA GGKPFQLYKS GVFDGPCGTK LDHAVTAVGYGTSDGKNYII IKNSWGPNWG EKGYMRLKRQ SGNSQGTCGVYKSSYYPFKG FA

[0617] Disulfide: 156-197; 190-229; 287-338 (counting with 134 aa N-terminal)

[0618] Function: Thiol protease.

[0619] Chymotrypsin

[0620] Accession number: P54414

32MTTSAARKGL RTRGSACPRA TRSASSISSR AQVIVAGPITDKLAQRTVAH LLALAEDSDE PINMLISSPG GHVESGDMIHDVIKFIRPTV RTIGLAWVAS AGALIFVGAD KFNRYCLPNTRELIHQPSVG IGGTSTDMMI QAEQVRLMRD RLNQIFAEATGQPVERIEKD TQRDFWLNTQ EALDYGLLGK VIRSVDELK

[0621] Function: serine protease.

[0622] Big Endothelin

[0623] Sequence: CSCS SLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRS

[0624] Function: endothelins are endothelium derived vasoconstrictor peptides.

[0625] Clostridium botulinum toxin type A

[0626] Accession number: Q45894

33Sequence A-light chain:PFVNKQFNYK DPVNGVDIAY IKIPNAGQMQ PVKAFKIHNKIWVIPERDTF TNPEEGDLNP PPEAKQVPVS YYDSTYLSTD NEKDNYLKGVTKLFERIYST DLGRMLLTSI VRGIPFWGGS TIDTELKVID TNCHNVIQPD GSYRSEELNLVIIGPSADII QFECKSFGHD VLNLTRNGYG STQYIRFSPD FTFGFEESLE VDTNPLLGAGKFATDPAVTL AHELIHAEHR LYGIATNPNR VFKVNTNAYY EMSGLEVSFEELRTFGGHDA KFIDSLQENE FRLYYYNKFK DVASTLNKAK SIIGTTASLQYMKNVFKEKY LLSEDTSGKF SVDKLKFDKL YKMLTEIYTE DNFVNFFKVINRKTYLNFDK AVFRINIVPD ENYTIKDGFN LKGANLSTNF NGQNTEINSRNFTRLKNFTG LFEFYKLLCV RGIIIPFKTKS LDEGYNKSequence A-heavy chain:ALN DLCIKVNNWD LFFSPSEDNF TNDLDKVEEITADTNIEAAE ENISLDLIQQ YYLTFDFDNE PENISIENLS SDIIGQLEPM PNIERFPNGKKYELDKYTMF HYLRAQEFEH GDSRIILTNS AEEALLKPNV AYTFFSSKYVKKINKAVEAF MFLNWAEELV YDFTDETNEV TTMDKIADIT IIVPYIGPALNIGNMLSKGE FVEAIIFTGV VAMLEFIPEY ALPVFGTFAI VSYIANKVLTVQTINNALSK RNEKWDEVYK YTVTNWLAKV NTQIDLIREK MKKALENQAEATKAIINYQY NQYTEEEKNN TNFNIDDLSS KLNESTNSAM TNTNKFLDQCSVSYLMNSMI PYAVKRLKDF DASVRDVLLK YIYDNRGTLV LQVDRLKDEVNNTLSADIPF QLSKYVDNKK LLSTFTEYIK NIVNTSILSI VYKIKDDLIDL SRYGAKINIGDRVYYDSIDK NQIKLINLES STIEVILKNA IVYNSMYENF STSFWIKIIPK YFSKTNLNNEYTITNCIENN SGWKVSLNYG EIIWTLQDNK QNIQRVVFKY SQMVNISDYINRWIFVTITN NRLTKSKIYI NGRLIDQKIN SNLGNIHASN KTMFKLDGCR DPRRYIMIKYFNLFDKELNE KEIKDLYDSQ SNSGILKDFW GNYLQYDKPY YMLNLFDPNKYVDVNNIGIR GYMYLKGPRG SVVTTNIYLN STLYEGTKFI IKKYASGNEDNIVRNNDRVY TNVVVKNKEY RLATNASQAG VEKILSALEI PDVGNLSQVVVMKSKDDQGI RNKCKMNLQD NNGNDIGFIG FHLYDNIAKL VASNWYNRQVGKASRTFGCS WEFIPVDDGW GESSL

[0627] Disulfide: 429-453 INTERCHAIN (BY SIMILARITY); 1234-1279

[0628] Function: blocking neurotransmitter release by hydrolysis of snap25.

[0629] Clostridium botulinum toxin type B

[0630] Accession number: P10844

34Sequence:PVTINNFNYN DPIDNNNIIM MEPPFARGTG RYYKAFKITD RIWIIPERYTFGYKPEDFNK SSGIFNRDVC EYYDPDYLNT NDKKNIFLQT MIKLFNRIKSKPLGEKLLEM IINGIPYLGD RRVPLEEFNT NIASVTVNKL ISNPGEVERK KGIFANLIIFGPGPVLNENE TIDIGIQMIF ASREGFGGIM QMKFCPEYVS VFNNVQENKGASIFNRRGYF SDPALILMHE LIHVLHGLYG IKVDDLPIVP NEKKFFMQSTDAIQAEELYT FGGQDPSIIT PSTDKSIYDK VLQNERGIVD RLNKVLVCIS DPNININIYKNKEKDKYKFV EDSEGKYSID VESFDKLYKS LMFGFTETNI AENYKIKTRASYFSDSLPPV KIKNLLDNEI YTIEEGFNIS DKDMEKEYRG QNKATNKQAYEEISKEHLAV YKIQMCKSVK APGICIDVDN EDLFFIADKN SFSDDLSKNERIEYNTQSNY IENDFPINEL ILDTDLISKI ELPSENTESL TDFNVDVPVY EKQPAIKKIFTDENTIFQYL YSQTFPLDIR DISLTSSFDD ALLFSNKVYS FFSMDYIKTANKVVEAGLFA GWVKQIVNDF VIEANKSNTM DKIADISLIV PYIGLALNVGNETAKGNFEN AFEIAGASIL LEFIPELLIP VVGAFLLESY IDNKNKIIKT IDNALTKRNEKWSDMYGLIV AQWLSTVNTQ FYTIKEGMYK ALNYQAQALE EIIKYRYNIYSEKEKSNINI DFNDINSKLN EGINQAIDNI NNFINGCSVS YLMKKMIPLAVEKLLDFDNT LKKNLLNYID ENKLYLIGSA EYEKSKVNKY LKTIMPFDLSIYTNPTILIE MFNKYNSEIL NNIILNLRYK DNNLIDLSGY GAKVEVYDGVELNDKNQFKL TSSANSKIRV TQNQNIIFNS VFLDFSVSFW IRIPKYKNDGIQNYIHNEYT IINCMKNNSG WKISIRGNFI IWTLIDTNGK TKSVFFEYNI REDISEYINRWFFVTITNNL NNAKIYINGK LESNTDIKDI REVIANGEII FKLDGDIDRT QFIWMKYFSIFNTELSQSNI EERYKIQSYS EYLKDFWGNP LMYNKEYYMF NAGNKNSYIKLIKDSPVGEI LTRSKYNQNS KYINYRDLYI GEKFIIRRKS NSQSTNDDIV RKEDYIYLDFFNLNQEWRVY TYKYFKKEEE KLFLAPISDS DEFYNTIQIK EYDEQPTYSCQLLFKKDEES TDEIGLIGIH RFYESGIVFE EYKDYFCISK WYLKEVKRKPYNLKLGCNWQ FIPKDEGWTE

[0631] Disulfide: 436-445 INTERCHAIN (PROBABLE).

[0632] Function: endopeptidase that cleaves synaptobrevin-2 and thus blocks neurotransmission.

[0633] Collagen

[0634] Accession number: P30754

35Sequence:YRAGPRYIQA QVGPIGPRGP PGPPGSPGQQ GYQGLRGEPGDSGPMGPIGK RGPPGPAGIA GKSGDDGRDG EPGPRGGIGPMGPRGAGGMP GMPGPXGHRG FRGLSGSXGE QGKSGNQGPDGGPGPAGPSG PIGPRGQTGE RGRDGKSGLP GLRGVDGLAGPPGPPGPIGS TGSPGFPGTP GSKGDRGQSG IXGAQGLQGPVGLSGQPGVA GENGHPGMPG MDGANGEPGA SGESGLPGPSGFPGPRGMPG TAGSPGQAGA XGDGGPTGEQ GRPGAPGVXGSSGPPGDVGA PGHAGEAGKR GSPGSPGPAG SPGPQGDRGLPGSRGLPGMT GASGAMGIPG EKGPSGEPGA KGPTGDTGRQGNQGTPGIAG LPGNPGSDGR PGKDGRPGIR GKDGKQGEQGPQGPQGLAGL QGRAGPPGAR GEPGKNGAPG EPGAHGEQGDAGKDGETGAA GPPGAAGPTG ARGPPGPRGQ QGFQGLAGAQGTPGEAGKTG ERGAVGATGP SGPAGPGGER GAPGDRGNVGPRGMPGERGA TGPAGPTGSP GVAGAKGQGG PPGPAGLVGLPGERGPKGVG GSXGSRGDIG PRGKAGERGK DGERGERGENGLPGPSGLAA SXGERGDMGS PGERGSPGPA GERGPAGSQGIQGQPGPPGD AGPAGTXGDI GFPGERGTRG ATGKQGARGPRGLAGKRGLR GAGGSRGETG AQGEIGLPGS PGQPGLPGPSGQPGPSGPAG TAGKQGVXGA RGSPGLVGKQ GDRGSDGEPGRDGTXGERGE DGPPGVSGPT GAPGQQGERG MPGMVGLRGETGPMGGQGMX GDGGPPGPSG DRGERGNAGP QGPTGPSGQAGAPGQEGAPG KDGLPGLAGR PGERGEPGVA GRAGSQGLAGLMGQRGLPGA AGPPGDRGER GEPGGQGVQG PVGAPGSQGPAGIMGMXGEA GGKGAXGDKG WTGLPGLQGL QGTPGHSGESGPPGAPGPRG ARGEAGGRGS QGPPGKDGQP GPSGRVGPRGPSGDDGRSGP PGPPGPPGPP GNSDYGA

[0635] Function: fibril formation

[0636] Collagenase

[0637] Accession number: P08897

36Sequence:IINGYEAYTG LFPYQAGLDI TLQDQRRVWC GGSLIDNKWILTAAHCVHDA VSVVVYLGSA VQYEGEAVVN SERIISHSMFNPDTYLNDVA LIKIPHVEYT DNIQPIRLPS GEELNNKFENIWATVSGWGQ SNTDTVILQY TYNLVIDNDR CAQEYPPGIIVESTICGDTC DGKSPCFGDS GGPFVLSDKN LLIGVVSFVSGAGCESGKPV GFSRVTSYMD WIQQNTGIIF

[0638] Disulfide: 60-76; 181-196; 206-234

[0639] Function: Serine protease.

[0640] Corticotropin, ACTH

[0641] Accession number: P01189

37Sequence:WCLE SSQCQDLTTE SNLLECIRAC KPDLSAETPM FPGNGDEQPLTENPRKYVMG HFRWDRFGRR NSSSSGSSGA GQKREDVSAGEDCGPLPEGG PEPRSDGAKP GPREGKRSYS MEHFRWGKPVGKKRRPVKVY PNGAEDESAE AFPLEFKREL TGQRLREGDGPDGPADDGAG AQADLEHSLL VAAEKKDEGP YRMEHFRWGSPPKDKRYGGF MTSEKSQTPL VTLFKNAIIK NAYKKGE

[0642] Disulfide: 28-50 (counting with 26 aa signal)

[0643] Function: melanocyte stimulation.

[0644] Dornase alfa

[0645] Accession number: P24855

38LKIAAFNI QTFGETKMSN ATLVSYIVQI LSRYDIALVQEVRDSHLTAV GKLLDNLNQD APDTYHYVVS EPLGRNSYKERYLFVYRPDQ VSAVDSYYYD DGCEPCGNDT FNREPAIVRFFSRFTEVREF AIVPLHAAPG DAVABIDALY DVYLDVQEKWGLEDVMLMGD FNAGCSYVRP SQWSSIRLWT SPTFQWLIPDSADTTATPTH CAYDRIVVAG MLLRGAVVPD SALPFNFQAAYGLSDQLAQA ISDHYPVEVM LK

[0646] Disulfide: 123-126; 195-231 (counted with 21 aa extra N-terminal)

[0647] Function: endonucleolytic, binds G-actin.

[0648] Eptacog alpha (factor VII)

[0649] Accession number: P08709

39Sequence:NAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLFWISYSDGDQC ASSPCQNGGS CKDQLQSYIC FCLPAFEGRNCETHKDDQLI CVNENGGCEQ YCSDHTGTKR SCRCHEGYSLLADGVSCTPT VEYPCGKIPI LEKRNASKPQ GRIVGGKVCPKGECPWQVLL LVNGAQLCGG TLINTIWVVS AAHCFDKIKNWRNLIAVLGE HDLSEHDGDE QSRRVAQVII PSTYVPGTTNHDIALLRLHQ PVVLTDHVVP LCLPERTFSE RTLAFVRESLVSGWGQLLDR GATALELMVL NVPRLMTQDC LQQSRKVGDSPNITEYMFCA GYSDGSKDSC KGDSGGPHAT HYRGTWYLTGIVSWGQGCAT VGHFGVYTRV SQYIEWLQKL MRSEPRPGVL LRAPFP

[0650] Disulfide: 77-82; 110-121; 115-130; 132-141; 151-162; 158-172; 174-187; 195-322; 219-224; 238-254; 370-389; 400-428 (counted with 61 aa N-terminally)

[0651] Function: coagulation.

[0652] Etanercept

[0653] Accession number: P20333

40Sequence:LPAQVAFT PYAPEPGSTC RLREYYDQTA QMCCSKCSPGQHAKVFCTKT SDTVCDSCED STYTQLWNWV PECLSCGSRCSSDQVETQAC TREQNRICTC RPGWYCALSK QEGCRLCAPLRKCRPGFGVA RPGTETSDVV CKPCAPGTFS NTTSSTDICRPHQICNVVAI PGNASRDAVC TSTSPTRSMA PGAVHLPQPVSTRSQHTQPT PEPSTAPSTS FLLPMGPSPP AEGSTGDFALPVGLIVGVTA LGLLIIGVVN CVIMTQVKKK PLCLQREAKVPHLPADKARG TQGPEQQHLL ITAPSSSSSS LESSASALDRRAPTRNQPQA PGVEASGAGE ARASTGSSDS SPGGHGTQVNVTCIVNVCSS SDHSSQCSSQ ASSTMGDTDS SPSESPKDEQVPFSKEECAF RSQLETPETL LGSTEEKPLP LGVPDAGMKP S

[0654] Disulfide: 40-53; 54-67; 57-75; 78-93; 96-110; 100-118; 120-126; 134-143; 137-161; 164 179

[0655] (counted with 22 aa extra N-terminally)

[0656] Function: receptor TNF-alpha.

[0657] Erythropoietin

[0658] Accession number: P01588

41Sequence:APP RLICDSRVLE RYLLEAKEAE NITTGCAEHC SLNENITVPDTKVNFYAWKR MEVGQQAVEV WQGLALLSEA VLRGQALLVNSSQPWEPLQL HVDKAVSGLR SLTTLLRALG AQKEAISPPDAASAAPLRTI TADTFRKLFR VYSNFLRGKL KLYTGEACRT GDR

[0659] Disulfide: 34-188; disulfide: 56-60 (counted with 27 aa N-terminally)

[0660] Function: erythropoiese.

[0661] Exendin-4

[0662] Accession number: P26349

[0663] Sequence: MPVESGL SSEDSASSES FASKIKRHGE GTFTSDLSKQ MEEEAVRLFI EWLKNGGPSS GAPPPSG

[0664] 86 AMIDATION (G-87 PROVIDE AMIDE GROUP). (counted with 23 aa signal N-terminally)

[0665] Function: secretin-like.

[0666] Factor VIII

[0667] Accession number: P00451

42Sequence:A TRRYYLGAVE LSWDYMQSDL GELPVDARFP PRVPKSFPFNTSVVYKKTLF VEFTDHLFNI AKPRPPWMGL LGPTIQAEVYDTVVITLKNM ASHPVSLHAV GVSYWKASEG AEYDDQTSQREKEDDKVFPG GSHTYVWQVL KENGPMASDP LCLTYSYLSHVDLVKDLNSG LIGALLVCRE GSLAKEKTQT LHKFILLFAVFDEGKSWHSE TKNSLMQDRD AASARAWPKM HTVNGYVNRSLPGLIGCHRK SVYWHVIGMG TTPEVHSIFL EGHTFLVRNIRQASLEISPI TFLTAQTLLM DLGQFLLFCH ISSHQHDGMEAYVKVDSCPE EPQLRMKNNE EAEDYDDDLT DSEMDVVRFDDDNSPSFIQI RSVAKKHPKT WVHYIAAEEE DWDYAPLVLAPDDRSYKSQY LNNGPQRIGR KYKKVRFMAY TDETFKTREAIQHESGILGP LLYGEVGDTL LIIFKNQASR PYNIYPHGITDVRPLYSRRL PKGVKHLRDF PILPGEIFKY KWTVTVEDGPTKSDPRCLTR YYSSFVNMER DLASGLIGPL LICYKESVDQRGNQIMSDKR NVILFSVFDE NRSWYLTENI QRFLPNPAGVQLEDPEFQAS NIMHSTNGYV FDSLQLSVCL HEVAYWYILSIGAQTDFLSV FFSGYTFKHK MVYEDTLTLF PFSGETVFMSMENPGLWILG CHNSDFRNRG MTALLKVSSC DKNTGDYYEDSYBDISAYLL SKNNAIEPRS FSQNSRHPST RQKQFNATTIPENDIEKTDP WFAHRTPMPK IQNVSSSDLL MLLRQSPTPHGLSLSDLQEA KYETFSDDPS PGAIDSNNSL SEMTHFRPQLHHSGDMVFTP ESGLQLRLNE KLGTTAATEL KKLDFKVSSTSNNLISTIPS DNLAAGTDNT SSLGPPSMPV HYDSQLDTTLFGKKSSPLTE SGGPLSLSEE NNDSKLLESG LMNSQESSWGKNVSSTESGR LFKGKRAHGP ALLTKDNALF KVSISLLKTNKTSNNSATNR KTHIDGPSLL IENSPSVWQN ILESDTEFKKVTPLIHDRML MDKNATALRL NHMSNKTTSS KNMEMVQQKKEGPIPPDAQN PDMSFFKMLF LPESARWIQR THGKNSLNSGQGPSPKQLVS LGPEKSVEGQ NFLSEKNKVV VGKGEFTKDVGLKEMVFPSS RNLFLTNLDN LHENNTHNQE KKIQEEIEKKETLIQENVVL PQIHTVTGTK NFMKNLFLLS TRQNVEGSYDGAYAPVLQDF RSLNDSTNRT KKHTAHFSKK GEEENLEGLGNQTKQIVEKY ACTTRISPNT SQQNEVTQRS KRALKQFRLPLEETELEKRI IVDDTSTQWS KNMKHLTPST LTQIDYNEKEKGAITQSPLS DCLTRSHSIP QANRSPLPIA KVSSFPSIRPIYLTRVLFQD NSSHLPAASY RKKDSGVQES SHFLQGAKKNNLSLAILTLE MTGDQREVGS LGTSATNSVT YKKVENTVLPKPDLPKTSGK VELLPKVHIY QKDLFPTETS NGSPGHLDLVEGSLLQGTEG AIKWNEANRP GKVPFLRVAT ESSAKTPSKLLDPLAWDNHY GTQTPKEEWK SQEKSPEKTA FKKKDTILSLNACESNHAIA ATNEGQNKPE IEVTWAKQGR TERLCSQNPPVLKRHQREIT RTTLQSDQEE IDYDDTISVE MKKEDFDIYDEDENQSPRSF QKKTRHYFIA AVERLWDYGM SSSPHVLRNRAQSGSVPQFK KVVFQEFTDG SFTQPLYRGE LNEHLGLLGPYIRAEVEDNI MVTFRNQASR PYSFYSSLIS YEEDQRQGAEPRKNFVKPNE TKTYFWKVQH HMAPTKDEFD CKAWAYFSDVDLEKDVHSGL IGPLLVCHTN TLNPAHGRQV TVQEFALFFTIFDETKSWYF TENMERNCRA PCNIQMEDPT FKENYRFHAINGYIMDTLPG LVMAQDQRIR WYLLSMGSNE NIHSIHFSGHVFTVRKKEEY KMALYNLYPG VFETVEMLPS KAGIWRVECLIGEHLHAGMS TLFLVYSNTK QTPLGMASGH IRDFQITASGQYGQWAPKLA RLHYSGSTNA WSTKEPFSWI KVDLLAPMIIHGIKTQGARQ KFSSLYISQF IIMYSLDGKK WQTYRGNSTGTLMVFFGNVD SSGHKHNIFN PPIIARYIRL HPTHYSIRSTLRMELMGCDL NSCSMPLGME SKAISDAQIT ASSYFTNMFATWSPSKARLH LQGRSNAWRP QVNNPKEWLQ VDFQKTMKVTGVTTQGVKSL LTSMYVKEFL ISSSQDGHQW TLFFQNGKVKVFQGNQDSFT PVVNSLDPPL LTRYLRIHPQ SWVHQIALRMEVLGCEAQDL Y

[0668] Disulfide: 172-198;547-573; 1851-1877; 2040-2188; 2193-2345 (counted with 19 aa extra N-terminally)

[0669] Function: coagulation.

[0670] Factor IX

[0671] Accession number: P00740

43Sequence:Light chain:NSG KLEEFVQGNL ERECMEEKCS FEEAREVFEN TERTTEFWKQYVDGDQCESN PCLNGGSCKD DINSYECWCP FGFEGKNCEL DVTCNIKNGRCEQFCKNSAD NKVVCSCTEG YRLAENQKSC EPAVPFPCGR VSVSQTSKLT RHeavy chain:AEAVFPDVD YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPWQVVLNGKVDA FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHTEQKRNVIRII PHHNYNAAIN KYNHDIALLE LDEPLVLNSY VTPICIADKE YTNIFLKFGSGYVSGWGRVF HKGRSALVLQ YLRVPLVDRA TCLRSTKFTI YNNMFCAGFHEGGRDSCQGD SGGPHVTEVE GTSFLTGIIS WGEECAMKGK YGIYTKVSRYVNWIKEKTKL T

[0672] Disulfide: 64-69; 97-108; 102-117; 119-128; 134-145; 141-155; 157-170 (counted in the precursor)

[0673] Function: coagulation.

[0674] Factor X

[0675] Accession number: P00742

44Sequence:Light chain:ANSFLEEMKK GHLERECMEE TCSYEEAREV FEDSDKTNEFWNKYKDGDQC ETSPCQNQGK CKDGLGEYTC TCLEGFEGKN CELFTRKLCSLDNGDCDQFC HEEQNSVVCS CARGYTLADN GKACIPTGPY PCGKQTLERHeavy chain:R KRSVAQATSS SGEAPDSITW KPYDAADLDP TENPFDLLDFNQTQPERGDN NLTRIVGGQE CKDGECPWQA LLINEENEGF CGGTILSEFYILTAAHCLYQ AKRFKVRVGD RNTEQEEGGE AVHEVEVVIK HNRFTKETYDFDIAVLRLKT PITFRMNVAP ACLPERDWAE STLMTQKTGI VSGFGRTHEKGRQSTRLKML EVPYVDRNSC KLSSSFIITQ NMFCAGYDTK QEDACQGDSGGPHVTRFKDT YFVTGIVSWG EGCARKGKYG IYTKVTAFLK WIDRSMKTRGLPKAKSHAPE VITSSPLK

[0676] Disulfide: 90-101; 95-110; 112-121; 129-140; 136-149; 151-164; 172-342; 241-246; 261 277; 390-404; 415-443 (counted with 40 aa signal sequence)

[0677] Function: coagulation, factor Xa (part of factor X-heavy chain) is a vitamin K-dependent glycoprotein that converts prothrombin into thrombin in the presence of amongst others anionic phospholipid.

[0678] Factor XIII

[0679] Accession number: P00488

45Sequence:VN LQEFLNVTSV HLFKERWDTN KVDHHTDKYE NNKLIVRRGQSFYVQIDFSR PYDPRRDLFR VEYVIGRYPQ ENKGTYIPVPIVSELQSGKW GAKLVMREDR SVRLSIQSSP KCIVGKFRNYVAVWTPYGVL RTSRNPETDT YILFNPWCED DAVYLDNEKEREEYVLNDIG VIFYGEVNDI KTRSWSYGQF EDGILDTCLYVMDRAQMDLS GRGNPIKVSR VGSAMVNAKD DEGVLVGSWDNIYAYGVPPS AWTGSVDILL EYRSSENPVR YGQCWVFAGVFNTFLRCLGI PARIVTNYFS AHDNDANLQM DIFLEEDGNVNSKLTKDSVW NYHCWNEAWM TRPDLPVGFG GWQAVDSTPQENSDGMYRCG PASVQAIKHG HVCFQFDAPF VFAEVNSDLIYITAKKDGTH VVENVDATHI GKLIVTKQIG GDGMMDITDTYKFQEGQEEE RLALETALMY GAKKPLNTEG VMKSRSNVDMDFEVENAVLG KDFKLSITFR NNSHNRYTIT AYLSANITFYTGVPKAEFKK ETFDVTLEPL SFKKEAVLIQ AGEYMGQLLEQASLHFFVTA RINETRDVLA KQKSTVLTIP EIIIKVRGTQVVGSDMTVTV QFTNPLKETL RNVWVHLDGP GVTRPMKKMFREIRPNSTVQ WEEVCRPWVS GHRKLIASMS SDSLRHVYGELDVQIQRRPS M

[0680] Function: coagulation, indirectly stabilizing fibrin chains.

[0681] Fibronectin

[0682] Accession number: P02751

46Sequence:QAQQMVQPQ SPVAVSQSKP GCYDNGKHYQ INQQWERTYLGNALVCTCYG GSRGFNCESK PEAEETCFDK YTGNTYRVGDTYERPKDSMI WDCTCIGAGR GRISCTIANR CHEGGQSYKIGDTWRRPHET GGYMLECVCL GNGKGEWTCK PIAEKCFDHAAGTSYVVGET WEKPYQGWMM VDCTCLGEGS GRITCTSRNRCNDQDTRTSY RIGDTWSKKD NRGNLLQCIC TGNGRGEWKCERHTSVQTTS SGSGPFTDVR AAVYQPQPHP QPPPYGHCVTDSGVVYSVGM QWLKTQGNKQ MLCTCLGNGV SCQETAVTQTYGGNSNGEPC VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTSNYEQDQKYSF CTDHTVLVQT QGGNSNGALC HFPFLYNNHNYTDCTSEGRR DNMKWCGTTQ NYDADQKFGF CPMAAHEEICTTNEGVMYRI GDQWDKQHDM GHMMRCTCVG NGRGEWTCIAYSQLRDQCIV DDITYNVNDT FHKRHEEGHM LNCTCFGQGRGRWKCDPVDQ CQDSETGTFY QIGDSWEKYV HGVRYQCYCYGRGIGEWHCQ PLQTYPSSSG PVEVFITETP SQPNSHPIQWNAPQPSHISK YILRWRPKNS VGRWREATIP GHLNSYTIKGLRPGVVYEGQ LISIQQYGHQ EVTRFDFTTT STSTPVTSNTVTGETTPFSP LVATSESVTE ITASSFVVSW VSASDTVSGFRVEYELSEEG DEPQYLDLPS TATSVNIPDL LPGRKYIVNVYQISEDGEQS LILSTSQTTA PDAPPDPTVD QVDDTSIVVRWSRPQAPITG YRIVYSPSVE GSSTELNLPE TANSVTLSDLQPGVQYNITI YAVEENQEST PVVIQQETTG TPRSDTVPSPRDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VTPVNLPGEHGQRLPISRNT FAEVTGLSPG VTYYFKVFAV SHGRESKPLTAQQTTKLDAP TNLQFVNETD STVLVRWTPP RAQITGYRLTVGLTRRGQPR QYNVGPSVSK YPLRNLQPAS EYTVSLVAIKGNQESPKATG VFTTLQPGSS IIPYNTEVTE TTIVITWTPAPRIGFKLGVR PSQGGEAPRE VTSDSGSIVV SGLTPGVEYVYTIQVLRDGQ ERDAPIVNKV VTPLSPPTNL HLEANPDTGVLTVSWERSTT PDITGYRITT TPTNGQQGNS LEEVVHADQSSCTFDNLSPG LEYNVSVYTV KDDKESVPIS DTIIPAVPPPTDLRFTNIGP DTMRVTWAPP PSIDLTNFLV RYSPVKNEEDVAELSISPSD NAVVLTNLLP GTEYVVSVSS VYEQHESTPLRGRQKTGLDS PTGIDFSDIT ANSFTVHWIA PRATITGYRIRHHPEHFSGR PREDRVPHSR NSITLTNLTP GTEYVVSIVALNGREESPLL IGQQSTVSDV PRDLEVVAAT PTSLLISWDAPAVTVRYYRI TYGETGGNSP VQEFTVPGSK STATISGLKPGVDYTITVYA VTGRGDSPAS SKPISINYRT EIDKPSQMQVTDVQDNSISV KWLPSSSPVT GYRVTTTPKN GPGPTKTKTAGPDQTEMTIE GLQPTVEYVV SVYAQNPSGE SQPLVQTAVTNIDRPKGLAF TDVDVDSIKI AWESPQGQVS RYRVTYSSPEDGIHELFPAP DGEEDTAELQ GLRPGSEYTV SVVALHDDMESQPLIGTQST AIPAPTDLKF TQVTPTSLSA QWTPPNVQLTGYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKYEVSVYALKDTLT SRPAQGVVTT LENVSPPRRA RVTDATETTITISWRTKTET ITGFQVDAVP ANGQTPIQRT IKPDVRSYTITGLQPGTDYK IYLYTLNDNA RSSPVVIDAS TAIDAPSNLRFLATTPNSLL VSWQPPRARI TGYIIKYEKP GSPPREVVPRPRPGVTEATI TGLEPGTEYT IYVIALKNNQ KSEPLIGRKKTDELPQLVTL PHPNLHGPEI LDVPSTVQKT PFVTHPGYDTGNGIQLPGTS GQQPSVGQQM IFEEHGFRRT TPPTTATPIRHRPRPYPPNV GEEIQIGHIP REDVDYHLYP HGPGLNPNASTGQEALSQTT ISWAPFQDTS EYIISCHPVG TDEEPLQFRVPGTSTSATLT GLTRGATYNI IVEALKDQQR HKVREEVVTVGNSVNEGLNQ PTDDSCFDPY TVSHYAVGDE WERMSESGFKLLCQCLGFGS GHFRCDSSRW CHDNGVNYKI GEKWDRQGENGQMMSCTCLG NGKGEFKCDP HEATCYDDGK TYHVGEQWQKEYLGAICSCT CFGGQRGWRC DNCRRPGGEP SPEGTTGQSYNQYSQRYHQR TNTNVNCPIE CFMPLDVQAD REDSRE

[0683] Disulfide: 52-78; 76-87; 97-125; 123-135; 141-169; 167-179; 186-215; 213-225; 231-260; 258-270; 308-335; 333-342; 360-386; 374-401; 420-446; 434-461; 470-498; 496-508; 518 545; 543-555; 561-589; 587-599; 2206-2235; 2233-2245; 2251-2278; 2276-2288; 2295-2319; 2317-2333; 2367-2367; 2371-2371 INTERCHAIN (WITH 2367 OF OTHER CHAIN). (counted with 31 aa extra N-terminally)

[0684] Function: wound healing, cell shape.

[0685] Fibrinogen

[0686] Accession number: P02671

47Sequence:GPRVV ERHQSACKDS DWPFCSDEDW NYKCPSGCRM KGLIDEVNQDFTNRTNKLK NSLFEYQKNN DSHSLTTNIM EILRGDFSSANNRDNTYNRV SEDLRSRIE LKRKVIEKVQ HIQLLQKNVRAQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQQKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQLQKVPPEWKA LTDMPQMRME LERPGGNEIT RGGSTSYGTGSETESPRNPS SAGSWNSGSS GPGSTGNRNP GSSGTGGTATWKPGSSGPGS TGSWNSGSSG TGSTGNQNPG SPRPGSTGTWNPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGSGNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDKELRTGKEKVT SGSTTTTRRS CSKTVTKTVI GPDGHKEVTKEVVTSEDGSD CPEAMDLGTL SGIGTLDGFR HRHPDEAAFFDTASTGKTFP GFFSPMLGEF VSETRSRGSE SGIFTNTKESSSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKSYKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHPSGTQSGIFNI KLPGSSKIFS VYCDQETSLG GWLLIQQRMDGSLNFNRTWQ DYKRGFGSLN DEGEGEFWLG NDYLHLLTQRGSVLRVELED WAGNEAYAEY HFRVGSEAEG YALQVSSYEGTAGDALIEGS VEEGAEYTSH NNMQFSTFDR DADQWEENCAEVYGGGWWYN NCQAANLNGI YYPGGSYDPR NNSPYEIENGVVWVSFRGAD YSLRAVRMKI RPLVTQ

[0687] Disulfide: 47-47 INTERCHAIN (WITH C-47′); 55-55 INTERCHAIN (WITH C-95 IN BETA); 64-64 INTERCHAIN (WITH C-49 IN GAMMA); 68-68 INTERCHAIN (WITH C-106 IN BETA); 180-180 INTERCHAIN (WITH C-165 IN GAMMA); 184-184 INTERCHAIN (WITH C-223 IN BETA); 461-491

[0688] Function: fibrin formation, platelet aggregation.

[0689] Filgrastim

[0690] Accession number: P09919

48Sequence:TPLGPASSLP QSFLLKCLEQ VRIKIQGDGAA LQEKLVSECATYKLCHPEEL VLLGHSLGIP WAPLSSCPSQ ALQLAGCLSQLHSGLFLYQG LLQALEGISP ELGPTLDTLQ LDVADFATTIWQQMEELGMA PALQPTQGAM PAFASAFQRR AGGVLVASHLQSFLEVSYRV LRHLAQP

[0691] Disulfide: 69-75; 97-107 (counted with 30 aa N-terminally)

[0692] Function: granulocyte stimulation.

[0693] Follitropin alpha

[0694] Accession number: P37036

49Sequence:FPBGZFTMZG CPZCKLKZBK YFSKLGAPIY ZCMGCCFSRAYPTPARSKKT MLVPKNITSZ ATCCVAKAFT KATVMGBARVZNHTZCHCST CYYHKS

[0695] Disulfde: 11-35; 14-64; 32-86; 36-88; 63-91

[0696] Function: follicle stimulation.

[0697] Follitropin beta

[0698] Accession numbers: P01225

50Sequence:S CELTNITIAI EKEECRFCIS INTTWCAGYC YTRDLVYKDP ARPKIQKTCTFKELVYETVR VPGCAHHADS LYTYPVATQC HCGKCDSDST DCTVRGLGPSYCSFGEMKE

[0699] Disulfide: 21-69; 35-84; 38-122; 46-100; 50-102; 105-112 (counted with 18 aa N-terminally)

[0700] Function: follicle stimulation.

[0701] Growth hormone releasing hormone

[0702] Accession number: P48144

[0703] Sequence: HADGLLDR ALRDILVQLS ARKYLHSLTA VRVGEEEEDE EDSEPLS

[0704] Function: growth hormone release.

[0705] Pituitary adenylate cyclase activating polypeptide

[0706] Accession number: P48144

[0707] Sequence: H SDGIFTDSYS RYRKQMAVKK YLAAVLGRRY RQRFRN (amidation of last residue)

[0708] Function: see name.

[0709] Hyaluronidase

[0710] Accession number: P38567

51Sequence:LNFRA PPVWNVPFL WAWNAPSEFC LGKFDEPLDM SLFSFIGSPRINATGQGVTI FYVDRLGYYP YIDSITGVTV NGGIPQKISLQDHLDKAKKD ITFYMPVDNL GMAVIDWEEW RPTWARNWKPKDVYKNRSIE LVQQQNVQLS LTEATEKAKQ EFEKAGKDFLVETIKLGKLL RPNHLWGYYL FPDCYNHHYK KPGYNGSCFNVEIKRNDDLS WLWNESTALY PSIYLNTQQS PVAATLYVRNRVREAIRVSK IPDAKSPLPV FAYTRIVFTD QVLKYLSQDELVYTFGETVA LGASGIVIWG TLSIMRSMKS CLLLDNYMETILNPYIINVT LAAKMCSQVL CQEQGVCTRK NWNSSDYLHLNPDNFAIQLE KGGKFTVRGK PTLEDLEQFS EKFYCSCYSTLSCKEKADVK DTDAVDVCIA DGVCIDAFLK PPMETEEPQIFYNASPSTLS ATMFIVSILF LIISSVASL

[0711] Function: glycosyl hydrolase.

[0712] Hirudin II

[0713] Accession number: P28504

[0714] Sequence: ITYTDCTESG QDLCLCEGSN VCGKGNKClL GSNGEENQCV TGEGTPKPQS HNDGDFEEIP EEYLQ

[0715] Disulfide: 6-14; 16-28; 22-39

[0716] Function: thrombin inhibitor.

[0717] Imiglucerase

[0718] Accession number: PO4062

52Sequence:A RPCIPKSFGY SSVVCVCNAT YCDSFDPPTF PALGTFSRYESTRSGRRMEL SMGPIQANHT GTGLLLTLQP EQKFQKVKGFGGAMTDAAAL NILALSPPAQ NLLLKSYFSE EGIGYNIIRVPMASCDFSIR TYTYADTPDD FQLHNFSLPE EDTKLKIPLIHRALQLAQRP VSLLASPWTS PTWLKTNGAV NGKGSLKGQPGDTYHQTWAR YFVKFLDAYA EHKLQFWAVT AENEPSAGLLSGYPFQCLGF TPEHQRDFIA RDLGPTLANS THHNVRLLMLDDQRLLLPHW AKVVLTDPEA AKYVHGIAVH WYLDFLAPAKATLGETHRLF PNTMLFASEA CVGSKFWEQS VRLGSWDRGMQYSHSIITNL LYHVVGWTDW NLALNPEGGP NWVRNTVDSPIIVDITKDTF YKQPMFYHLG HFSKFIPEGS QRVGLVASQKNDLDAVALMH PDGSAVVVVL NRSSKDVPLT IKDPAVGFLETISPGYSIHT YLWHRQ

[0719] Function: Glucohydrolase.

[0720] Interleukin 2

[0721] Accession number: P01585

53Sequence:APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNIPKLTRMLTFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHLRPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT

[0722] Disulfide: 78-125 (counted with 20 aa signal N-terminally)

[0723] Function: growth factor.

[0724] Interferon alpha-4

[0725] Accession numbers: P01562

54Sequence:CDLPETH SLDNRRTLML LAQMSRISPS SCLMDRHDFGFPQEEFDGNQ FQRAPAISVL HELIQQIFNL FTTKDSSAAWDEDLLDKFCT ELYQQLNDLE ACVMQEERVG ETPLMNADSILAVKKYFRRI TLYLTEKKYS PCAWEVVRAE IMRSLSLSTNLQERLRRKIE

[0726] Disulfide: 24-122; 52-162 (counted with 23 aa N-terminally)

[0727] Function: Antiviral, interferon stimulates the production of two enzymes, a protein kinase and an oligoadenylate synthetase.

[0728] Interferon-beta

[0729] Accession numbers: P01575

55Sequence:INYKQLQLQ ERTNIRKCQE LLEQLNGKTN LTYRADFKTPMEMTEKMQKS YTAFAIQEML QNVFLVFRNN FSSTGWNETIVVRLLDELHQ QTVFLKTVLE EKQEERLTWE MSSTALHLKSYYWRVQRYLK LMKYNSYAWM VVRAEIFRNF LIIRRLTRNF QN

[0730] Function: antiviral, antibacterial and anticancer.

[0731] Intrinsic factor

[0732] Accession number: P27352

56Sequence:ST QTQSSCSVPS AQEPLVNGIQ VLMENSVTSS AYPNPSILIAMNLAGAYNLK AQKLLTYQLM SSDNNDLTIG HLGLTIMALTSSCRDPGDKV SILQRQMENW APSSPNAEAS AFYGPSLAILALCQKNSEAT LPIAVRFAKT LLANSSPFNV DTGAMATLALTCMYNKIPVG SEEGYRSLFG QVLKDIVEKI SMKIKDNGIIGDIYSTGLAM QALSVTPEPS KKEWNCKKTT DMILNEIKQGKFHNPMSIAQ ILPSLKGKTY LDVPQVTCSP DHEVQPTLPSNPGPGPTSAS NITVIYTINN QLRGVELLFN ETINVSVKSGSVLLVVLEEA QRKNPMFKFE TTMTSWGLVV SSTNNIAENVNHKTYWQFLS GVTPLNEGVA DYIPFNHEHI TANFTQY

[0733] Disulfide: 26-246; 103-288; 143-182 (counted with 18 aa N-terminally extra)

[0734] Function: cobalamin endocytosis.

[0735] Invertase

[0736] Accession number: Q60115

57Sequence:MFNFNASRWT RAQAMKVNKY DLTTSMPEIG TDFPIMRDDLWLWDTWPLRD INGNPVSFKG WNVIFSLVAD RNIPWNDRHSHARIGYFYSK DGKSWVYGGH LLQESANTRT AEWSGGTIMAPGSRNQVETF FTSTLFDKNG VREAVAAVTK GRIYADSEGVWFKGFDQSTD LFQADGLFYQ NYAENNLWNF RDPHVFINPEDGETYALFEA NVATVRGEDD IGEDEIGPVP ANTVVPKDANLCSASIGIAR CLSPDRTEWE LLPPLLTAFG VNDQMERPHVIFQNGLTYLF TISHDSTYAD GLTGSDGLYG FVSENGIFGPYEPLNGSGLV LGGPASQPTE AYAHYIMNNG LVESFINEIIDPKSGKVIAG GSLAPTVRVE LQGHETFATE VFDYGYIPASYAWPVWPFPD RRK

[0737] Function: sucrase.

[0738] Lepirudin

[0739] Accession number: P01050

58Sequence:VVYTDCTESG QNLCLCEGSN VCGQGNKCIL GSDGEKNQCVTGEGTPKPQS HNDGDFEEIP EEYLQ

[0740] Disulfides: 6-14; 16-28

[0741] Function: thrombin inhibitor.

[0742] LHRH

[0743] Accession number: P01148

59Sequence:QHWSYGL RPGGKRDAEN LIDSFQEIVK EVGQLAETQRFECTTHQPRS PLRDLKGALE SLIEEETGQK KI

[0744] Function: luteinizing hormone release.

[0745] Lutropin beta

[0746] Accession number: P01229

60Sequence:SREPLRPWCH PINAILAVEK EGCPVCITVN TTICAGYCPTMMRVLQAVLP PLPQVVCTYR DVRFESIRLP GCPRGVDPVVSFPVALSCRC GPCRRSTSDC GGPKDHPLTC DHPQLSGLLF L

[0747] Disulfide: 29-77; 43-92; 46-130; 54-108; 58-110; 113-120

[0748] Function: stimulates synthesis of steroids.

[0749] Lysozyme

[0750] Accession number: P21270

61Sequence:MDPRLREEVV RLIIALTSDN GASLSKIRLQS RVSALEKTSQIHSDTILRIT QGLDDANKRI IALEQSRDDL VASVSDAQLAISRLESSIGA LQTVVNGLDS SVTQLGARVG QLETGLADVRVDHDNLVARV DTAERNIGSL TTELSTLTLR VTSIQADFESRISTLERTAV TSAGAPLSIR NNRITMGLND GLTLSGNNLAIRLPGNTGLN IQNGGLQFRF NTDQFQIVNN NLTLKTTVFDSINSRIGATE QSYVASAVTP LRLNSSTKVL DMLIDMSTLEINSSGQLTVR STSPNLRYPI ADVSGGIGMS PNYRFR

[0751] Function: hydrolysis peptidoglycan.

[0752] Metalloproteinase inhibitor

[0753] Accession number: P16035

62Sequence:CSCS PVHPQQAFCN ADVVIRAKAV SEKIVDSGND IYGNPIKRIQYEIKQIKMFK GPEKDIEFIY TAPSSAVCGV SLDVGGKKEYLIAGKAEGDG KMHITLCDFI VPWDTLSTTQ KKSLNHRYQMGCECKITRCP MIPCYISSPD ECLWMDWVTE KNINGHQAKFFACIKRSDGS CAWYRGAAPP KQEFLDIEDP

[0754] Disulfides: 27-98; 29-127; 39-152; 154-201; 159-164; 172-193 (counted with 26 aa N-terminally)

[0755] Function: inactivation protease.

[0756] Neurophysin

[0757] Accession number: P01185

63Sequence:AMSDLELRQ CLPCGPGGKG RCFGPSICCA DELGCFVGTAEALRCQEENY LPSPCQSGQK ACGSGGRCAA FGVCCNDESCVTEPECREGF HRRA

[0758] Disulfide: 41-85; 44-58; 52-75; 59-65; 92-104; 98-116; 105-110

[0759] Function: Neurophysin binds vasopressin.

[0760] Papain

[0761] Accession number: P00784

64Sequence:VY MGLSFGDFSI VGYSQNDLTS TERLIQLFES WMLKHNKIYKNIDEKIYRFE IFKDNLKYID ETNKKNNSYW LGLNVFADMSNDEFKEKYTG SIAGNYTTTE LSYEEVLNIG DVNIPEYVDWRQKGAVTPVK NQGSCGSCWA FSAVVTIEGI IKIRTGNLNEYSEQELLDCD RRSYGCNGGY PWSALQLVAQ YGIHYRNTYPYEGVQRYCRS REKGPYAAKT DGVRQVQPYN EGALLYSIANQPVSVVLEAA GKDFQLYRGG IFVGPCGNKV DHAVAAVGYGPNYILIKNSW GTGWGENGYI RIKRGTGNSY GVCGLYTSSF YPVICN

[0762] Disulfide: 155-196; 189-228; 286-333 (counted with 18 aa N-terminally)

[0763] Function: Proteinase.

[0764] Pepsin

[0765] Accession number: P00790

65Sequence:VDEQPLEN YLDMEYFGTI GIGTPAQDFT VVFDTGSSNLWVPSVYCSSL ACTNHNRFNP EDSSTYQSTS ETVSITYGTGSMTGILGYDT VQVGGISDTN QIFGLSETEP GSFLYYAPFDGILGLAYPSI SSSGATPVFD NIWNQGLVSQ DLFSVYLSADDQSGSVVIFG GIDSSYYTGS LNWVPVTVEG YWQITVDSITMNGEAIACAE GCQAIVDTGT SLLTGPTSPI ANIQSDIGASENSDGDMVVS CSAISSLPDI VFTINGVQYP VPPSAYILQSEGSCISGFQG MNLPTESGEL WILGDVFIRQ YFTVFDRANNQVGLAPVA

[0766] Disulfide: 107-112; 268-272; 311-344 (counted with 62 aa N-terminally)

[0767] Function: Peptidase.

[0768] Plasminogen

[0769] Accession number: P00747

66Sequence:E PLDDYVNTQG ASLFSVTICKQ LGAGSIEECA AKCEEDEEFTCRAFQYHSKE QQCVIMAENR KSSIIIRMRD VVLFEKKVYLSECKTGNGKN YRGTMSKTKN GITCQKWSST SPHRPRFSPATHPSEGLEEN YCRNPDNDPQ GPWCYTTDPE KRYDYCDILECEEECMHCSG ENYDGKISKT MSGLECQAWD SQSPHAHGYIPSKYPNKNLK KNYCRNPDRE LRPWCFTTDP NKRWELCDIPRCTTPPPSSG PTYQCLKGTG ENYRGNVAVT VSGHTCQHWSAQTPHTHNRT PENFPCKNLD ENYCRNPDGK RAPWCHTTNSQVRWEYCKIP SCDSSPVSTE QLAPTAPPEL TPVVQDCYHGDGQSYRGTSS TTTTGKKCQS WSSMTPHRHQ KTPENYPNAGLTMNYCRNPD ADKGPWCFTT DPSVRWEYCN LKKCSGTEASVVAPPPVVLL PDVETPSEED CMFGNGKGYR GKRATTVTGTPCQDWAAQEP HRHSIFTPET NPRAGLEKNY CRNPDGDVGGPWCYTTNPRK LYDYCDVPQC AAPSFDCGKP QVEPKKCPGRVVGGCVAHPH SWPWQVSLRT RFGMHFCGGT LISPEWVLTAAHCLEKSPRP SSYKVILGAH QEVNLEPHVQ EIEVSRLFLEPTRKDIALLK LSSPAVITDK VIPACLPSPN YVVADRTECFITGWGETQGT FGAGLLKEAQ LPVIENKVCN RYEFLNGRVQSTELCAGHLA GGTDSCQGDS GGPLVCFEKD KYILQGVTSWGLGCARPNKP GVYVRVSRFV TWIEGVMRNN

[0770] Disulfide: 49-73; 53-61; 103-181; 124-164; 152-176; 185-262; 188-316; 206-245; 234-257; 275-352; 296-335; 324-347; 377-454; 398-437; 426-449; 481-560; 502-543; 531-555; 567-685; 577-585; 607-623; 699-766; 729-745; 756-784

[0771] Function: Protease.

[0772] Protamine

[0773] Accession number: P04554

67Sequence:MVRYRVRSLS ERSHEVYRQQ LHGQEQGHHG QEEQGLSPEHVEVYERTHGQ SHYRRRHCSR RRLHRIHRRQ HRSCRRRKRRSCRHRRRHRR GCRTRKRTCR RH

[0774] Function: histon substitution.

[0775] Prothrombin

[0776] Accession number: P12259

68Sequence:AQ LRQFYVAAQG ISWSYRPEPT NSSLNLSVTS FKKIVYREYEPYFKKEKIPQS TISGLLGPTL YAEVGDIIKV HFKNKADKPL SIHPQGIRYSKLSEGASYLD HTFPAEKMDD AVAPGREYTY EWSISEDSGP THDDPPCLTHIYYSHENLIE DFNSGLIGPL LICKKGTLTE GGTQKTFDKQ IVLLFAVFDE SKSWSQSSSLMYTVNGYVNG TMPDITVCAH DHISWHLLGM SSGPELFSIH FNGQVLEQNHHKVSAITLVS ATSTTANMTV GPEGKWIISS LTPKHLQAGM QAYIDIKNCPKKTRNLKIKIT REQRRHMKRW EYFIAAEEVI WDYAPVIPAN MDKKYRSQHLDNFSNQIGKH YKKVMYTQYE DESFTKHTVN PNMKEDGILG PIIRAQVRDTLKIVFKNMAS RPYSIYPHGV TFSPYEDEVN SSFTSGRNNT MIRAVQPGETYTYKWNILEF DEPTENDAQC LTRPYYSDVD IMRDIASGLI GLLLICKSRSLDRRGIQRAA DIEQQAVFAV FDENKSWYLE DNINKFCENP DEVKRDDPKFYESNIMSTIN GYVPESITTL GFCFDDTVQW HFCSVGTQNE ILTIHFTGHSFIYGKRHEDT LTLFPMRGES VTVTMDNVGT WMLTSMNSSP RSKKLRLKFRDVKCIPDDDE DSYEIFEPPE STVMATRKMH DRLEPEDEES DADYDYQNRLAAALGIRSFR NSSLNQEEEE FNLTALALEN GTEFVSSNTD IIVGSNYSSP SNISKFTVNNLAEPQKAPSH QQATTAGSPL RHLIGKNSVL NSSTAEHSSP YSEDPIEDPLQPDVTGIRLL SLGAGEFKSQ EHAKHKGPKV ERDQAAKHRF SWMKLLAHKVGRHLSQDTGS PSGMRPWEDL PSQDTGSPSR MRPWKDPPSD LLLLKQSNSSKILVGRWHLA SEKGSYEIIQ DTDEDTAVNN WLISPQNASR AWGESTPLANKPGKQSGHPK FPRVRHKSLQ VRQDGGKSRL KKSQFLIKTR KKKKEKHTHHAPLSPRTFHP LRSEAYNTFS ERRLKHSLVL HKSNETSLPT DLNQTLPSMDFGWIASLPDH NQNSSNDTGQ ASCPPGLYQT VPPEEHYQTF PIQDPDQMHSTSDPSHRSSS PELSEMLEYD RSHKSFPTDI SQMSPSSEHE VWQTVISPDL SQVTLSPELSQTNLSPDLSH TTLSPELIQR NLSPALGQMP ISPDLSHTTL SPDLSHTTLS LDLSQTNLSPELSQTNLSPA LGQMPLSPDL SHTTLSLDFS QTNLSPELSH MTLSPELSQTNLSPALGQMP ISPDLSHTTL SLDFSQTNLS PELSQTNLSP ALGQMPLSPD PSHTTLSLDLSQTNLSPELS QTNLSPDLSE MPLFADLSQI PLTPDLDQMT LSPDLGETDLSPNFGQMSLS PDLSQVTLSP DISDTTLLPD LSQISPPPDL DQIFYPSESS QSLLLQEFNESFPYPDLGQM PSPSSPTLND TFLSKIFNPL VIVGLSKDGT DYIEIIPREE VQSSEDDYAEIDYVPYDDPY KTDVRTNINS SRDPDNIAAW YLRSNNGNRR NYYIAAEEISWDYSEFVQRE TDIEDSDDIP EDTTYKKVVF RKYLDSTFTK RDPRGEYEEHLGILGPIIRA EVDDVIQVRE KNLASRPYSL HAHGLSYEKS SEGKTYEDDSPEWFKEDNAV QPNSSYTYVW HATERSGPES PGSACRAWAY YSAVNPEKDIHSGLIGPLLI CQKGILHKDS NMPVDMREFV LLFMTFDEKK SWYYEKKSRSSWRLTSSEMK KSHEFHAING MIYSLPGLKM YEQEWVRLHL LNIGGSQDIHVVHFHGQTLL ENGNKQHQLG VWPLLPGSFK TLEMKASKPG WWLLNTEVGENQRAGMQTPF LIMDRDCRMP MGLSTGIISD SQIKASEFLG YWEPRLARLNNGGSYNAWSV EKLAAEFASK PWIQVDMQKE VIITGIQTQG AKHYLKSCYTTEFYVAYSSN QINWQIFKGN STRNVMYFNG NSDASTIKEN QFDPPIVARYIRISPTRAYN RPTLRLELQG CEVNGCSTPL GMENGKIENK QITASSFKKSWWGDYWEPFR ARLNAQGRVN AWQAKANNNK QWLEIDLLKI KKITAIITQGCKSLSSEMYV KSYTIHYSEQ GVEWKPYRLK SSMVDKIFEG NTNTKGHVKNFFNPPIISRF IRVIPKTWNQ SITLRLELFG CDIY

[0777] Disulfide: 167-193; 500-526; 1725-1751; 1907-2061; 2066-2221 (counted with 28 N-terminal aa)

[0778] Function: Coagulation.

[0779] Protirelin

[0780] Accession number: P20396

69Sequence:QPEAAQ QEAVTAAEHP GLDDFLRQVE RLLFLRENIQ RLQGDQGEHSASQIFQSDWL SKRQHPGKRE EEEEEGVEEE EEEEGGAVGPHKRQHPGRRE DEASWSVDVT QHKRQHPGRR SPWLAYAVPKRQHPGRRLAD PKAQRSWEEE EEEEEREEDL MPEKRQHPGKRALGGPCGPQ GAYGQAGLLL GLLDDLSRSQ GAEEKRQHPGRRAAWVREPL EE

[0781] Function: thyrotropin release.

[0782] SC3

[0783] Accession number: P16933

[0784] Sequence:

70GGHPGT TTPPVTTTVT VTTPPSTTTI AAGGTCTTGS LSCCNQVQSASSSPVTALLG LLGIVLSDLN VLVGISCSPL TVIGVGGSGCSAQTVCCENT QFNGLINIGC TPINIL

[0785] Function: hydrophobin.

[0786] Sermorelin

[0787] Accession number: P01286

[0788] Sequence: YADAIFTNS YRKVLGQLSA RKLLQDIMSR QQGESNQERG ARARL

[0789] Function: growth hormone release.

[0790] Streptodornase

[0791] Accession number: P26295

71IPPYHH NTVLAKTVSV NQTYGEYKDY YTVIGESNID QSAFPKIYKTTERVYKGQGT SEKRVTVSDV VYNPLDGYKR STGAYGVVTKDMIDMSKGYR EKWETNPEPS GWFRFYNRAD NEEISEKEYDSRRTKSYKVT NNVPVVLTTL KGKKYNSHLF VASHLFADSLGGKSIRKNAI TGTQMQNVGT RKGGMQYIEK KVLSHITKNPDVYVFYSAIP EYQGAELLAR SVLVSALSSD GVINETVRVFNTADGFNINY EKGGLLTESP VSEIDNIEDS TTDEIENSVDDSEEIVYNDT TTEEEEN

[0792] Function: DNAse.

[0793] Streptokinase

[0794] Accession number: P00779

72Sequence:IAGP EWLLDRPSVN NSQLVVSVAG TVEGTNQDIS LKFFEIDLTSRPAHGGKTEQ GLSPKSKPFA TDSGAMSHKL EKADLLKAIQEQLIANVHSN DDYFEVIDFA SDATITDRNG KVYFADKDGSVTLPTQPVQE FLLSGHVRVR PYKEKINQNQ AKSVDVEYTVQFTPLNPDDD FRPGLKDTKL LKTLAIGDTI TSQELLAQAQSILNKNHPGY TIYERDSSIV THDNDIFRTI LPMDQEFTYRVKNREQAYRI NKKSGLNEEI NNTDLISEKY YVLKKGEKPYDPFDRSHLKL FTIKYVDVDT NELLKSEQLL TASERNLDFRDLYDPRDKAK LLYNNLDAFG IMDYTLTGKV EDNHDDTNRIITVYMGKRPE GENASYHLAY DKDRYTEEER EVYSYLRYTGTPIPDNPND

[0795] Function: activating plasminogen.

[0796] Thyroglobulin

[0797] Accession number: P01266

73Sequence:N IFEYQVDAQP LRPCELQRET AFLKQADYVP QCAEDGSFQTVQCQNDGRSC WCVGANGSEV LGSRQPGRPV ACLSFCQLQK QQILLSGYINSTDTSYLPQC QDSGDYAPVQ CDVQQVQCWC VDAEGMEVYG TRQLGRPKRCPRSCEIRNRR LLHGVGDKSP PQCSAEGEFM PVQCKFVNTT DMMIFDLVHSYNRFPDAFVT FSSFQRRFPE VSGYCHCADS QGRELAETGL ELLLDEIYDTIFAGLDLPST FTETTLYRIL QRRFLAVQSV ISGRFRCPTK CEVERFTATS FGHPYVPSCRRNGDYQAVQC QTEGPCWCVD AQGKEMHGTR QQGEPPSCAE GQSCASERQQALSRLYFGTS GYFSQHDLFS SPEKRWASPR VARFATSCPP TIKELFVDSGLLRPMVEGQS QQFSVSENLL KEAIRAIFPS RGLARLALQF TTNPKRLQQNLFGGKFLVNV GQFNLSGALG TRGTFNFSQF FQQLGLASFL NGGRQEDLAKPLSVGLDSNS STGTPEAAKK DGTMNKPTVG SFGFETNLQE NQNALKFLASLLELPEFLLF LQHAISVPED VARDLGDVME TVLSSQTCEQ TPERLFVPSCTTEGSYEDVQ CFSGECWCVN SWGKELPGSR VRGGQPRCPT DCEKQRARMQSLMGSQPAGS TLFVPACTSE GHFLPVQCFN SECYCVDAEG QAIPGTRSAIGKPKKCPTPC QLQSEQAFLR TVQALLSNSS MLPTLSDTYI PQCSTDGQWRQVQCNGPPEQ VFELYQRWEA QNKGQDLTPA KLLVKIMSYR EAASGNFSLFIQSLYEAGQQ DVFPVLSQYP SLQDVPLAAL EGKRPQPREN ILLEPYLFWQILNGQLSQYP GSYSDFSTPL AHFDLRNCWC VDEAGQELEG MRSEPSKLPTCPGSCEEAKL RVLQFIRETE EIVSASNSSR FPLGESFLVA KGIRLRNEDL GLPPLFPPREAFAEQFLRGS DYAIRLAAQS TLSFYQRRRF SPDDSAGASA LLRSGPYMPQCDAFGSWEPV QCHAGTGHCW CVDEKGGFIP GSLTARSLQI PQCPTTCEKSRTSGLLSSWK QARSQENPSP KDLFVPACLE TGEYARLQAS GAGTWCVDPASGEELRPGSS SSAQCPSLCN VLKSGVLSRR VSPGYVPACR AEDGGFSPVQCDQAQGSCWC VMDSGEEVPG TRVTGGQPAC ESPRCPLPFN ASEVVGGTILCETISGPTGS AMQQCQLLCR QGSWSVFPPG PLICSLESGR WESQLPQPRACQRPQLWQTI QTQGHFQLQL PPGKMCSADY AGLLQTFQVF ILDELTARGFCQIQVKTFGT LVSIPVCNNS SVQVGCLTRE RLGVNVTWKS RLEDIPVASLPDLHDIERAL VGKDLLGRFT DLIQSGSFQL HLDSKTFPAE TIRFLQGDHFGTSPRTWFGC SEGFYQVLTS EASQDGLGCV KCPEGSYSQD EECIPCPVGFYQEQAGSLAC VPCPVGRTTI SAGAFSQTHC VTDCQRNEAG LQCDQNGQYRASQKDRGSGK AFCVDGEGRR LPWWETEAPL EDSQCLMMQK FEKVPESKVIFDANAPVAVR SKVPDSEFPV MQCLTDCTED EACSFFTVST TEPEISCDFYAWTSDNVACM TSDQKRDALG NSKATSFGSL RCQVKVRSHG QDSPAVYLKKGQGSTTTLQK RFEPTGFQNM LSGLYNPIVF SASGANLTDA HLFCLLACDRDLCCDGFVLT QVQGGAIICG LLSSPSVLLC NVKDWMDPSE AWANATCPGVTYDQESHQVI LRLGDQEFIK SLTPLEGTQD TFTNFQQVYL WKDSDMGSRPESMGCRKDTV PRPASPTEAG LTTELFSPVD LNQVIVNGNQ SLSSQKHWLFKHLFSAQQAN LWCLSRCVQE HSFCQLAEIT ESASLYFTCT LYPEAQVCDDIMESNAQGCR LILPQMPKAL FRKKVILEDK VKNFYTRLPF QKLMGISIRNKVPMSEKSIS NGFFECERRC DADPCCTGFG FLNVSQLKGG EVTCLTLNSLGIQMCSEENG GAWRILDCGS PDIEVHTYPF GWYQKPIAQN NAPSFCPLVVLPSLTEKVSL DSWQSLALSS VVVDPSIRHF DVAHVSTAAT SNFSAVRDLCLSECSQHEAC LITTLQTQPG AVRCMFYADT QSCTHSLQGQ NCRLLLREEATHIYRKPGIS LLSYEASVPS VPISTHGRLL GRSQAIQVGT SWKQVDQFLGVPYAAPPLAE RRFQAPEPLN WTGSWDASKP RASCWQPGTR TSTSPGVSEDCLYLNVFIPQ NVAPNASVLV FFHNTMDREE SEGWPAIDGS FLAAVGNLIVVTASYRVGVF GFLSSGSGEV SGNWGLLDQV AALTWVQTHI RGFGGDPRRVSLAADRGGAD VASIHLLTAR ATNSQLFRRA VLMGGSALSP AAVISHERAQQQALALAKEV SCPMSSSQEV VSCLRQKPAN VLNDAQTKLL AVSGPFHYWGPVIDGHFLRE PPARALKRSL WVEVDLLIGS SQDDGLTNRA KAVKQFEESRGRTSSKTAFY QALQNSLGGE DSDARVEAAA TWYYSLEHST DDYASFSRALENATRDYFII CPIIDMASAW AKRARGNVFM YHAPENYGHG SLELLADVQFALGLPFYPAY EGQFSLEEKS LSLKIMQYFS HFIRSGNPNY PYEFSRKVPTFATPWPDFVP RAGGENYKEF SELLPNRQGL KKADCSFWSK YISSLKTSADGAKGGQSAES EEEELTAGSG LREDLLSLQE PGSKTYSK

[0798] Function: precursor thyroid hormone.

[0799] Urokinase,

[0800] accession: P00749

74Sequence:MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYF FTSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYFTHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEEFTLKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISAFTTHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKWTRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLIFTSHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRG FT CALKDKPGVYTRVSHFLPWIRSHTKEENGLAL

[0801] Function: plasminogen activation.

75TABLE 2Leader Peptides:Epicidin-280MENKKDLFDLEIKKDNMENNNELEAQPep-5MKNNKNLFDLEIKKETSQNTDELEPQEpilancin-K7MNNSLFDLNLNKGVETQKSDLSPQNisin-A/ZMSTKDFNLDLVSVSKKDSGASPRSubtilinMSKFDDFDLDVVKVSKQDSKITPQEpiderminMEAVKEKNDLFNLDVKVNAKESNDSGAEPRGalliderminMEAVKEKNELFDLDVKVNAKESNDSGAEPRMutacin-1140/IIIMSNTQLLEVLGTETFDVQEDLFAFDTTDTTIVASNDDPD TRLacticin-481MKEQNSFNLLQEVTESELDLILGAVariacinMTNAFQALDEVTDAELDAILGGMutacin-IIMNKLNSNAVVSLNEVSDSELDTILGGStreptococcin-A-FF22MEKNNEVINSIQEVSLEELDQIIGASalivaricin-AMNAMKNSKDILNNAIEEVSEKELMEVAGGSublancinMEKLFKEVKLEELENQKGSLactocin-SMKTEKKVLDELSLHASAKMGARDVESSMNADRuminococcin AMRNDVLTLTNPMEEKELEQILGGButyrivibriocin OR79AMNKELNALTNPIDEKELEQILGGStreptococcin A-M49MTKEHEIINSIQEVSLEELDQIIGABacteriocin J46MKEQNSFNLLQEVTESELDLILGASalivaricin A1MKNSKDILTNATEEVSEKELMEVAGGStreptinMNNTIKDFDLDLKTNKKDTATPYPlantaricin-W alphaMKISKIEAQARKTDFFKKIDTNSNLLNVNGALacticin-3147A1MNKNEIETQPVTWLEEVSDQNFDEDVFGAStaphylococcin-C55 alphaMKSSFLEKDIEEQVTWFEEVSEQEFDDDIFGAPlantaricin-W betaMTKTSRRKNAIANYLEPVDEKSINESFGAGDPEARLacticin-3147A2MKEKNMKKNDTIELQLGKYLEDDMIELAEGDESHGGStaphylococcin-C55 betaMKNELGKFLEENELELGKFSESDMLEITDDEVYAACytolysin-LLMENLSVVPSFEELSVEEMEAIQGSGDVQAECytolysin-LSMLNKENQENYYSNKLELVGPSFEELSLEEMEAIQGSGDV QAECinnamycinMTASILQQSVVDADFRAALLENPAAFGASAAALPTPVEAQD QASLDFWTKDIAATEAFAMersacidinMSQEAIIRSWKDPFSRENSTQNPAGNPFSELKEAQMDKLVGAG DNEAA

Export and modification of (poly)peptides in the lantibiotic way

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)